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ABSTRACT 
 
THE STRUCTURAL PROTEOMICS OF S-NITROSYLATION: FROM GLOBAL 
IDENTIFICATION TO ELUCIDATING PROTEIN FUNCTION THROUGH 
STRUCTURAL BIOINFORMATICS 
Jennifer L. Greene 
 
Harry Ischiropoulos, Ph.D. 
 
 
S-nitrosylation is the covalent addition of nitric oxide to reduced cysteine residues 
on proteins. It has been well documented that not all proteins are S-nitrosylated and more 
specifically, not all cysteine residues within an S-nitrosylated protein are modified. 
Therefore, it is very important to determine how this specificity is derived. Additionally, 
the mechanism by which nitric oxide can modify cysteines is still unclear. Even with the 
discovery of functional consequences of S-nitrosylation, there are still large deficits in 
our understanding and validation that it is a newly identified means of nitric oxide 
signaling within the body.  
These gaps in knowledge primarily exist due to a lack of tools necessary for 
identifying in vivo sites of S-nitrosylation. To this end, complementary mercury-based 
mass spectrometric approaches were developed for the identification of endogenous S-
nitrosoproteomes. This resulted in the identification of 328 SNO-cysteines coordinated to 
192 proteins in the mouse liver, 97% of which corresponded to novel targets of S-
nitrosylation. Bioinformatic analysis of these targets then revealed that multiple 
mechanisms of S-nitrosylation may occur in vivo, one of which involving S-
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nitrosoglutathione (GSNO). To test this hypothesis, the SNO-proteome of mice incapable 
of metabolizing GSNO was resolved. Quantum mechanics/molecular mechanics 
calculations coupled with molecular dynamics simulations proposed a novel GSNO-
mediated mechanism of transnitrosation. Basic residues in the surrounding cysteine 
microenvironment were shown to catalyze the formation of protein S-nitrosocysteine 
residues. Collectively, these data suggest that the specificity of cysteines targeted for S-
nitrosylation is driven by the surrounding protein microenvironment.  
Additionally, with only 9 structures of S-nitrosylated proteins our present 
understanding of the structural consequences of S-nitrosylation is limited. Using an in 
vivo model, attempts were made to correlate changes in enzymatic activity as a function 
of S-nitrosylation. Normal mode analysis revealed local motions near the site of S-
nitrosylation which may alter product release. In summary, this thesis utilized a global 
proteomic approach to craft a more targeted investigation into the specificity and 
molecular mechanism of S-nitrosylation.  
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CHAPTER ONE 
 
1.1 Introduction 
 
Nitric oxide (
•
NO) received the distinction of a signaling molecule in physiology 
when Furchgott, Ignarro, and Murad were awarded the 1998 Nobel Prize in Medicine & 
Physiology for their combined efforts in elucidating the role of 
•
NO in vasodilation. It 
was concluded that 
•
NO produced by endothelial cells can bind to the heme iron of 
soluble guanylate cyclase (sGC) thereby converting GTP to cGMP and resulting in a 
cascade of events leading to smooth muscle relaxation. Because it is well known that 
•
NO 
can react with many intracellular targets, the mechanism by which 
•
NO selectively 
reacted with sGC became of significance. Stamler et al. hypothesized that 
•
NO could also 
propagate its signal by forming stable adducts with protein thiols that would then deliver 
nitric oxide to a specific target (Stamler et al. 1992). This study resulted in the first 
observation that nitric oxide could react with cysteine residues in proteins to form protein 
S-nitrosocysteine.  
Over the past 2 decades, hundreds of proteins have been identified as being S-
nitrosylated. S-nitrosylation is defined as the covalent addition of nitric oxide to selective 
protein cysteine residues that can regulate protein activity across a variety of organs and 
cellular systems. Their cellular functions have ranged from oxidoreductases to ion 
channels to histone deacetylases, suggesting that S-nitrosylation appears to be a 
widespread biological mechanism of nitric oxide signaling. Nevertheless, fundamental 
questions regarding this emerging posttranslational modification (PTM) still remain 
unanswered. It is difficult to convince the scientific community that upon generation of 
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this small highly reactive molecule, 
•
NO selectively modifies a specific cysteine residue. 
The mechanism by which 
•
NO can modify cysteines is still unclear. For other more 
characterized PTMs such as acetylation (which is of comparable relative size to 
•
NO), 
specific enzymes are necessary to catalyze its reaction with its target protein. Therefore, 
with the unequivocal identification of such enzyme(s) for S-nitrosylation, it is difficult to 
ascertain how specificity is achieved. Answers to these pressing questions will expand 
our understanding of S-nitrosylation and offer insight as to how to better regulate this 
emerging posttranslational modification.  
1.2 Nitric oxide 
1.2.1 Chemical properties of nitric oxide  
Nitric oxide (also known as nitrogen monoxide) is a colorless, diatomic gas 
composed of one nitrogen atom and one oxygen atom. It was first described as “nitrous 
air” in 1774 by Joseph Priestley in his book titled Experiments and Observations on 
Different Kinds of Air, Vol. 1. An uncharged free radical, nitric oxide has one unpaired 
electron. With an oil/water partition coefficient ~6.5 (Kow measured at 37°C) and a low 
solubility in water, 
•
NO is capable of easily diffusing through hydrophobic environments 
such as cell membranes (Balbatum et al. 2003). In aqueous solutions, nitric oxide reacts 
primarily with oxygen and its half-life is proportional to its concentration.  
The half-life of 
•
NO can be altered by its interactions with different targets. Nitric 
oxide can react with a wide range of molecules to form end products with various 
functions. Upon its reaction with molecular oxygen (O2), nitric oxide is oxidized to form 
relative stable metabolites nitrite (NO2
-
) and nitrate (NO3
-
). Nitric oxide can also react 
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with free radicals such as superoxide (O2
-•
) to generate the strong oxidant peroxynitrite 
(ONOO
-
). This reaction has been observed to be near diffusion limited suggesting that it 
is only restricted by the ability of the molecules to come into contact with one another 
(Beckman et al. 1990; Koppenol, et al. 2001). The interaction of nitric oxide with lipid-
derived radicals has also been characterized as being a diffusion-limited reaction 
(O’Donnell et al. 1997). •NO has been most classically described by its coordination to 
transition metals such as copper or iron to form M-NO (Wink et al. 1994; Wade & Castro 
1990).  
In general, the chemical reactivity of 
•
NO is contingent upon its surrounding 
environment. Therefore, when attempting to understand the role of nitric oxide in 
biological processes, it is important to know when and where it is produced within the 
body.  
1.2.2 Biological synthesis of nitric oxide  
 
In 1916, Mitchell, Shonle, and Grindley first noticed that the amount of nitrates 
and nitrites excreted through urine from healthy subjects was more than the amount that 
could be ingested from the diet (Mitchell, et al. 1916). Using 
15
N-labelled nitrate (
15
NO3
-
), Tannenbaum et al. monitored nitrate metabolism and quantified an excess of excreted 
nitrates in human urine compared to dietary intake, supporting this 65-year old 
observation (Tannenbaum, et al. 1978; Green et al. 1981, PNAS). These experiments 
allowed them to conclude that an endogenous metabolic process was responsible for 
forming nitrogen oxides. Over the following decade, an elegant series of experiments 
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across different research groups biochemically characterized this mechanism and its 
necessary components (Stuehr & Marletta 1985; Hibbs et al. 1987; Iyengar et al. 1987; 
Marletta et al. 1988). It was discovered that the radical nitric oxide is an endogenously 
synthesized intermediate generated during the process of nitrite and nitrate formation 
(Ignarro et al. 1987a; Ignarro et al. 1987b; Palmer et al. 1987; Palmer et al. 1988).  
•
NO is synthesized from L-arginine and oxygen by the enzyme nitric oxide 
synthase (NOS) (Moncada & Higgs, 1993). Nitric oxide synthases are 150 kiloDaltons 
and composed of a homodimer containing an oxygenase domain and a reductase domain 
that are linked by a calmodulin recognition site. The oxygenase domain contains binding 
sites for the cofactors tetrahydrobiopterin (BH4), protoporphyrin IX haem, and L-arginine 
while the reductase domain contains binding sites for the electron carriers FAD & FMN, 
and the reductant NADPH (Ghosh & Stuehr 1995). In summary, electrons supplied by 
NADPH are shuttled across the reductase domain by FAD and FMN to the heme iron of 
the oxygenase domain where they can oxidize L-arginine. A guanidino nitrogen of L-
arginine undergoes a 5-electron oxidation via two mono-oxygenation steps to form 
•
NO 
and L-citrulline (Marletta et al. 1993; White & Marletta et al. 1992; Mayer et al. 1991; 
Bredt & Snyder 1990; Bredt et al. 1991). Binding of calmodulin is required for the flow 
of electrons from the reductase domain to the oxygenase domain.  
Three nitric oxide synthase isoforms exist: neuronal nitric oxide synthase (nNOS; 
NOS1), inducible nitric oxide synthase (iNOS; NOS2), and endothelial nitric oxide 
synthase (eNOS; NOS3). They differ in their regulation, quantity, and location of 
•
NO 
production. Neuronal NOS was the first isoform to be purified and cloned (Bredt & 
Snyder 1990) using extracts from rat cerebellum (Bredt et al. 1991). It is expressed in the 
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brain and skeletal muscle (Salter et al. 1991; Nakane et al. 1993). Endothelial NOS is 
found in endothelial cells, cardiac myocytes, neurons, and epithelial cells. Typical output 
from eNOS and nNOS is in the nM range.  iNOS produces a large burst of 
•
NO in 
response to cytokines and endotoxins across a variety of cell types including neutrophils, 
epithelial cells, vascular smooth muscle, hepatocytes and chondrocytes (Xie et al. 1992; 
Lincoln et al. 1997). nNOS and eNOS differ from iNOS in their dependency upon 
calcium (Ca
2+
) to produce synthesize 
•
NO (Cho et al. 1992;Garcin et al. 2004; Dudzinski 
et al. 2007; Venema et al. 1996). The efficiency of calmodulin binding for nNOS and 
eNOS is mediated by intracellular calcium levels whereas calmodulin is already tightly 
bound to iNOS.   
The presence of so many cofactors suggests that nitric oxide synthases are very 
highly regulated. Lack of the cofactor BH4 can cause the uncoupling of the eNOS dimer 
leading to production of superoxide (Chen et al. 2011). NOSs have also been shown to be 
regulated by posttranslational modifications. S-Glutathionylation can also uncouple the 
eNOS dimer serving as an autoregulatory mechanism for 
•
NO production (Chen et al. 
2010). S-nitrosylation of iNOS has also been shown to destabilize the dimer (Rosenfeld 
et al. 2010).  
1.2.3 Nitric oxide in health and disease 
 
Nitric oxide has long played an important role in human health and disease, even 
when it had not yet been identified as the culprit (Butler et al. 2006). As with most great 
scientific discoveries, it all began with an observation. An English surgeon noticed that 
when he had a patient suffering from severe chest pain, he could alleviate the symptoms 
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by removing blood (Butler et al. 2006). This suggested to him that the remedy for angina 
pectoris was somehow related to lowering blood pressure. The surgeon’s friend told him 
of how inhaling amyl nitrite helped to lower the blood pressure of his animals and so the 
surgeon commenced in using this therapeutic remedy for those suffering from chest pain 
(Gamgee et al. 1868; Brunton et al. 1867). Nitroglycerin which contained a nitro group (-
NO2) was also used as a vasodilator over the next century. It would be many years later 
before a series of experiments conducted by Moncada, Furchgott, Ignarro & Murad 
revealed the identity of nitric oxide as the true vasodilator. This Nobel Prize winning 
discovery will be discussed in the following section. 
Nitric oxide has been classically identified as having a role in the body’s innate 
immune response and neurotransmission. As was previously described, macrophages 
were instrumental in revealing the endogenous production of nitric oxide (Hibbs et al. 
1987; Stuehr et al. 1989; Marletta et al. 1988; Hibbs, et al. 1989). In response to certain 
stimuli, iNOS can produce a burst of the 
•
NO which targets invading pathogens and 
participates in anti-tumor activities through a variety of mechanisms. Mice lacking the 
gene for iNOS are much more susceptible to parasitic infection and replication of bacteria 
(Wei et al. 1991; MacMicking et al. 1995). 
•
NO has been shown to impair mitochondrial 
function by disrupting iron-sulfur centers within oxidoreductases as well as altering 
mitochondrial membrane potential (Kroncke et al. 1995; Hibbs et al. 1987; Stuehr et al. 
1989). 
•
NO can also react with non-heme iron, resulting in Fe release which might also 
promote lipid peroxidation and serve as an additional mechanism of cellular damage 
(Reif et al. 1990).  
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While all three isoforms of NOS are found throughout the brain, nitric oxide 
produced from neuronal NOS has been the best characterized within the central nervous 
system. A few of its important roles involve neuroprotection, neurotoxicity, and synaptic 
plasticity. Glutamate binds to the NMDA-receptor which allows calcium (Ca
2+
) entry into 
the neurons thereby activating NOS. Once it is produced, 
•
NO acts as a retrograde 
messenger to strengthen synaptic activity. It has been postulated that this function of 
nitric oxide is important during long term potentiation (LTP), an important process 
underlying learning and memory in the brain.  
Nitric oxide can also serve a neuroprotective function by regulating its own 
production. Disulfide bridge formation in the NMDA-receptor channel has been 
previously shown to decrease the influx of Ca
2+
 through the channel (Lei et al. 1992). 
Nitric oxide can modify these same two cysteines and help promote the formation of this 
disulfide bridge (Lipton, Singel, & Stamler, 1994; Lipton & Stamler, 1994). In addition, 
•
NO can also inhibit the binding of glutamate to the NMDA receptor, preventing the flow 
of Ca
2+
 through the channel and regulate NO synthesis.  
When observing the presence of 
•
NO throughout the central nervous system, 
peripheral nervous system, and immune system, it is easy to imagine how its dysfunction 
might lead to disease. Dysregulation of nitric oxide has been implicated in ischemia 
(Mugge et al. 1991; Harrison et al. 1992; Maseri et al. 1991), atherosclerosis (Rubanyi et 
al. 1993), septic shock (Thiemermann et al. 1993; Petros et al. 1991), pre-eclampsia 
(Buhimschi et al. 1998) and many others disorders.  
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Nitric oxide has also been used as a therapeutic agent as it has been found to play 
an important role in wound healing (Frank et al. 2002; Shi et al. 2000) and protection 
after ischemic injury (Lima et al. 2009). In fact, researchers Jonathan Stamler and Joseph 
Bonaventura hold a United States patent for “Red blood cells loaded with S-nitrosothiol 
and its uses”. As the patent abstract states, “loaded red blood cells can be used in methods 
of therapy for conditions which are characterized by abnormal O2 metabolism of tissues, 
oxygen-related toxicity, abnormal vascular tone, abnormal red blood cell adhesion, or 
abnormal O2 delivery by red blood cells.” United States Patent #6153186 
(http://www.wikipatents.com/US-Patent-6153186/red-blood-cells-loaded-with-s-
nitrosothiol-and-uses-therefor). Direct inhalation of nitric oxide has been used to treat 
preterm infants with bronchopulmonary dysplasia (Kinsella, et al. 2007). As researchers 
continue to identify the role of nitric oxide in human physiology, it is even more pressing 
to identify the mechanisms by which nitric oxide may exert its function and how these 
functions are regulated.  
1.2.4 Nitric oxide as a signaling molecule  
 
Although nitrovasodilators such as nitroglycerin were known to alleviate the 
symptoms of pectoris angina since 1867, their mechanism of action was not fully 
elucidated until over 120 years later. The discovery of nitric oxide as an endogenous 
vasodilator came from a series of elegantly designed experiments across multiple 
laboratories. In 1977 & 1978, the Murad laboratory demonstrated that both gaseous 
•
NO 
and 
•
NO released from different nitrovasodilators could activate guanylate cyclase, 
converting GTP to cyclic GMP (Katsuki et al. 1977; Arnold et al. 1977; Schultz & 
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Schultz, 1977). It was also noted that this effect was inhibited by hemoglobin and 
myoglobin (Murad, et al. 1978). Shortly thereafter, the Ignarro laboratory reported that 
activation of guanylate cyclase by 
•
NO resulted in smooth muscle relaxation (Gruetter, et 
al. 1979); however, it was still unknown that 
•
NO existed endogenously.  
The Furchgott Laboratory monitored the response of the aorta to the cholinergic 
agonist carbachol using a protocol which required the isolation of aortic rings; however, 
when a new technician prepared helical strips of the aorta instead of rings, he found that 
he could no longer induce smooth muscle relaxation. This finding highlighted two 
important discoveries: 1) an intact endothelium was necessary for smooth muscle 
relaxation and 2) acetylcholine must bind to receptors on the surface of the endothelium 
to produce the molecule responsible for smooth muscle relaxation (Furchgott et al. 1980). 
This yet identified molecule was later termed “endothelium-derived relaxation factor” 
(EDRF).  
While both Furchgott and Ignarro independently speculated that EDRF was in 
fact 
•
NO, it still remained inconclusive (Moncada et al. 1988).  Once concurrent research 
identified the endogenous synthesis of nitrites and nitrates (Ignarro, et al. 1981; Iyengar, 
et al. 1987), this speculation immediately became more concrete. A series of experiments 
by Moncada and Ignarro finally revealed that EDRF was nitric oxide (Ignarro, et al. 
1987; Ignarro, et al. 1987; Palmer et al. 1987) and it was synthesized from terminal 
guanidine nitrogen of L-arginine in vascular endothelial cells (Palmer et al. 1988).  
In 1998, Furchgott, Ignarro, and Murad were awarded the Nobel Prize in 
Medicine and Physiology for their combined contributions in elucidating the role of nitric 
oxide in vasodilation. The press release accompanying the award made mention of nitric 
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oxide as a “signaling molecule”. This newly identified role for nitric oxide was clinched 
with the key discovery that eNOS produced 
•
NO within endothelial cells. Previous work 
had shown that nitric oxide was produced in response to a stimulus, specifically targeted 
to the heme of soluble guanylate cyclase, and necessary for a specific physiological 
response, i.e. dephosphorylation of myosin light chain resulting in vasodilation. This new 
discovery added that nitric oxide was spatially restricted after its production by eNOS. 
This series of events became the canonically described cGMP-dependent pathway 
whereby which nitric oxide can act as a second messenger and induce a physiological 
response.  
1.3 S-nitrosylation as an emerging posttranslational 
modification 
Once it was determined that nitric oxide bound to the heme of soluble guanylate 
cyclase, it still remained unclear how 
•
NO stably diffused from nitric oxide synthase to its 
target sGC. As was previously described, 
•
NO can react with a variety of intracellular 
targets. Nitric oxide derived species are known to react with sulfhydryls and form more 
stable adducts of S-nitrosothiols (Oae, et al. 1983). Stamler et al. hypothesized that 
•
NO 
could prolong its half-life and deliver 
•
NO to targets such as sGC by reacting with 
reduced thiols on protein cysteine residues (Stamler, et al. 1992). By using both 
endogenous and exogenous sources of 
•
NO, they found that several proteins could form 
S-nitroso adducts, including serum albumin. A series of later experiments by this same 
group detected S-nitrosylated serum album circulating in human plasma, suggesting that 
S-nitrosylated proteins could serve as endogenous intermediates for 
•
NO delivery 
(Stamler et al. 1992).  
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 In 1996, the Stamler group identified an S-nitrosylated cysteine residue on the 
Beta chain of hemoglobin (Cysβ93) (Jia, et al. 1996). Upon oxygenation of hemoglobin, 
Cysβ93 was S-nitrosylated (SNO-Hb) in the lung resulting in release of nitric oxide and 
delivery of O2 to peripheral tissues through circulation. This suggested that SNO-Hb may 
be involved in the normal regulation of blood flow and maintenance of blood pressure. 
The role of 
•
NO in vasodilation was thought to be a very well characterized mechanism. 
Therefore, the identification of a new role for nitric oxide in vasodilation was a bit 
shocking, especially since it involved a new role for an enzyme which had also been 
heavily scrutinized for decades previously.  
Even with the discovery of functional consequences of S-nitrosylation, there are 
still large deficits in our understanding and validation that it is a newly identified means 
of nitric oxide signaling within the body. The mechanism by which S-nitrosylation occurs 
has not conclusively been identified. Additionally, how specificity is derived still remains 
unclear. The following sections discuss how recent advances in the identification of S-
nitrosylated proteins have increased our knowledge of this emerging posttranslational 
modification.  
1.3.1 Methods for identification of S-nitrosylated cysteines  
 
The crux to categorizing any emerging posttranslational modification is to 
identify its targets. With recent advances in technology, the development of techniques 
for detecting S-nitrosylated proteins has exponentially enhanced our understanding of S-
nitrosylation and helped to elucidate its ubiquitous role in nitric oxide signaling. Proof of 
an S-nitrosylation event initially began using spectroscopic techniques to identify S-
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Nitroso bovine serum albumin (Stamler et al. 1992). Stamler et al. utilized UV-Visible 
spectroscopy and NMR spectroscopy to show that 
•
NO was bound to the protein. To 
quantify the amount of SNO present, they developed an assay which lysed the S–NO 
bond resulting in liberated 
•
NO which could be detected via chemiluminescence after its 
reaction with ozone (Stamler et al. 1992; Stamler & Feelisch, 1996). Utilizing Saville 
chemistry, mercury (II) chloride (HgCl2) was also used to remove nitric oxide for the 
purposes of quantification (Saville et al. 1958; Xu et al. 1998; Mannick et al. 1999). In 
the case of hemoglobin, a very well characterized protein, UV-Vis spectroscopy proved 
extremely informative in proving that nitric oxide was bound to a thiol and not the heme 
(Jia et al. 1996). However, it required its isolation, thereby mandating previous 
knowledge of its identity. Therefore, initial identifications of S-nitrosylated proteins did 
not allow for a priori hypotheses regarding their existence or identification.  
In 2001, Jaffrey et al. published the first method which globally identified S-
nitrosylated proteins contained within complex mixtures such as tissues (Jaffrey et al. 
2001). The biotin switch technique (BST) consisted of three main steps: 1) the blocking 
of reduced thiols with methyl methanethiosulfonate (MMTS), 2) reduction of S-
nitrosylated cysteine residues using ascorbate, and 3) biotinylation of previously S-
nitrosylated cysteine residues with N-[6-(biotinamido)hexyl]-3’-(2’-
pyridyldithio)propionamide (biotin–HPDP). Because MMTS is a thiol-specific agent, 
ascorbate selectively decomposes nitrosothiols, and biotin-HPDP is a sulfhydryl-specific 
agent, the method allows for the specific labeling of S-nitrosylated cysteine residues. 
Biotinylated proteins were purified using avidin, then separated and resolved using SDS-
PAGE. Known proteins can be probed with the corresponding antibody or individual 
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bands can be excised and identified by mass spectrometric analysis. While the BST was 
the first tool of its kind, concerns still exist regarding its efficiency to identify S-
nitrosylated proteins. The reduction of S-nitrosothiols by ascorbate has been called into 
question due to its poor sensitivity and its ability to reduce disulfide bonds (Zhang, et al. 
2005; Giustarini et al. 2008). Moreover, a key objective for identifying scores of S-
nitrosylated proteins is to reveal the specificity of cysteines endogenously targeted for 
this modification. However, this is impossible to do when identifying the protein without 
the specific site of modification. Two papers were published in 2006 which offered 
proteomic techniques for identifying sites of S-nitrosylation in complex mixtures (Hao et 
al. 2006; Greco et al. 2006). Briefly, the two comparable methods introduced a 
trypsinization step before biotinylation which allowed for enrichment of peptides 
containing modified cysteines.  
 Since the development of the BST in 2001, there have been many derivatives 
aimed at improving its deficiencies (Sun et al. 2007; Kettenhofen et al. 2008,; Sinha et al. 
2010) and development of other promising techniques which directly label and detect S-
nitrosocysteine (Torta et al. 2010; Wang et al. 2008; Faccenda et al. 2010; Zhang et al. 
2010). More recently, Benhar et al. developed a quantitative BST method using stable 
isotope labeling by amino acids in cell culture (SILAC) (Benhar et al. 2010). The authors 
employed their technique to characterize the denitrosylation of SNO-cysteines by 
thioredoxin in Jurkat cells. While the above described methods point toward significant 
advances in the field of S-nitrosylation, detection of S-nitrosylated proteins is often still 
dependent upon supplementation by exogenous sources of nitric oxide. An optimal 
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method would be sensitive enough to detect and accurately quantify endogenous S-
nitrosylation events.  
1.3.2 Alteration of protein activity as a function of S-
nitrosylation 
With the advent of the Biotin Switch Technique and its derivatives, many more 
proteins have been identified as S-nitrosylated. For many researchers, S-nitrosylation has 
provided the missing link between observing a role of nitric oxide in human physiology 
and pinpointing its specific mechanism of action. A comprehensive discussion of all such 
proteins would prove to be impossible within the limits of this dissertation; therefore, 
several key studies are highlighted which demonstrate how S-nitrosylation can alter a 
wide range of protein functions and further extend the role of nitric oxide in human 
health and disease.   
Nitric oxide has long been known to play an important role in neurophysiology. In 
2004, the Lipton group identified a role for S-nitrosylation in sporadic Parkinson’s 
disease (Yao et al. 2004). S-nitrosylation of the E3 ubiquitin ligase parkin in SH-SY5Y 
cells led to an increase in its activity and ultimately resulted in its own ubiquitination. 
Inhibition of parkin can result in a decreased clearance of its substrates and ultimately 
lead to cell death. This fact is made even more apparent by the detection of S-nitrosylated 
parkin in human brains of those with sporadic Parkinson’s disease. Later studies 
involving the S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
led to an additional role of nitric oxide in regulating E3 ubiquitin ligase activity. It has 
been well established that GAPDH translocates to the nucleus during apoptosis (Sawa, et 
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al. 1997; Ishitani, et al. 1998; Dastoor, et al. 2001). Because GAPDH lacks a nuclear 
localization signal, how GAPDH is able to enter the nucleus has remained a mystery. In 
2005, Hara et al. showed that nitric oxide S-nitrosylates GAPDH thereby increasing its 
ability to bind to the E3 ubiquitin ligase Siah1, and induces translocation of the complex 
into the nucleus (Hara et al. 2005). Once inside, GAPDH promotes the stabilization of 
Siah1, allowing for it to carry out its role in apoptosis. This discovery propelled a myriad 
of studies which continue to identify how this mechanism is regulated (Sen, et al. 2008; 
Sen, et al. 2009; Kornberg, et al. 2010).  
In addition to regulating the activity of ubiquitin ligases, S-nitrosylation has also 
been shown to modulate other posttranslational modifications such as phosphorylation. 
Previous reports have shown that nitric oxide can negatively regulate the signaling 
cascade of c-Jun N-terminal kinases also known as JNKs (Park et al. 1996; Lo, et al. 
1996; Kim et al. 1997; Wang et al. 1998; Lander et al. 1996; Jun et al. 1999). As a 
member of the mitogen activated protein (MAP) kinase family, JNKs are important in the 
cellular response to different stresses. They are activated through phosphorylation by 
MAP kinases MKK4 and MMK7 and typically inactivated by phosphatases (Ip, et al. 
1998). Park et al. demonstrated that endogenous production of 
•
NO by activation of iNOS 
resulted in suppression of JNK activity in microglia and macrophages (Park et al. 2000). 
Using a series of experiments, the authors showed that JNK activity was attenuated by 
nitric oxide, more specifically, by a cGMP-independent chemical modification of Cys116 
which they identified as S-nitrosylation. Conversely, S-nitrosylation has also been shown 
to enhance the activity of other kinases. Rahman et al. presented an investigation into 
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tyrosine kinase c-Src and found that S-nitrosylation of Cys498 resulted in its activation 
and ultimately its invasion into cancer cells (Rahman, et al. 2010).  
S-nitrosylation has also been shown to play a role in the regulation of DNA 
transcription. NF-κB is a transcription factor thought to regulate over 200 genes which 
are involved in the inflammatory response (Marshall, et al. 2000; Shishodia, et al. 2004; 
Xie, et al. 1994). It is activated by its release from inhibitory proteins within the 
cytoplasm and translocation to the nucleus. IκB kinase (IKK) is one of the proteins 
responsible for inducing the degradation of these inhibitory proteins thereby activating 
NF-κB. Reynaert et al. demonstrated that S-nitrosylation of Cys179 in IKK inhibited its 
activity resulting in prolonged inactivation of NF-κB (Reynaert et al. 2004). By inhibiting 
endogenous production of 
•
NO in Jurkat cells, the authors were able to again activate 
IKK. Interestingly, additional evidence has also shown that NF-κB itself is S-nitrosylated, 
offering an additional mechanism for by which 
•
NO can regulate its transcriptional 
activity (Matthews, et al. 1996; delaTorre, et al. 1997).  
Major classes of proteins have been found to be S-nitrosylated. Coupled with the 
discovery of S-nitrosylation across different types of cells and tissues (Gow et al., 2002), 
this underscores the widespread effects that nitric oxide can have across different 
biological processes. Nevertheless, it is important to acknowledge that identifying a 
protein as being susceptible to S-nitrosylation does not prove that it is endogenously S-
nitrosylated. Lack of sensitive detection technologies often mandate that proteins are 
frequently supplemented with exogenous sources of nitric oxide to aid in their 
identification. Exogenous donors can vary greatly in the nitric oxide moiety that is 
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produced. And as is described in the following sections, the chemistry of a nitric oxide 
moiety may influence which cysteines are actually targeted.  
1.3.3 Proposed mechanisms of S-nitrosylation formation 
Perusing the literature on S-nitrosylation may leave the reader slightly confused 
due to the assorted terminology. Several key terms are used to describe this newly 
emerging protein modification by nitric oxide. The difference in their definitions stems 
from the proposed mechanism by which 
•
NO modifies cysteine residues to form S-
nitrosocysteine (Protein-Cys-NO). The most commonly used term is “S-nitrosylation”. 
This historically describes the reaction of a nitric oxide radical with a transition metal 
(“nitrosylation”) to form a product which then reacts with a protein cysteine thiol (“S-
nitrosylation”) (Stamler, et al. 1992). Another term very commonly used is “nitrosation” 
or “transnitrosation”. This term traditionally refers to the addition or transfer of a 
nitrosonium ion (NO
+
) to a thiolate anion (SH
-) whereas “trans-S-nitrosation” specifies 
the transfer to a protein cysteine residue. “S-nitrosylation” is now more routinely used to 
encompass any reaction resulting in the addition of a nitric oxide moiety to a protein 
cysteine thiol.  
There are several proposed mechanisms which can result in the formation of 
protein S-nitrosocysteine. The first mechanism describes the direct reaction of an NO 
radical with a transition metal. 
•
NO can react with a metal at a heme center such as Fe
3+
 
to form Fe
2+
 and NO
+
 (Pacher et al. 2007). The nitrosonium ion is then capable of 
reacting with the reduced thiol of nearby cysteine residues (Wade & Castro 1990). An 
additional metal-catalyzed mechanism hypothesizes that proteins can react with free 
18 
 
pools of iron in the cell to form dinitrosyliron complexes which can S-nitrosylate cysteine 
residues (Bosworth et al. 2009; Boese et al. 1995).  
Additional mechanisms for forming S-nitrosocysteine involve the transfer of a 
nitrosonium ion to a reduced thiol of a cysteine residue. It has been proposed that S-
nitrosoglutathione (GSNO), a major endogenous S-nitrosothiol, is involved in the 
transnitrosation of protein cysteine. Although it can be synthesized within the laboratory 
using sodium nitrite and GSH in an acidic environment, the mechanism by which GSNO 
forms endogenously still remains unclear (Zhang et al. 2004; Keszler et al. 2009; Gow et 
al. 1997; Tullett et al. 2001). It is also possible for S-nitrocysteine residues within 
proteins to then react with the reduced thiols of GSH or other protein cysteine residues 
and transfer a nitrosonium ion. This is what is referred to as a “protein-assisted” 
transnitrosation. This mechanism was observed with the protein thioredoxin (Mitchell et 
al. 2005). After its own reaction with GSNO, SNO-thioredoxin (SNO-Trx) can 
transnitrosate a select cysteine residue in the enzyme caspase-3. Experiments conducted 
by the Marletta group illustrate that SNO-Trx and not GSNO is the favored mechanism 
by which this specific cysteine forms S-nitrosocysteine (Mitchell et al. 2007).  
The last proposed mechanism of S-nitrosation involves the autoxidation of 
•
NO to 
form higher oxides that serve as transnitrosating agents. Due to its lipophilic character, 
•
NO is known to favor hydrophobic environments (Moller et al. 2007). Therefore, 
•
NO 
can congregate in hydrophobic regions of the protein where it can also react with O2 and 
nitrogen dioxide to form the transnitrosating agent dinitrogen trioxide N2O3 (Nedospasov 
et al. 2000; Gow et al. 1997; Liu et al. 1998; Moller, et al. 2007).   
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There is a diversity of mechanisms which ultimately result in the formation of 
protein-SNO, each of which is dependent upon the chemical structure of nitric oxide. 
Therefore, being able to identify the chemical species of nitric oxide may help to pinpoint 
which mechanism is occurring and may contribute to our understanding of the specificity 
of this posttranslational modification. 
1.3.4 Denitrosylation: Reversing the signal 
To convincingly describe S-nitrosylation as a signaling mechanism of nitric 
oxide, it is essential to show the reversibility of the modification. There are two major 
endogenous systems which have been identified to influence the stability of S-
nitrosocysteine: the GSH/S-nitosoglutathione/S-nitrosoglutathione reductase system and 
the thioredoxin/thioredoxin reductase system. Thioredoxin (Trx) is directly involved in 
an enzyme-mediated mechanism of denitrosylation whereas the glutathione system 
indirectly mediates S-nitrosylation through metabolism of GSNO by the enzyme S-
nitrosoglutathione reductase (GSNOR). 
In addition to its roles as both a reductant and transnitrosating agent (Mitchell et 
al. 2005; Mitchell et al. 2007), thioredoxin has also been shown to serve as a 
denitrosylating enzyme. Nikitovic and Holmgren first demonstrated an indirect role for 
the thioredoxin system through its metabolism of the low molecular weight thiol GSNO 
(Nikitovic et al. 1996). Stoyanovsky and colleagues further demonstrated that the Trx 
system was also capable of denitrosating protein-SNO (Sengupta, et al. 2007). The 
proposed mechanism involves active site cysteines 32 and 35 (Sengupta, et al. 2007). 
Because of its increased nucleophilicity, Cys32 is thought to be the target of NO. Cys32 
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and Cys35 then form a disulfide bond allowing NO to then be transferred 
intramolecularly to the other cysteine residues (Cys62, Cys69, & Cys72) which have 
previously been shown to be S-nitrosylated. For protein denitrosation, the work of 
Mitchell & Marletta with caspase-3 may provide insight as to how thioredoxin might 
interact with target proteins (Mitchell et al. 2007). E70A/K72A mutations in hTrx 
resulted in some loss of contact, suggesting that these charged residues may help 
facilitate protein-protein interactions between the denitrosating agent and its targets. 
Proteomic studies have also been used to identify proteins which might be potential 
denitrosylation targets of thioredoxin (Benhar et al. 2010). Using a model which 
overexpressed Trx, recent work done by Fu et al. identified 55 putative protein targets of 
thioredoxin in the mouse heart (Fu et al. 2009). Interestingly, previous reports have 
identified several of these proteins as being targets of S-nitrosylation.  
The thioredoxin system can be regulated through a variety of mechanisms. 
Stamler and colleagues first demonstrated that caspase-3 activation was tightly tethered 
to its denitrosylation upon induction of the Fas apoptotic pathway (Mannick et al. 1999). 
Nearly 10 years later, they were able to show that denitrosylation of caspase-3 was 
carried out by mitochondrial thioredoxins (Benhar et al. 2008), suggesting a stimulus-
coupled regulatory mechanism. Recently, Forrester and colleagues have identified 
Thioredoxin-interacting protein (Txnip), a protein which can also regulate the 
denitrosation activities of thioredoxin (Forrester et al. 2009). And most obviously, 
thioredoxin requires the presence of NADPH and thioredoxin reductase to control the 
redox state of its catalytic cysteines. 
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Glutathione has long been known for its essential antioxidant properties in the 
cell. Although the specific in vivo mechanism remains elusive, GSH can react with a 
nitric oxide moiety to form the transnitrosating agent GSNO (Zhang et al. 2005; Gow et 
al. 1997). Once it was determined that GSNO readily forms S-nitrosocysteine 
endogenously, understanding how this process was regulated became of great 
importance. In 2001, Liu et al. identified GSNO reductase (GSNOR), an endogenous 
enzyme which could regulate the intracellular levels of GSNO (Liu et al. 2001). GSNOR 
is an endogenous alcohol dehydrogenase (Class III) which can oxidize an alcohol to a 
ketone or aldehyde. Previous investigations showed that it was highly specific for GSNO 
(Jensen et al. 1998). GSNOR regulates the availability of GSNO by converting it to 
oxidized glutathione (GSSG) in the presence of NADPH. The Stamler group generated 
knockouts of this enzyme showing increased levels of SNO-hemoglobin as compared to 
wildtype (Liu et al. 2004). This suggests that the equilibrium that exists between GSNO 
and protein-SNO is disrupted upon removal of GSNOR.     
Glutathione itself is also capable of denitrosating protein-cysteine residues 
(Romero et al. 2009; Paige et al. 2008). Denitrosation of proteins by GSH was 
investigated using a quantitative proteomic method which monitored the stability of S-
nitrosylated cysteine residues (Paige et al. 2008). The authors revealed a subset of 
proteins that were insensitive to denitrosation via GSH and even remained modified after 
synthesis of 
•
NO was inhibited. Additional experiments with the reductant DTT also 
revealed no decrease in S-nitrosylation. Only after the proteins were denatured were they 
able to remove SNO. This suggested that conformational changes within the protein may 
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take place to prevent denitrosation from occurring, thereby increasing the longevity of S-
nitrosocysteine.   
Investigations continue into identifying additional proteins which might serve as 
denitrosating agents or aid in the process of regulating denitrosylation events. To date 
studies have shown that other enzymes including protein disulfide isomerase (Sliskovic et 
al. 2005), xanthine oxidase (Trujillo et al. 1998), superoxide dismutase (Jourd’heuil et al. 
1999; Johnson et al. 2001), and glutathione peroxidase (Hou et al. 1996) may play a role 
in the metabolism of S-nitrosothiols.   
1.4 Specificity of cysteines targeted for S-nitrosylation  
A large gap in knowledge exists regarding the specificity of endogenous S-
nitrosylation. While it has been well documented that not all proteins are S-nitrosylated 
and more specifically, not all cysteine residues within an S-nitrosylated protein are 
modified, it is very important to determine how this specificity is derived. The best 
example for illustrating this phenomenon is the skeletal muscle Ca
2+
 release 
channel/ryanodine receptor 1 (RYR1) protein (Sun et al. 2001). With a total of 50 
cysteines per subunit, only a single cysteine, Cys3635, has been identified as being S-
nitrosylated (Sun et al. 2003). 
1.4.1 Cysteine reactivity 
 
Although cysteine residues are not the most frequently occurring amino acids, 
they are among one of the most conserved (Fomenko et al. 2008). Cysteine residues are 
most notably known for their role in maintaining protein structure by forming disulfide 
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bonds. However, with a nucleophilic sulfhydryl side chain and a pKa of 8.3, cysteines are 
highly reactive under physiological conditions. Not only are they susceptible to 
oxidation, but they can be coordinated to metals, serve as catalytic sites, or sites of 
posttranslational modification. Many investigations have been aimed at predicting the 
propensity of cysteines to undergo different chemical modifications (Fomenko et al. 
2007). Marino et al. utilized the structures of oxidoreductases and the biophysical 
properties of their catalytic cysteines to predict similarly reactive cysteine residues 
(Marino et al. 2009). They developed an algorithm which took into account the primary 
and secondary structures, cysteine accessibility, and reactivity. This algorithm was then 
applied to a test set of proteins as well as the entire Saccharomyces cerevisiae proteome. 
Their results correctly identified all thiol oxidoreductases in the test set and identified 42 
proteins in the S. cerevisiae proteome, 33 of which were known oxidoreductases. This 
suggests that the reactivity of cysteines to undergo a specific chemical modification can 
be deciphered from its surrounding environment. This was also seen in global 
investigations into disulfide bridge formation (Petersen et al. 1999). In addition, 
identifying the specificity of cysteines which undergo S-glutathionylation has long been a 
subject of interest (Thomas et al. 1995; Giustarini et al. 2005; Tao et al. 2004).  
1.4.2 S-nitrosylation and the cysteine microenvironment 
A study conducted by Marino and Gladyshev was the first comprehensive 
interrogation into the specificity of S-nitrosylation (Marino & Gladyshev 2010). Using a 
dataset of S-nitrosylated cysteines (and a randomly chosen set of Cys residues) curated 
from the literature, the authors investigated their structural and biophysical properties in 
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an attempt to uncover any attributes specific to S-nitrosylation. As was described 
previously, a potential mechanism of S-nitrosylation is the autoxidation of 
•
NO which is 
favored in hydrophobic environments (Liu et al. 1998; Nedaspov et al. 2000; Moller et al. 
2007); therefore, cysteines targeted for S-nitrosylation via this mechanism would likely 
be present in hydrophobic regions of a protein. Hydrophobic SNO-cysteines were 
observed in several proteins including the ryanodine receptor and argininosuccinate 
synthetase (Hao et al. 2004; Sun et al. 2001). Using both the flanking amino acid 
sequence and an 8 Angstrom radius, Kyte-Doolittle hydropathy indices were calculated 
for each SNO-Cys and random Cys. Both approaches revealed no significant difference 
between modified and random cysteines, suggesting that hydropathy was not a major 
determinant.  
Based upon an observation of SNO-Cys93β in hemoglobin, Stamler et al. 
hypothesized that the presence of charged residues flanking a cysteine residue may 
regulate its nucleophilicity and ultimately target it for S-nitrosylation (Stamler et al. 
1997). Using these data, the authors derived a linear consensus motif of 
(H,K,R)(C)(hydrophobic)X(D, E) where X can be any amino acid (Stamler et al. 1997). 
Perez-Mato et al. later proposed that pairs of charged residues could also play a role in 
navigating GSNO-mediated mechanisms of transnitrosation (Perez-Mato et al. 1999). 
Many individual S-nitrosylated proteins have since been identified as containing either a 
linear or structural acid/base motif within a 6 Å radius (Choi et al 2000; Kim et al. 2002). 
Several studies have attempted proteomic investigations into the occurrence of this 
acid/base motif, but were limited in their findings due to low numbers (Greco et al. 2006; 
Hao et al. 2006). Marino et al. found that a more distant motif existed with surface 
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exposed charged residues which were thought to help stabilize GSNO and/or facilitate 
protein-protein interactions necessary for transnitrosation.   
Surface exposure has also been used to evaluate the ability of cysteines to be S-
nitrosylated. With several proposed S-nitrosylation mechanisms, the size of the S-
nitrosylating or transnitrosating agent would undoubtedly influence its accessibility to 
different cysteines within the protein. A high-resolution structure of tubulin illustrated 
this fact when only one of the four cysteines modified endogenously was found to be 
surface exposed; however, upon supplementation with GSNO, four additional cysteine 
residues were modified (Nogales et al. 1999; Roychowdhury et al. 2000; Kim et al. 
2004). Knipp et al. demonstrated that Cys221 of Zn(II)-free dimethylarginase-1 (DDAH-
1) was S-nitrosylated via gaseous 
•
NO yet supplementation by S-nitrosohomocysteine 
only modified solvent-accessible cysteine residues (Knipp et al. 2003). Marino et al. 
found used a 1.2 Å probe to calculate that 35% of SNO-cysteines were buried and not 
accessible to a 
•
NO molecule.  
The investigation by Marino et al. represents a great effort into the global 
investigation of the specificity of S-nitrosylation. While the diversity of data initially 
appears to be inconclusive for a specific mechanism, the authors themselves suggest that 
this may represent that different cysteines are modified by different mechanisms. The 
better experiment would be to isolate a specific population or subpopulation of S-
nitrosylated cysteine and characterize its attributes specific to its precise mechanism. An 
additional limitation of the Marino et al. study is the use of proteins that are modified ex 
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vivo and therefore represent putative targets but not necessarily the in vivo sites of S-
nitrosylation.  
1.5 Structural implications of S-nitrosylation 
1.5.1 Insights from the structures of S-nitrosylated proteins 
While a host of proteins have been identified as being S-nitrosylated, a current 
search of the Protein Data Bank yields only 9 structures of S-nitrosylated proteins, four of 
which are related structures of similar proteins. It has been suggested that this obvious 
deficit of structures is due not only to the lability of the modification (Derakshan et al. 
2008) but also to the sensitivity of the S-NO bond to radiation (Scheiter et al. 2007; 
Weischel et al. 2007; Rosenfeld et al. 2010).  Therefore, our present understanding of the 
structural consequences of S-nitrosylation is limited to these six unique/individual (non-
redundant) proteins.  
Not surprisingly, the first published structure of an S-nitrosylated protein was that 
of human hemoglobin (SNO-HbA: PDBid 1BUW) (Chan et al. 1998). The Arnone Group 
at the University of Iowa determined the X-ray crystal structure at a resolution of 1.8 Å. 
Crystals of SNO-HbA were prepared by repeatedly exposing the carbonmonoxy form of 
the protein to gaseous NO under anaerobic conditions over a time-course of 10 days. This 
resulted in residue Cysteine-93 of both β chains being converted from cysteine to S-
nitrosocysteine (with nitric oxide additionally replacing the four CO ligands bound to the 
heme of each tetramer). Of the 6 total cysteines contained within hemoglobin, Cys-93 
was the single residue modified (Chan et al. 1998; Jia et al. 1996).  
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Previous studies have shown that Cysteine-93 is more reactive than its 
unmodified counterparts (Chiancone et al. 1989). Additionally, it has been well 
characterized that Cys93 is more susceptible to modification (S-nitrosylation) while 
hemoglobin is in its relaxed state rather than tense state. Therefore, it was originally 
thought that Cys93 became more surface accessible due to conformational changes 
resulting from oxygen binding. Surface accessible calculations proved, however, that the 
residue remained buried and only partially exposed when comparing the oxyHbA R 
structure, the carbonmonoxyHbA R2 structure, and the deoxyHbA structure (Fermi et al. 
1984; Kavanaugh et al. 1992). Hydrogen exchange experiments in conjunction with a 
comparison of the B-factors of high resolution hemoglobin structures revealed an 
increase in mobility and local unfolding near of COOH-termini of β-subunits (Englander 
et al. 1992). Because cysteine-93 is in such close proximity to the COOH-terminus, it 
was deduced that this increased mobility upon ligand binding allows for transient 
exposure of the residue, thereby making it susceptible/accessible to S-nitrosylation.  
Comparison of the carbonmonoxyHbA and SNO-nitrosylHbA structures revealed 
an obvious absence of electron density at the COOH-termini of SNO-nitrosylHbA. 
Residues Tyr145β and His146β (which are present in the carbonmonoxy form of the 
protein) are highly disordered and no longer visible after S-nitrosylation of Cysteine-93. 
Examination of carbonmonoxyHbA reveals that Cys93β lies near the end of an α-helix 
and is adjacent to Tyr145β. Upon S-nitrosylation, Cys93β clashes with the side chain of 
Tyr145β, disrupting the binding pocket that it also shares with Val98β and Pro100β and 
causing residues 145-146 to become disordered. While S-nitrosylation of hemoglobin 
induced no obvious conformational changes in the quaternary structure of the protein, 
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this study offered the first crystallographic evidence of any structural changes which may 
occur as a structural consequence of S-nitrosylation.  
The second structure of a S-nitrosylated protein is an isoform of N
ω
,N
ω
-dimethyl-
L-arginine dimethylaminohydrolase (DDAH-1) which was published nearly 8 years later 
(PDBid: 2CI1) (Frey, et al. 2008) [clean up]. A cysteine hydrolase, DDAH is responsible 
for the in vivo metabolism of L-N
ω
-methylarginine (MMA) and L-N
ω
, N
ω
-
dimethylarginine (ADMA), two well characterized inhibitors of NOS (Ogawa et al. 
1989). There are two isoforms of DDAH in mammals, DDAH-1 and DDAH-2 (Leiper et 
al. 1999) which share less than 50% sequence homology. DDAH-2 is found primarily in 
the heart, placenta, lung, liver, skeletal muscle, kidney, and pancreas (Leiper et al. 1999). 
In addition to the liver, kidney, pancreas, and skeletal muscle at very low levels, DDAH-
1 is also detected in the brain (Leiper et al. 1999). Increases in DDAH-1 and neuronal 
NOS expressions were found in injured neurons, underscoring the important role of 
DDAH-1 in regulation of neuronal nitric oxide generation (Nakagomi et al. 1999).  
It was originally discovered that DDAH-1 is inhibited when Zn(II) is coordinated 
to the enzyme via two sulfur atoms belonging to cysteine residues (Fundel et al. 1996; 
Bogumil et al. 1998; Knipp, et al. 2001). More recently, it has been shown that DDAH-1 
is susceptible to S-nitrosylation when Zn(II) is not bound resulting in abatement of its 
activity (Knipp et al. 2003). Therefore, S-nitrosylation serves as an additional regulatory 
mechanism for inhibiting DDAH-1 activity.  Upon incubation with the NO donor DEA 
NONOate (2-N,N-diethylamino)-diazenolate-2-oxide)), Knipp et al. identified Cys221 
and Cys273 (the active site cysteine) as being S-nitrosylated in bovine DDAH-1 (Knipp 
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et al. 2003). At the time this study was conducted, there were no available crystal 
structures of a mammalian DDAH. Therefore, a crystal structure of DDAH from the 
bacterium Pseudomonas aeruginosa (PDBid: 1H70) was used to build a homology model 
of DDAH-1 (Murray-Rust et al. 2001).  
The homology model suggests a conservation of five (5) ββαβ-modules from 
bacterial DDAH to bovine DDAH-1. However, the two structures diverge significantly 
when observing the secondary structure near the opening of the active site. An N-terminal 
loop closes the active site in the bacterial protein whereas a helix-turn-helix motif exists 
in the homology model. The S-nitrosylated form of bovine DDAH-1 was obtained by 
incubating the protein with S-nitroso-L-homocysteine before crystallization (Frey et al. 
2008).  Upon binding of S-nitroso-L-homocysteine, the lid of the protein which opens the 
active site adopts a closed conformation. Instead of Cys221 and Cys273 which were 
previously identified as being S-nitrosylated, Cysteine-83 is the only residue found to be 
modified. This was thought to be an off target effect since cysteine 83 is solvent-exposed 
and on the opposite end of the pore, away from the active site. Modification of cysteine-
83 does not appear to alter the overall structure of the protein. It is thought that the major 
structural changes observed in the structure are due to substrate binding (SNO-cys) rather 
than the posttranslational modification.  
Human SNO-thioredoxin was first crystallized by Weischel et al. in 2007 and 
then by Hashemy & Holmgren in 2008 (Weischel et al. 2007; Hashemy & Holmgren 
2008). Because a comparison of the two resolved structures shows conflicting results, 
SNO-thioredoxin is one of the most well-studied S-nitrosylated proteins. At a resolution 
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of 1.65 Å, the structure by Weischel et al. revealed the formation of S-nitrosocysteine at 
residues Cys62 and Cys69 after exogenous treatment of S-nitrosoglutathione. 
Comparison of the wildtype and SNO-form revealed a 0.5 Angstrom rotation of a helix 
after S-nitrosocysteine formation which is hypothesized to move out even farther to 
accommodate GSNO. This same helix was found to be disordered in the S-nitrosylated 
form, showing that large [dynamic] motions were taking place as was previously 
hypothesized (Watson et al. 2003). An additional structure of thioredoxin was determined 
in 2008 by Hashemy & Holmgren. When thioredoxin was fully reduced, S-
nitrosocysteine formed on Cys69 and Cys73 after treatment with S-nitrosoglutathione. 
When two-disulfide bonds were formed in thioredoxin, only Cys73 was S-nitrosylated. 
This showed that the redox state of the protein was important in which cysteine residues 
were susceptible to S-nitrosylation.  
The fourth structure of an S-nitrosylated protein was that of blackfin tuna 
myoglobin (PDBid: 2NRM), (Schreiter et al. 2007). Tuna myoglobins contain a single 
cysteine within an N-terminal helix. Based upon the reactivity of the single cysteine 
residue in human myoglobin, it was hypothesized that tuna myoglobins might also be 
susceptible to S-nitrosylation in vivo (Rayner et al 2005; Witting et al. 2001).  Crystals of 
SNO-Mb were obtained by reacting purified blackfin tuna myoglobin with a 10-fold 
excess of S-nitrosocysteine. This led to a structure of S-nitrosomyoglobin at 1.09 Å 
resolution using a rotating copper anode x-ray generator [rotating anode source]. The 
authors attempted to collect structures of SNO-Mb at an even higher resolution using a 
synchrotron source but found that this resulted in loss of the NO moiety. The presence of 
a NO moiety near cysteine-10 was confirmed with electron density maps. Two unique 
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conformations were observed which displayed different rotations around the Cα-Cβ bond 
(χ1 rotamer).  When compared to the reduced cysteine in the unmodified structure of 
myoglobin, the first conformation (conformer A) was rotated 25° whereas the second 
conformation (conformer B) displayed a χ1 rotamer of 115°. The χ3 values of both 
conformers however remained near 0°.  
S-nitrosylation of blackfin tuna myoglobin induced significant changes/alterations 
in the positions of secondary structural elements near the site of modification. 
Superimposing the unmodified (PDBid: 2NRL) and S-nitrosylated structures resulted in a 
RMSD value of 1.2 Å for this particular region of the protein. To prevent steric clashes 
between residues, Leucine-117 (in Loop GH) and Alanine-6 (in Helix A) were wedged 
apart moved to accommodate the NO moiety. As a result, Helix H and Loop EF (which 
lie next to Helix A) were also displaced.  The authors demonstrated that these structural 
changes were a direct consequence of S-nitrosylation. With sodium dithionite, they were 
able to reduce the S-nitrosylated cysteine and observed that the structure of the protein 
was identical to the unmodified form of myoglobin (“reverts to the same conformation it 
had prior to S-nitrosylation”). Upon reduction of SNO-cysteine, the authors demonstrate 
that the NO moiety is removed from cysteine-10 and binds to the heme of myoglobin 
converting it to its ferrous nitrosyl (FE
II
-NO) form. When Cys10 is S-nitrosylated, a 
water molecule is bound to the iron at the heme. After removal of the NO moiety, NO is 
then free to react with the iron at the heme converting the protein to its ferrous nitrosyl 
form (Fe
II
 – NO).  
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The S-nitrosylated structure of protein-tyrosine phosphatase 1B (PTP1B) was 
resolved in 2008 by Chen et al. (Chen et al. 2008). In the presence of the NO-donor 
SNAP, PTP1B was crystallized and resolved at a 2.6 Angstrom resolution. S-
nitrosocysteine formed at Cys215 which is located in the active site of the protein. 
Examination of the structure revealed a subtle conformational change in the positions of 
side chains near Cys215. By comparing the reduced and S-nitrosylated forms of PTP1B, 
the authors show the emergence of a hydrogen bond network which they hypothesize 
might play a role in the stabilization of the structure. 
The most recently resolved structure of an S-nitrosylated protein is that of 
hypoxia inducible factor prolyl hydroxylase domain 2 (EGLN). After treatment with NO 
donors, the structure of EGLN exhibited a positive difference density consistent with S-
nitrocysteine formation at Cys302; however, attempts to further refine the structure using 
stereochemical restraints for an S-nitrosocysteine residue failed since the SNO group 
could not be fitted within the experimental electron density. The authors concluded that 
what they were not observing S-nitrosocysteine but instead a reaction intermediate of 
•
NO with the thiol.  
A comprehensive study conducted by Marino et al. superimposed the structures of 
these same S-nitrosylated proteins with their corresponding non-nitrosylated structures 
(Marino et al. 2010). Most strikingly, the authors found that charged residues within the 
proteins were the most responsive to S-nitrosocysteine formation as they were the major 
residues which were rearranged. Collectively, these data suggest that the protein does 
make an attempt to accommodate the presence of S-nitrosocysteine in place of a reduced 
33 
 
thiol. However, the ultimate assessment would be to examine only those structures which 
are endogenously modified.  
1.5.2 Computational tools for extracting structural information 
from S-nitrosylated proteins  
While the aforementioned studies may provide novel insight into the structural 
consequences of S-nitrosylation, it is presumptive to draw conclusions about hundreds of 
proteins based upon six different structures. Therefore, it is important to extract as much 
information as possible from the wildtype structures of proteins found to be S-
nitrosylated.  
Three-dimensional structures of proteins which have been resolved by NMR or 
X-ray crystallography are made available in the RCSB Protein Data Bank (www.pdb.org) 
which presently contains 76,288 structures (as of 10/04/11). In identifying S-nitrosylation 
as a far-reaching posttranslational modification, SNO-proteins encompass those which 
have been very well characterized as well as those which are not as well known. 
Therefore, homology models are often generated for S-nitrosylated proteins without 
corresponding structures.  
Several interesting cases exist where additional information was gleaned by 
generating homology models of S-nitrosylated proteins. In their investigations into the 
role of S-nitrosylation in Alzheimer’s disease, Cho et al. generated a homology model of 
dyanamin-related protein 1 (DRP-1) using the structure of bacterial dynamin-like protein 
(Cho et al. 2009). The three dimensional structure of the protein revealed a spatial 
consensus motif flanking S-nitrosocysteine and that the modified cysteine was highly 
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surface accessible. S-nitrosylation results in the dimer formation of DRP-1, contributing 
to neuronal synaptic damage or cell death. The authors hypothesize that due to the 
increased presence of copper found in human AD brains, DRP-1 may be S-nitrosylated 
via a metal-catalyzed mechanism. Therefore, understanding how the protein environment 
plays a role in such mechanism may assist in developing DRP-1 as a potential drug 
target.  
Molecular dynamics (MD) simulations are another useful tool for understanding 
the influence of S-nitrosocysteine formation on the remaining structure of the protein. 
The motions of a protein can be monitored over time to see if there is a global or local 
response to different stimuli. Han et al. conducted a molecular dynamics simulation of S-
nitrosylated thioredoxin in its oxidized and reduced states (Han et al. 2008). Because S-
nitrosocysteine is not a commonly occurring amino acid, the author had to first develop 
force field parameters which could characterize the movements and constraints of SNO-
proteins. Comparison of thioredoxin with and without SNO-Cys-69 across MD 
trajectories showed no large global motions. The RMSD of oxidized thioredoxin was 
rigid when compared to the RMSD of reduced thioredoxin; however, this difference was 
also observed independent of S-nitrosocysteine. This suggests that differences in 
structural constraints are due instead to the redox state of the protein. While MD 
simulations may not have been fruitful in the case of thioredoxin, when combined with 
homology modeling, it can serve as a powerful tool for structurally interrogating the 
influence of S-nitrosocysteine on any protein.  
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1.6 Rationale and Objectives 
S-nitrosylation proves to be an exhaustive body of work which only seems to 
increase as time goes on. With the advances in technology over the past 10 years, S-
nitrosylated proteins modified in vivo are being identified on a much more consistent 
basis. They have been found to play a role in biological and cellular processes already 
thought to be very well characterized, sometimes involving proteins which are much less 
characterized. 
However, as more information emerges regarding S-nitrosylation, there are still 
several large gaps in our knowledge which prevent us from better understanding S-
nitrosylation. Firstly, we want to understand why certain cysteines are targeted for S-
nitrosylation and not others. Identifying the specificity of S-nitrosylation will help us to 
better regulate the activity of S-nitrosylation. This mandates that we need to identify S-
nitrosylated cysteines and their unmodified counterparts in vivo. Chapter 2 describes a 
novel method which allows for the global identification of S-nitrosylated cysteines within 
the mouse liver. This large dataset also provides a control comparison of SNO-cysteines 
to their unmodified counterparts allowing for a side-by-side comparison of reactive vs. 
non-reactive cysteines.  
Once 
•
NO is produced, it is important to understand the mechanism by which S-
nitrosylated proteins are formed. As was previously described, several hypotheses exist 
regarding how SNO-proteins are formed. Therefore, being able to identify which 
mechanism is responsible for modifying which cysteines will provide us with a greater 
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understanding of how to regulate this process. To this end, Chapter 3 describes a novel 
proposed mechanism of GSNO-mediated transnitrosation.  
Lastly, I explored the proposition that S-nitrosocysteine formation alters the 
structure of a protein. While hundreds of proteins have been identified as being modified, 
very few structures of S-nitrosylated proteins exist which offer a structural explanation of 
the observed alteration in protein functionality. Chapter 4 describes a comprehensive 
study beginning with the identification of an S-nitrosylated protein directly involved in 
the beta oxidation of fatty acids and attempts to unravel the structural consequences of S-
nitrosylation in relation to its observed alterations in protein activity.  
This body of work illustrates how the development of a global technique has 
allowed for the generation of several testable hypotheses. Chapter 5 concludes with a 
discussion regarding the implications of the results described in the preceding chapters as 
well as a comprehensive analysis of future works in the field of S-nitrosylation.  
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CHAPTER 2 
 
 
STRUCTURAL PROFILING OF ENDOGENOUS S-
NITROSOCYSTEINE RESIDUES REVEALS UNIQUE FEATURES 
THAT ACCOMMODATE DIVERSE MECHANISMS FOR PROTEIN 
S-NITROSYLATION 
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2.1 Abstract 
S-nitrosylation, the selective posttranslational modification of protein cysteine 
residues to form S-nitrosocysteine, is one of the molecular mechanisms by which nitric 
oxide influences diverse biological functions. In this study, unique MS-based proteomic 
approaches precisely pinpointed the site of S-nitrosylation in 328 peptides in 192 proteins 
endogenously modified in WT mouse liver. Structural analyses revealed that S-
nitrosylated cysteine residues were equally distributed in hydrophobic and hydrophilic 
areas of proteins with an average predicted pKa of 10.01±2.1. S-nitrosylation sites were 
over-represented in α-helices and under-represented in coils as compared with 
unmodified cysteine residues in the same proteins (χ2 test, P < 0.02). A quantile–quantile 
probability plot indicated that the distribution of S-nitrosocysteine residues was skewed 
toward larger surface accessible areas compared with the unmodified cysteine residues in 
the same proteins. Seventy percent of the S-nitrosylated cysteine residues were 
surrounded by negatively or positively charged amino acids within a 6-Å distance. The 
location of cysteine residues in α-helices and coils in highly accessible surfaces bordered 
by charged amino acids implies site directed S-nitrosylation mediated by protein–protein 
or small molecule interactions. Moreover, 13 modified cysteine residues were 
coordinated with metals and 15 metalloproteins were endogenously modified supporting 
metal-catalyzed S-nitrosylation mechanisms. Collectively, the endogenous S-
nitrosoproteome in the liver has structural features that accommodate multiple 
mechanisms for selective site-directed S-nitrosylation. 
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2.2 Introduction 
Cysteine S-nitrosylation is a post-translational modification that results from the 
formal transfer of nitrosonium from a nitrosating agent to a reduced cysteine (S-
nitrosation) and is a mechanism by which nitric oxide can regulate important biological 
processes within a variety of organs and cellular systems (Hess et al. 2005; Whalen et al. 
2007; Hara et al. 2005; Cho et al. 2009; Rizzo et al. 2003; Guo et al. 2008).  Data 
gathered from individual proteins have collectively indicated that this reversible and 
apparently selective post-translational modification regulates protein activity, 
localization, and stability (Hara et al. 2005; Cho et al. 2009; Rizzo et al. 2003).  Despite 
the considerable biological importance of this post-translational modification significant 
gaps exist regarding its in vivo specificity and origin.  The identification of in vivo S-
nitrosylated proteins has indicated that not all reduced cysteine residues, and not all 
proteins with reduced cysteine residues, are modified implying a biased selection.  
Several biological chemistries have been proposed to account for the S-nitrosylation of 
proteins in vivo (Hess et al. 2005; Bosworth et al. 2009; Zhang et al. 2005). Broadly these 
include: i) oxidative nitrosation by higher oxides of nitric oxide, ii) trans-nitrosation by 
either small molecular weight nitric oxide carriers such as S-nitrosoglutathione or 
dinitrosyliron complexes, iii) catalysis by metalloproteins and iv) protein-assisted 
transnitrosation as elegantly documented for the S-nitrosylation of caspase-3 by S-
nitrosothioredoxin (Mitchell et al. 2005; Benhar et al. 2008).  With the exception of the 
protein-assisted trans-nitrosylation and metalloprotein catalyzed S-nitrosylation, which 
we presume necessitates protein-protein interaction, the other proposed mechanisms are 
rather non-discriminatory unless the microenvironment of selective cysteine residues in 
proteins can specifically accommodate these chemical modifications.  Therefore 
structural interrogation of endogenous S-nitrosylated proteins with site specific 
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identification of the modified cysteine residues could provide valuable insights to 
appreciate the biological selectivity of this post-translational modification. Attempts to 
investigate this very important biological question have not been possible largely because 
of the deficit of datasets of in vivo modified proteins (Marino et al. 2010).  Previous 
structural analyses have been attempted using limited data sets or by including all sites of 
modification identified after exposing tissues or cells to S-nitrosylating agents (Marino et 
al. 2010).  However, as the authors of these articles have indicated these sites of 
modification represent putative sites but not necessarily those modified in vivo (Marino et 
al. 2010). We employed organomercury reagents that react directly, efficiently and 
specifically with S-nitrosocysteine and thus enable the precise identification of S-
nitrosocysteine containing peptides and independently S-nitrosylated proteins to assemble 
the in vivo S-nitrosocysteine proteome of the mouse liver.  Using bioinformatic tools we 
then interrogated this enriched endogenous S-nitrosocysteine proteome to define the 
biochemical, biophysical and structural environment of the cysteine residues modified by 
S-nitrosylation, elements that might inform on how specificity of S-nitrosylation is 
achieved.  
 
2.3 Materials and Methods 
Chemicals and Reagents. All HPLC solvents were purchased from Burdick and Jackson, 
and unless stated all other reagents were purchased from Sigma-Aldrich (St. Louis, MO).  
Mercury/PEG/biotin compound was designed by us and synthesized by SoluLink (San 
Diego, CA).  Mercury resin was synthesized as described in Supplementary Methods. 
Mouse monoclonal antibodies against Hsp70 and GAPDH were purchased from 
Stressgen (Ann Arbor, MI) and Abcam (Cambridge, MA) respectively. Rabbit polyclonal 
antibody against very long chain specific acyl-CoA dehydrogenase (VLCADH) was 
obtained from Santa Cruz (Santa Cruz, CA).  
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Isolation and preparation of mouse liver protein homogenates for capture of S-
nitrosylated proteins.  All mouse studies were reviewed and approved by the Institutional 
Animal Care and Use Committee of the Children’s Hospital of Philadelphia Research 
Institute. Wild type or Nos3
tm1Unc 
(eNOS
-/-
) C57BL/6J adult mice were obtained from 
Jackson Laboratories (Bar Harbor, ME). Mice were anesthetized by CO2 and perfused 
through the left ventricle. Intact livers were collected, immediately frozen in liquid 
nitrogen and stored at -80 °C until use. Liver tissues were homogenized in preparation for 
proteomic analysis as described in Supplementary Methods online. 
Capture of S-nitrosylated proteins using organomercury resin (MRC). MRC solid-phase 
capture columns were prepared and activated as described in Supplementary Methods. 
Protein homogenates were loaded onto activated MRC columns, and incubated under 
stationary conditions for 1h at RT. Next, the columns were extensively washed followed 
by elution of the bound proteins under reducing conditions. Samples were concentrated 
500-fold and analyzed by GeLC-MS/MS analysis as described below and in the 
Supplementary Methods.  
Labeling and affinity capture of S-nitrosylated proteins using organomercury-
polyethyleneglycol-biotin (mPEGb). Livers lysates were prepared and then captured by 
mPEGb compound as described in the Supplementary Methods. After capture, 
biotinylated proteins were precipitated with 3 volumes of acetone and protein 
concentration was determined by the BCA assay. Equal protein amounts were incubated 
with washed neutravidin-agarose beads for 2h at RT with gentle rocking. The supernatant 
was discarded and the beads were extensively washed. Bound proteins were then eluted 
under reducing conditions for 20 min at RT under gentle rocking. Samples were 
concentrated 25-fold and analyzed by gel electrophoresis liquid chromatography-mass 
spectrometry analysis as described below and in the Supplementary Methods.  
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Protein digestion and neutravidin affinity peptide capture. For neutravidin affinity 
capture of biotinylated peptides, S-nitrosylated proteins were labeled with mPEGb, 
precipitated and resuspended into ammonium bicarbonate containing 0.1 % SDS. Equal 
amounts of proteins were transferred to Ultra-free MC 10kDa cut-off filters (rinsed with 
methanol and washed with water) and incubated with trypsin (1:100 enzyme:protein 
ratio) in the dark for 16h at 37 
o
C.  Biotinylated peptides were recovered by 
centrifugation of the filters and incubated with neutravidin beads for 2 hours at RT with 
gentle rocking. Beads were then extensively washed and peptides were released by 
reduction of the mercury-thiol bond with 3 % performic acid. Eluted peptides were 
reduced in volume by Speedvac to < 5 ul and resuspended in 10 ul of 0.1% formic acid. 
A volume of 5 ul was analyzed by LC-MS/MS. A detailed protocol is available in the 
Supplementary Methods. 
GeLC-MS/MS analysis. The protein fractions obtained from MRC and mPEGb protein 
capture methods were analyzed by GeLC-MS/MS as described in the Supplementary 
Methods online. Peptides obtained from mPEGb peptide capture method were analyzed 
by LC-MS/MS directly as described in the Supplementary Methods. 
Generation and evaluation of SEQUEST peptide assignments. A detailed protocol for the 
generation and evaluation of SEQUEST peptide assignments is available in 
Supplementary Methods. See Supplementary Figure 2.2 for an overview of the criteria 
for SEQUEST peptide assignment evaluation.   
Denitrosylation assays. Denitrosylation assay was performed by exposing liver lysates to 
150 nM Trx, 150 nM Trx reductase and 100 mM NADPH for 30 min at 37 
o
C. Proteins 
were processed by both MRC and mPEGb protein capture methods, followed by GeLC-
MS/MS analysis. 
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Gene ontology and functional protein analysis. Subcellular localization was determined 
by either existing UniProt (www.uniprot.org) annotation, while gene ontology 
classification and analysis was performed by UniProt and FatiGO (www.fatigo.org).  
Protein sequence and structural analysis. The unprocessed protein precursors obtained 
from UniProt (www.uniprot.org) were used for all sequence analyses (see accession 
numbers in Supplementary Table 2.1). Prediction of consensus S-nitrosylation sequence 
motifs was examined by motif-x, a linear sequence prediction algorithm).  Kyte-Doolittle 
hydropathy plots were generated for each protein using a window of 13 with hydropathy 
values greater than zero considered hydrophobic.  Three-dimensional protein structures 
were obtained from the Protein Data Bank (PDB, requiring greater than 50 % homology 
and conservation of the modified cysteine residue. The predicted pKa’s for ionizable 
cysteine residues were calculated using PROPKA 2.0, while relative residue surface 
accessibility was calculated by Naccess 2.1.1 
(http://www.bioinf.manchester.ac.uk/naccess/).  
Statistical analyses. Graphs were constructed and statistical analyses were performed 
using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).  Statistical 
significance was determined by either paired or unpaired non-parametric two-tailed t-
tests using either the Mann-Whitney (unpaired) or Wilcoxon matched pairs test. 
 
2.4 Results and Discussion 
Complementary MS-Based Proteomics Identify the Endogenous Liver S-
Nitrosocysteine Proteome 
The reaction of phenylmercury compounds with S-nitrosocysteine results in the 
formation of a relatively stable thiol–mercury bond (Saville et al. 1958). Therefore, we 
used an organomercury resin (MRC) synthesized by conjugation of ρ-amino-
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phenylmercuric acetate to N-hydroxysuccinimide–activated Affi-Gel 10 agarose beads 
and a phenylmercury-polyethyleneglycol-biotin (mPEGb) compound to capture S-
nitrosylated proteins and peptides (Fig.S2.1). The method consists of three steps: (i) 
blocking of reduced cysteine residues with methyl methanethiosulfonate (MMTS), (ii) 
capture and release of S-nitrosylated proteins or peptides, and (iii) liquid 
chromatography/tandem MS analysis. β-Mercaptoethanol or performic acid was used to 
release captured proteins or peptides, respectively. Mild performic acid was used to 
selectively and quantitatively release the bound peptides and more importantly oxidize 
cysteine thiols to sulfonic acid, thereby creating a unique MS signature that permits site-
specific identification of the modified cysteine residues (Pesavento et al. 2007). Under 
the workflow used (Fig. S2.1), 100% of cysteine-containing peptides were detected with 
the sulfonic acid modification. 
To further explore this possibility we used the Trx ex vivo denitrosylation assay 
(Paige et al. 2008) to identify sites of S-nitrosylation that can interact with Trx. Freshly 
isolated liver homogenates were treated with a Trx system (Trx/Trx-reductase/NADPH). 
This treatment resulted in a 72% reduction in protein S-nitrosocysteine levels as 
quantified by chemiluminescence. In comparison with the untreated liver S-
nitrosoproteome (Table S2.1), 72 proteins were no longer identified after Trx treatment 
(Table S2.4). Linear motif analysis revealed two motifs in this subset of S-nitrosylated 
proteins. The highest-scoring motif had exclusively aspartic acid at position −1, whereas 
the second motif had exclusively threonine at position +5 (Fig. 2.3E). Notably, both 
motifs contained charged amino acids at positions before and after the cysteine residue, 
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consistent with the idea that charged amino acids in S-nitrosocysteine–containing motifs 
may facilitate interaction with Trx. 
To control for the inclusion of false-positive protein S-nitrosocysteine that may 
result from incomplete blocking of reduced cysteine residues or nonspecific interactions 
with the resins 
during enrichment, pretreatment with UV, DTT, and copper ascorbate (Cu-Asc) 
reduction or reaction with mercury chloride were used to displace NO before the reaction 
with the phenylmercury compounds (Fig. 2.1A and Fig. S2.2A). For these experiments, 
we used mouse liver homogenates with 50 ± 10 pmol protein S-nitrosocysteine per 
milligram of protein as quantified by reductive chemistries coupled to ozone-based 
chemiluminescence. Displacement of NO from S-nitrosocysteine residues by 
pretreatment with UV, DTT, Cu-Asc, or mercury chloride decreased protein S-
nitrosocysteine levels by greater than 99% as quantified by chemiluminescence (n = 3) 
and also eliminated reaction with the phenylmercury compounds (Fig. 2.1A and Fig. 
S2.2A). On average, only 3% of peptides (Fig. 2.1B) and 5% of proteins (Fig. S2.2B) 
were identified as false positives (present in untreated and UV-pretreated samples), 
demonstrating that the method maintains high specificity at each step. This false positive 
rate compares favorably with the greater than 90% specificity reported for immobilized 
metal affinity 
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Figure 2.1: Site-specific identification and UV photolysis confirmation of S-
nitrosocysteine. (A) Representative short (approximately 2 cm) colloidal blue-stained 
protein gel of mPEGb protein capture from WT mouse liver that was processed by 
GeLC-MS/MS analysis. Colloidal blue protein staining of bound fractions from mPEGb 
protein capture of untreated liver homogenates showed protein enrichment. Pretreatment 
with UV (for 30 min), DTT (10 mM), Cu-Asc (5 mM Asc/copper 0.1 mM), or HgCl2 (20 
mM) prevented this capture, demonstrating specificity for protein S-nitrosocysteine. (B) 
Representative base peak chromatograms from mPEGb peptide capture demonstrates 
reduction in ion intensity after UV treatment (red) compared with the untreated sample 
(black). For clarity, the chromatogram corresponding to UV treatment was plotted with a 
y-axis offset of 1E4. Inset: Average false-positive identification rate (FIR ± SD) from 
mPEGb and MRC represented the percentage of peptides that were identified in both the 
UV-treated and untreated samples across three independent biological replicates. Also 
reported is the percent of noncysteinyl peptides identified (Supplemental Materials and 
Methods). (C) Representative MS spectra of doubly charged sulfonic acid-containing 
tryptic peptides, YLLGTSLARPC97IAR (monoisotopic m/z, 791.4256; Top, Left) and 
FELTC132YSLAPQIK (monoisotopic m/z, 780.8851; Bottom, Left), from 
argininosuccinate synthase. MS/MS spectra confirmed the sequence and site of sulfonic 
acid-containing peptides (C+48) from argininosuccinate synthase identified in mouse 
liver (Supplemental Materials and Methods). MS/MS spectra passed automatic and 
manual filter criteria (Fig. S2), and were identified with high SEQUEST cross correlation 
(Xc) scores at ppm mass error. Cys132 has been previously reported as a target of S-
nitrosylation in human argininosuccinate synthase (20), whereas the identification of 
Cys97 corresponded to a previously unidentified site of S-nitrosocysteine formation. (D) 
Colloidal blue protein staining of bound fractions from MRC and mPEGb enrichment of 
S-nitrosylated proteins from WT and eNOS−/− mouse livers. UV photolysis 
demonstrated specificity of the enrichment. The levels of protein S-nitrosocysteine were 
quantified by reductive chemistries coupled to chemiluminescent based detection (41). 
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The amount of S-nitrosylated protein captured by mPEGb from eNOS−/− livers (lane 8) 
was below the limit of detection by colloidal blue staining. (E) Western blot analysis of 
bound and unbound fractions from WT mouse liver that were processed by MRC protein 
capture. 
 
chromatography used for the enrichment of phosphopeptides from mouse liver (Villén et 
al. 2008). Therefore, pretreatment with UV served as negative control throughout based 
on previous studies that documented the elimination of S-nitrosocysteine without 
affecting other cysteine modifications (Forrester et al. 2007; Derakhshan et al. 2007). 
Collectively, these experiments showed that the reaction of protein S-nitrosocysteine with 
the phenylmercury compounds is specific and efficient and achieved selective 
identification of the modified residue, the ultimate qualifier for the unambiguous 
assignment of S-nitrosylated proteins through the inclusion of negative controls. 
The ability of the method to reveal endogenous S-nitrosoproteomes was assessed 
in WT mouse liver homogenates. Initially, three different mouse livers were analyzed 
independently for protein and peptide capture by using both the MRC and mPEGb 
approach with 3 mg of starting material. From the three biological replicates, sulfonic 
acid-containing peptides identified by SEQUEST database searches were pooled and 
those also present in the UV-pretreated samples were removed. Similarly, all proteins 
identified by protein capture were pooled (those also identified in the UV-pretreated 
samples were removed). The use of solid-phase and in-solution–based enrichment 
approaches was largely complementary, as the number of shared protein identifications 
between protein capture methods was approximately 50%, whereas each method 
individually contributed about the same number of unique protein identifications (Table 
S2.1). As the MRC capture method allows for higher input, site-specific peptide capture 
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by this method was also performed with the use of 30 mg of liver extract originating from 
three different mice. The inclusion of these additional biological replicates reduced 
biological variance and improved the depth of the analysis while maintaining less than 
3% false identification rate. Overall by matching sulfonic acid containing peptides with 
corresponding protein identifications, we precisely pinpointed 328 S-nitrosocysteine–
containing peptides in 192 proteins in untreated livers with a high level of confidence 
(complete list is provided in Table S2.1 and all of the MS/MS spectra from peptide 
capture can be viewed at http://www.research.chop.edu/tools/msms/spectra.pdf). The 
depth of this analysis represents a significant advancement versus present methodologies 
(Paige et al. 2008). The majority of the proteins identified in the current study, 186, 
corresponded to previously unidentified endogenous targets of S-nitrosylation in the 
mouse liver, whereas six proteins (GAPDH, hemoglobin, β-tubulin, argininosuccinate 
synthase, alcohol dehydrogenase, and catalase) have been previously identified as 
endogenously S-nitrosylated in hepatocytes and other organ systems (Jaffrey et al. 2001; 
Hao et al. 2006; Hao et al. 2004; López-Sánchez et al. 2008). Proteins were also 
distributed across a wide range of molecular weights (13–272 kDa) and cellular 
localization including membrane-associated proteins, demonstrating the efficacy of the 
method to identify S-nitrosocysteine independent of protein size and location. We 
selected very long chain specific acyl-CoA dehydrogenase, heat shock cognate 71 
protein, for which endogenous S-nitrosylation was not previously described, and 
GAPDH, which has been known to be S-nitrosylated and independently confirmed their 
selective enrichment by Western blot analysis after protein capture (Fig. 2.1E).  
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To further probe the biological specificity of our method while demonstrating its 
utility for comparison of endogenous S-nitrosoproteomes, we analyzed livers from mice 
lacking endothelial NO synthase (eNOS
−/−
). Using chemiluminescence-based 
quantification, a 10-fold decrease in protein S-nitrosocysteine levels of eNOS
−/−
 livers 
was measured as compared with WT livers. Concomitantly, a reduced reactivity with 
phenylmercury compounds was observed (Fig. 2.1D). From the eNOS
−/−
 livers, 36 
sulfonic acid-containing peptides in 26 proteins were identified (Supplemental Table 2.2), 
of which 24 were also identified in the WT liver. The data indicate that the majority of 
the endogenous liver S-nitrosoproteome is dependent on eNOS-generated NO. 
S-Nitrosylation Is Implicated in Multiple Metabolic Pathways 
Proteomic experiments generate rich, diverse datasets that benefit from 
computational analysis to extract biologically relevant and potentially novel information. 
Consequently, functional and ontological analyses were conducted to assist in identifying 
cellular, molecular, and biological functions in which S-nitrosylation may play a role in 
the liver. Sixty-five percent of S-nitrosylated proteins were localized to the cytoplasm 
and mitochondrion, representing a significant enrichment compared with the mouse 
genome (P=4.9e−34 and P=7.2e−22, respectively; Figure S2.3A). A subset of S-
nitrosylated proteins were found to be present in cell membranes, whereas the remaining 
proteins were distributed across nearly all cellular compartments (Figure S2.3A). Gene 
ontology analysis revealed that 99 S-nitrosylated proteins had catalytic activity largely 
composed of oxidoreductases (39%) and transferases (17%; Fig. S2.3B). These functions 
were also found to be significantly overrepresented (P=1.28e−20 and 3.2e−3, 
respectively) in the liver S-nitrosoproteome compared with the mouse genome (Al-
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Shahrour et al. 2004). This is not surprising, as the molecular functions of S-nitrosylated 
proteins were assigned to diverse metabolic processes (i.e., amino acid synthesis, energy 
synthesis, lipid metabolism) that take place within the liver. Analysis of the data has also 
confirmed the presence of multiple S-nitrosylated cysteine residues in nearly 45% (86 of 
192) of the liver S-nitrosoproteome. Poly-S-nitrosylation is present in all top-ranking 
molecular functions, suggesting that multiple sites of S-nitrosylation in vivo may regulate 
protein activity. This is in accordance with other known posttranslational modifications 
such as phosphorylation and lysine acetylation in which poly-phosphorylation and poly-
acetylation are considered regulators of protein function and signaling (Olsen et al. 2006; 
Choudhary et al. 2009). To place these functional assignments into the context of 
biochemical and molecular signaling pathways, S-nitrosylated proteins were assembled 
into biological protein interaction and signaling networks (Ingenuity Systems). The 
analysis was restricted to investigate liver-related pathways. Sixteen S-nitrosylated 
proteins were significantly clustered in a network that encompassed liver responses to the 
hormone leptin (Fig. S2.3C). Leptin is an adipocyte-secreted hormone that primarily acts 
on the central nervous system to regulate energy homeostasis. Leptin also regulates liver 
metabolism, evident by the significant accumulation of lipids (fatty liver) in mice 
deficient in leptin (ob/ob) (Halaas et al. 2005; Pelleymounter et al. 1995) or leptin long-
form receptor (db/db) (Mohan et al. 2008). The regulation of liver metabolism is 
attributed to the leptin-dependent repression of liver stearoyl-CoA desaturase-1, the rate 
limiting step in monosaturated fat biosynthesis (Cohen et al. 2004). In addition, recent 
data indicate that leptin also regulates liver mitochondrial respiratory chain protein 
expression, mitochondrial function and structure (Singh et al. 2009), remarkably similar 
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to the previously recognized regulation of mitochondrial function by NO (Brown et al. 
1994; Nisoli et al. 2004). Interestingly, delivery of S-nitroso-N-acetylcysteine by gavage 
to ob/ob mice prevented the development of fatty liver (de Oliveira et al. 2008). Mice 
deficient in eNOS also experience abnormal fat deposition in the liver (Schild et al. 
2008), which was attributed in part to regulation of mitochondrial fatty acid synthesis and 
activation of AMP-activated protein kinase (Schild et al. 2008). Moreover, 14 of the 16 
proteins in the leptin network (Fig. S2.3C) were absent in eNOS−/− liver S-
nitrosocysteine proteome analysis, suggesting a potential relationship between eNOS-
derived S-nitrosylation and leptin regulation of fatty acid metabolism. Although it 
requires further experimentation, the data indicate that S-nitrosylation may be a 
molecular link between the actions of leptin and NO in liver fatty acid biosynthesis and 
mitochondrial metabolism. Overall, cellular localization and functional analyses revealed 
that the S-nitrosylated proteins identified in the liver were largely cytosolic and 
mitochondrial enzymes that function as oxidoreductases and transferases, which are 
critical for regulating amino acid, energy, and lipid biosynthesis, and may coordinate the 
regulation of metabolic pathways by leptin and NO. 
 
Biochemical, Biophysical, and Structural Properties of the Modified Cysteine 
Residues 
This enriched S-nitrosoproteome was interrogated for the structural properties of 
the modified cysteine residues by using various bioinformatic tools and available crystal 
structures of proteins. Table 2.1 provides the basic biochemical and biophysical 
properties of the modified cysteine residues using reduced unmodified cysteine residues 
in the same proteins as a comparison group. Kyte-Doolittle hydropathy indices in 13-
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residue windows were calculated to determine the influence of primary structure of the 
protein on modified cysteine residues (Figure 2.2A).The average hydropathy index value 
was calculated to be −0.03 ± 0.69 (n=309) which did not differ significantly when 
compared with the mean value of the unmodified cysteines within the same proteins (0.10 
± 0.77, n = 1,382). Using crystal structures (Protein Data Bank) and the Propka 2.0 
algorithm (Li et al. 2005), the average predicted pKa of 142 cysteine residues S-
nitrosylated in vivo was 10.0, which was not significantly different from the average pKa 
of reduced unmodified cysteine residues in the same proteins (pKa of 9.88). Only 15 
modified cysteine residues had predicted pKa values lower than 7.4 (5.66 ± 1.24), 
indicating that these particular residues may be deprotonated at physiological pH (Figure 
2.2B). Secondary structure analysis revealed that S-nitrosocysteine residues were present 
in β-sheets (28%), helices (40%), and coils (32%). Unmodified cysteine residues within 
the same proteins were localized primarily  
 
Table 2.1: Biochemical and biophysical properties of S-nitrosylated and unmodified 
cysteine residues within the same proteins 
Variable S-nitrosocysteine 
residues 
Unmodified cysteine 
residues 
Hydropathy Index 0.03 ± 0.69 (n=309) 0.1 ± 0.77 (n=382) 
Predicted pKa 10.0 ± 2.10 (n=142) 9.88 ± 2.20 (n=559) 
Helices, %  40* 29 
β-sheets, % 28 32 
Coils, % 32# 39 
RSA^ 71% buried (n=99) 77% buried (n=561) 
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 29% exposed (n=40) 23% exposed (n=171) 
*P < 0.02, #P < 0.01 using unmodified residues as control group. 
^Residue surface accessibility (RSA) for cysteine residues was calculated by the accessible surface area 
normalized 
by the accessible surface area of cysteine in the extended tripeptide Ala-Cys-Ala. A value of ≤10% was 
used as 
cutoff to denote a buried cysteine. 
 
 
in coils (39%) and equally distributed across helices and β-sheets (Table 2.1). Statistical 
analysis revealed an overrepresentation and underrepresentation of modified cysteines in 
helices and coils, respectively (P < 0.02). None of the cysteine residues found to be S-
nitrosylated participate in disulfide bonding in their known structures and none has been 
reported to date to be modified by glutathiolation and alkylating agents 
(www.uniprot.org). Furthermore, by using predictive algorithms and literature searches, it 
was found that less than 20% of the cysteine residues were predicted to be sites of 
oxidation (Sanchez et al. 2008). These data and analysis indicate that the majority of the 
in vivo sites of S-nitrosylation represent a unique population of cysteine residues not 
chemically modified through other biological processes. 
 
S-Nitrosocysteine Residues Are Equally Distributed in Hydrophobic and 
Hydrophilic Areas of the Proteins 
The overall slightly negative hydropathy index (Table 2.1) is not indicative of a 
trend for S-nitrosylated cysteine residues to localize in hydrophilic regions of the protein. 
Further inspection of the hydropathy indices of modified cysteine residues revealed that 
139 of the 309 cysteine residues reside nearly in hydrophobic regions, whereas 170 of the 
309 are located in hydrophilic regions. This observation led us to further examine 
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whether S-nitrosylated cysteines belong to two distinct populations regarding their 
hydrophobicity/hydrophilicity. Kernel density estimation revealed that hydropathy 
indices exhibited a roughly normal distribution (Figure 2.2A, Left), indicating that they 
corresponded to a single population of cysteine residues. Unmodified cysteine residues 
within the same proteins also showed a roughly normal distribution as well (Figure 2.2A, 
Right), indicating that there is no distinction between S-nitrosylated and unmodified 
cysteine residues within the same proteins to localize in hydrophobic or hydrophilic areas 
of proteins. Previous studies have indicated that S-nitrosylation is favored in hydrophobic 
regions of the proteins (Nedospasov et al. 2000), presumably because of the increased 
localized concentration of NO-derived oxides, which may provide a suitable 
microenvironment for the S-nitrosylation of these cysteine residues. The present data 
imply that, for a subset of proteins, hydrophobicity may serve as a determinant for 
selective targeting of cysteine residues for S-nitrosylation. 
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Figure 2.2: Hydropathy index and pKa values of S-nitrosylated residues. (A) Kernel 
density plot of hydropathy indices for S-nitrosocysteine (Left) and unmodified cysteine 
residues (Right). Hydropathy index was calculated for all S-nitrosylated (n = 170 
hydrophilic, n = 139 hydrophobic) and unmodified (n = 635 hydrophilic, n = 747 
hydrophobic) cysteine residues within a 13 amino acid window, with a negative value 
indicating hydrophilicity. (B) Predicted pKa value for each S-nitrosylated cysteine was 
calculated from the experimental structures and the distribution was represented as a 
histogram. 
 
 
S-Nitrosylation Occurs on Cysteine Residues Adjacent to Flexible Regions Within 
the Protein 
To further explore the location of S-nitrosylated cysteine residues in protein 
secondary structure, the frequency of secondary structures for flanking residues 
(positions −10 to +10) was calculated and compared with the respective frequencies of 
the unmodified cysteine residues using the χ2 test. A shift in secondary structure mainly 
from coils to helices was observed over the range of positions from −6 to 0 (P < 0.05), 
consistent with the presence of the majority of S-nitrosocysteine residues in α-helices 
(Figure 2.3A). Moreover, a 10% increase in the frequency of coils from positions 0 to +3 
(P < 0.001) concomitant with a reduction in β-sheet frequency (P < 0.001) indicative of a 
change in secondary structure was observed C-terminal from the modified cysteine 
residues. Unmodified cysteine residues within the same proteins were localized primarily 
in coils and with lower frequency in β-sheets and helices (Fig. S2.4A). Moreover, the 
frequency of coils did not change significantly across all flanking residues (−10 to +10), 
indicating that shifts in secondary structure were only between helices and β-sheets. 
Collectively, these data demonstrate that modified cysteine residues are predominantly 
present in secondary structures of proteins which may facilitate site-directed S-
nitrosylation by protein-protein interactions. 
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Surface Accessibility of S-Nitrosocysteine Residues 
The relative residue surface accessibility (RSA) for all cysteines (modified and 
unmodified) within the S-nitrosoproteome was calculated with Naccess 2.1.1 using the 
radius of a water molecule (1.4 Å2) as a probe (Lee et al. 1971). Ninety-nine S-
nitrosylated residues (71%) were calculated with an RSA of 10% or lower, indicating that 
those residues were not accessible to the solvent, whereas the remaining 40 modified 
cysteines (29%) had a relative RSA greater than 10%, meaning they were solvent-
accessible. Unmodified cysteines within the same proteins exhibited similar distribution 
between buried (77%) and solvent-accessible residues (23%). A quantile–quantile 
probability plot was used to determine if there was enrichment for exposed or buried 
cysteines within the modified versus the un-modified group of cysteine residues (Figure 
2.3C). To produce this plot, the RSA values of modified and unmodified cysteine 
residues were sorted and values of RSA for each percentile were plotted against each 
other (i.e., RSA of smallest 1% of modified cysteine residues vs. RSA of smallest 1% of 
unmodified cysteine residues, smallest 2% vs. smallest 2%). The plot demonstrates that 
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Figure 2.3: Analysis of primary sequence, distribution in secondary structures, and 
surface accessibility of S-nitrosylated cysteine residues. (A) The frequency of S-
nitrosocysteine (n = 142; black bars) and unmodified cysteine residues (n = 473; white 
bars) within the same proteins in different secondary structures was calculated using the 
available crystal structures. (B) Distribution of residues flanking S-nitrosylated cysteines 
in secondary structures. SNO-cysteines are located at position 0 and the frequency for 10 
residues upstream (−10) and 10 residues downstream (+10) was calculated as described 
earlier. (C) Quantile–quantile plot of relative RSA for S-nitrosylated (x axis) versus 
unmodified (y axis) cysteine residues. RSA values were calculated from the biological 
assemblies defined by PISA (42) for available crystal structures. (D) Top three scoring 
sequence motifs for residues flanking S-nitrosylated cysteine residue. Note the presence 
of charged as well as aliphatic amino acids able to “accommodate” protein and small-
molecule binding. (E) Top two sequence motifs assigned to the residues sensitive to Trx 
system. 
 
 
S-nitrosocysteine residues have a distribution skewed toward larger surface-accessible 
areas than unmodified cysteine residues within the same proteins. In addition, 70% of S-
nitrosylated cysteine residues within 6 Å were surrounded by negatively or positively 
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charged amino acids that had their side chains pointed away from cysteine thiol groups. 
Although the presence of charged residues in the vicinity of the modified residues did not 
impact their predicted pKa, it may facilitate site specific modification by accommodating 
protein or S-nitrosoglutathione association. This is in agreement with findings of Mitchell 
et al., who demonstrated that charged residues near cysteine 73 were required for 
interaction and transnitrosylation of procaspase-3 (Mitchell et al. 2007).  Accordingly, the 
presence of cysteine residues in highly exposed areas of proteins and in proximity to 
charged amino acids suggests a protein or small molecule transnitrosation assisted 
mechanism of S-nitrosylation. 
 
Metal Catalyzed S-Nitrosylation 
Studies exploring the S-nitrosylation of proteins in cells indicated that more than 
50% of the cellular formation of protein S-nitrosocysteine is derived by dinitrosyliron 
complexes (Bosworth et al. 2009). Within the liver S-nitrosoproteome, 13 S-nitrosylated 
cysteine residues, which are directly involved in the chelation of metal ions, were 
identified (Table S2.3). Metal ligation may provide site-directed modification of these 
residues. Alternatively, dinitrosyliron complexes could be stabilized near cysteine 
residues by interactions with neighboring acidic residues. As stated, more than 70% of 
the modified cysteine residues are in close proximity (<6 Å) to acidic residues, which 
could serve as interacting sites for dinitrosyliron complexes. Moreover, 15 
metalloproteins were identified as endogenously S-nitrosylated, suggesting a self-
catalyzed mechanism of S-nitrosylation similar to the proposed mechanism for the 
selective S-nitrosylation of hemoglobin (Weichsel et al. 2005). The possibility also exists 
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that these metalloproteins can catalyze S-nitrosylation of interacting proteins, as has been 
indicated previously (Weichsel et al. 2005). This will require protein–protein association 
and, as discussed later, the majority of the S-nitrosylated proteins, either in primary 
sequence or within the tertiary structure, contain charged amino acids that can provide 
interactive interfaces for specific transfer of a NO equivalent from a metalloprotein to 
cysteine residues. 
 
Linear Motifs 
To further interrogate structural elements that may distinguish modified cysteines 
from unmodified within the same proteins, flanking amino acids were examined for the 
presence of linear motifs using the program Motif-X (Schwartz et al. 2005). The top 
scoring motif for modified cysteines (n = 37, 12%) had glycine exclusively at position −1 
(P ≤ 0.001) and consisted mostly of hydrophobic residues (Figure 2.3D). Remarkably, the 
second (n = 31, 10%) and third (n=25, 8%) top scoring motifs had negatively charged 
amino acids exclusively at positions +3 and −1, respectively (P ≤ 0.001; Figure 2.3D). 
The same analysis for unmodified cysteines within the same proteins revealed top 
sequence motifs lacking negatively charged amino acids flanking cysteine residues (Fig. 
S2.4B), indicating that specific elements of the primary structure are required for a 
cysteine to be S-nitrosylated in vivo. These motifs could serve as scaffolds for protein 
and small molecule binding such as thioredoxin (Trx) or S-nitrosoglutathione. To further 
explore this possibility we used the Trx ex vivo denitrosylation assay (Paige et al. 2008) 
to identify sites of S-nitrosylation that can interact with Trx. Freshly isolated liver 
homogenates were treated with a Trx system (Trx/Trx-reductase/NADPH). This 
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treatment resulted in a 72% reduction in protein S-nitrosocysteine levels as quantified by 
chemiluminescence. In comparison with the untreated liver S-nitrosoproteome (Table 
S2.1), 72 proteins were no longer identified after Trx treatment (Table S2.4). Linear 
motif analysis revealed two motifs in this subset of S-nitrosylated proteins. The highest-
scoring motif had exclusively aspartic acid at position −1, whereas the second motif had 
exclusively threonine at position +5 (Figure 2.3E). Notably, both motifs contained 
charged amino acids at positions before and after the cysteine residue, consistent with the 
idea that charged amino acids in S-nitrosocysteine–containing motifs may facilitate 
interaction with Trx. 
 
In conclusion, by using unique, highly specific MS-based proteomic methods, we 
identified an expanded endogenous S-nitrosoproteome from WT mouse liver. Despite 
that S-nitrosylated cysteine residues had, in general, similar hydropathy distribution and 
predicted pKa values as nonmodified cysteine residues in the same proteins, closer 
interrogation of the surrounding primary and secondary structures revealed distinctions 
that direct site-specific S-nitrosylation of certain cysteine residues. The structural analysis 
of these proteins also uncovered structural features that can accommodate multiple 
mechanisms for S-nitrosylation in vivo. In addition, the data also revealed a putative link 
among leptin, eNOS, and protein S-nitrosylation in the regulation of liver fatty acid 
metabolism. Overall, the use of global proteomic methods enabled structural and 
functional characterization of the in vivo S-nitrosocysteine proteome and the formulation 
of testable new hypotheses that can be explored in the future using targeted approaches. 
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2.5 Supplementary Methods 
Affi-Gel-10 mercury resin (MRC). An organomercurial derivative of Affi-Gel-10 N-
hydroxysuccinimide-activated agarose gel was synthesized according to the protocol on 
the Biorad web site (Hercules, CA).  One hundred ml of settled Affi-Gel 10 was 
transferred into a Buchner funnel and washed with 300 ml of anhydrous isopropyl 
alcohol. Two grams of para-amino-mercuric acetate, dissolved in 30 ml of 
dimethylformamide, was added to 100 ml of washed Affi-Gel 10 and incubated for 4h at 
RT with gentle rocking. Unreacted succinimide groups are then blocked with 130 mM 
ethanolamine for 1h at RT with gentle rocking. Next, the gel slurry is transferred into a 
Buchner funnel and washed sequentially with 250 ml dimethylformamide and 700 ml of 
anhydrous isopropyl alcohol. Resin was stored as a 1:1 slurry in anhydrous isopropyl 
alcohol at 4 
o
C and was used within 3 months (Mcdonagh et al. 1976). 
Synthesis of mPEG-biotin. Biotinyl (3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-
propyl)-amide (Scheme 2.1) 4: To a solution of 4,7,10-trioxododecane1,13-diamine (3; 
30 g; 145 mmol; 9 equiv; Fluka, Scheme 2.1) in anhydrous DMF (40 ml) was added drop  
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Scheme 2.1: Chemical synthesis of mPEG-biotin compound.  
 
wise a solution of biotin succinimidyl ester (2; 5.44 g 16.0 mmol; SigmaAldrich, Scheme 
2.1) in 120 ml dry DMF over 30 minutes under argon.  The resulting thick white 
suspension is stirred a further 30 min and the solid that formed was removed by filtration 
and washed with DMF.  The clear filtrate was concentrated and the crude product was 
precipitated by the addition of diethyl ether.  The solids were isolated by filtration and a 
slurry solution was made and filtered repeatedly with ether (3 times) and ethyl acetate (3 
times).  The solids were dried under high vacuum overnight to afford the crude 4 (6.05g, 
85% yield) as a white sticky solid (Scheme 2.1).  The product was purified by flash 
chromatography using dichloromethane/methanol/ triethylamine (95/5/1). 
Biotin/Peg3/(4-chloromercuriobenzamide) (Scheme 2.1, 1):  To a mixture of 4-
chloromercuriobenzoic acid (1.0 g: 2.8 mmol; Spectrum Chemical) in anhydrous DMF (5 
ml) was added a solution of pentafluorophenol (0.515 g; 2.8 mmol; SigmaAldrich) and 
EDC (0.537 g; 2.8 mmol; SigmaAldrich, Scheme 2.1).  The reaction mixture was stirred 
at room temperature for 5 hours until complete as determined by TLC (hexanes/ethyl 
acetate (1/2)).  Triethylamine (0.73 ml ml; 3 equivalents) and a solution of 4 (1.175 g; 1.0 
equivalents) in DMF (3 ml) were then added (Scheme 2.1).  The reaction was completed 
after stirring for 1 h as determined by TLC (DCM/MeOH/TEA (90/10/1; UV and 
dimethylaminocinnaldehyde spray detections).  The solvent was removed on the rotavap 
and the crude product was precipitated by the addition of diethyl ether.  The solids were 
washed repeatedly with ether (3X), ethyl acetate (3X).  The desired product 1 (0.57 g: 
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27.5% yield) was purified by flash chromatography using DCM/MeOH/TEA (90/10/1).  
Mass spectral analysis revealed a mass of 809 (785.6 + Na); expected mass =785.6.  
Quantification of Protein-SNO using reductive chemistries coupled to ozone-based 
chemiluminescence. Liver lysates were exposed to GSNO for 30 min or left untreated 
(endogenous levels of protein-SNO), followed by acetone precipitation to remove low 
molecular weight nitrosothiols. An aliquot of each sample was illuminated under a 
conventional UV-transilluminator for 7 or 30 min to serve as a negative control. The UV-
illuminated, untreated, and GSNO-exposed samples were blocked with MMTS. The 
reaction efficiency of the phenylmercury reagents was assessed by splitting the GSNO-
exposed sample into 3 aliquots. One aliquot was mixed for 1 hr at RT with 2 ml activated 
mercury resin (MRC), the second was mixed for 1h at RT with 3.5mM mPEG-biotin, and 
the third was left untreated (GSNO-treated control). The MRC-treated sample was 
centrifuged at 1000 x g for 5 min and the supernatant was collected. Protein from the 
mPEG-biotin-treated sample was precipitated with acetone to remove excess mPEG-
biotin and resuspended in MES/DTPA/SDS buffer. Total protein was normalized 
between all samples, and protein S-nitrosocysteine content was quantified by reductive 
chemistries coupled to ozone-based chemiluminescence as previously described (Fang et 
al. 1998; Greco et al. 2006). 
Isolation and preparation of mouse liver protein homogenates for capture of S-
nitrosylated proteins. Isolated livers were homogenized into 3 ml of lysis buffer (250 mM 
Hepes-NaOH, pH 7.7, containing 1 mM DTPA, 0.1 mM neocuproine, 1 % Triton X-100, 
and protease inhibitors) on ice using a Teflon pestle and a Jumbo Stirrer (Fisher 
Scientific). The homogenates were then centrifuged at 13, 000xg for 30 min at 4
 o
C. The 
soluble protein fraction was collected and the protein concentration was determined by 
the Bradford assay. Each sample consisted of 24 mg of protein in 48 ml of lysis buffer 
(0.5 mg/ml). Liver protein lysates were supplemented with 100 mM mannitol, 5 mM 
MMTS and split into equal aliquots (24 ml). One aliquot was illuminated under a 
conventional UV-transilluminator for 7 min on ice and the other left untreated on ice. As 
an alternative to UV photolysis, negative controls were generated by treatment with 10 
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mM DTT for 30 min at 37
 o
C unless otherwise mentioned. Next, samples were 
precipitated by the addition of 3 volumes of acetone for 20 min at -20 
o
C followed by 
centrifugation at 3,000xg for 10min at 4 
o
C. Pellets were then washed twice with 1ml of 
cold acetone, solubilized in 24 ml blocking buffer (250 mM HEPES-NaOH, pH 7.7, 
containing 1 mM DTPA, 0.1 mM neocuproine, 2.5% SDS, and 20 mM MMTS), and 
incubated for 30 min at 50 
o
C with frequent vortexing. Following blocking, excess 
MMTS was removed by protein precipitation with 3 volumes of acetone for 20 min at -20 
o
C followed by centrifugation at 3000xg for 10min at 4 
o
C. Protein pellets were 
resuspended into 5 ml of blocking buffer (without MMTS) per sample and precipitated as 
described above. Protein pellets were then resuspended in 1.6 ml of loading buffer (250 
mM MES, 1 mM DTPA, pH 6.0, 1% SDS) and aliquoted into 0.8 ml for analysis by 
organomercury resin and 0.8 ml for analysis by organomercury-polyethyleneglycol-
biotin-based enrichment, as described below. Both protein capture methods were 
performed in parallel and uninterrupted up to the point of Colloidal blue gel staining (see 
GeLC-MS/MS analysis below). 
Capture of nitrosylated proteins using organomercury resin (MRC). MRC solid-phase 
capture columns were prepared as follows: 4 ml of gel slurry was added to disposable 
polypropylene columns and washed with 3 bed volumes of isopropanol. Next the resin 
was washed with 6 bed volumes of H2O.  Then, the resin was activated by washing with 
40 ml of 0.1 M NaHCO3, pH 8.8, and then equilibrated by washing with 40 ml of 50 mM 
MES, pH 6.0, containing 50 mM NaCl, and 1 mM DTPA. Blocked protein lysates (0.4 
ml), prepared as described above, were diluted to 1.5 ml with loading buffer, applied to 
activated MRC columns and incubated under stationary conditions for 1h at RT. Next, 
the columns were washed with 10 bed volumes of 50 mM Tris-HCl, pH 7.4, containing 
300 mM NaCl, 1 % SDS, followed by 10 bed volumes of the same buffer except 
containing 1 % Triton X-100 instead of SDS. Columns were washed with 5 bed volumes 
of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl, followed by elution of the bound 
proteins with 10 ml of the same buffer containing 50 mM β-mercaptoethanol. Samples 
were concentrated 500-fold and analyzed by GeLC-MS/MS analysis. 
65 
 
On-column protein digestion (MRC peptide capture). Blocked protein lysates (0.8 ml) 
were adjusted to the volume of the resin bed using loading buffer and applied to activated 
MRC columns (as described above) and incubated under stationary conditions for 1h at 
RT. Next, the columns were washed with 20 bed volumes of 50 mM Tris-HCl, pH 7.4, 
containing 300 mM NaCl, 0.5 % SDS, followed by 20 bed volumes of the same buffer, 
except containing 1 % Triton X-100 instead of SDS and with 1M urea. Columns were 
then washed with 20 bed volumes of deionized water, followed by 2 bed volumes of 
0.1M ammonium bicarbonate. Lysates were incubated with 1 bed volume of 0.1M 
ammonium bicarbonate containing trypsin (5 g) in the dark for 16h at RT. The resin was 
washed with 20 volumes of 1 M ammonium bicarbonate, pH 7.4, containing 300 mM 
NaCl, followed by 20 volumes of the same buffer without NaCl. Columns were then 
washed with 20 volumes of 0.1 M ammonium bicarbonate followed by 50 volumes of 
deionized water.  To elute bound peptides, the resin was incubated with 1 bed volume of 
performic acid in water (produced by reacting 1.0 M formic acid with 0.8 M H2O2 for 30 
min in the dark) for 30 min at RT. Eluted peptides were recovered by washing the resin 
with 1 bed volume of deionized water. The volume is then reduced by Speedvac to < 5 l 
and adjusted to 10 L with 0.1% formic acid. Eluted peptides (5 l) were analyzed by 
LC-MS/MS as described below.  
Labeling and affinity capture of S-nitrosylated proteins using organomercury-
polyethyleneglycol-biotin (mPEG-biotin). Blocked protein lysates (0.8 ml) were adjusted 
to 3.5 mM mPEG-biotin (50 mM mPEG-biotin stock in DMSO) and incubated at RT for 
1h with gentle rocking. Biotinylated proteins were split into 2 equal aliquots (one for 
protein capture, one for peptide capture) and precipitated with 3 volumes of acetone. 
Protein pellets for mPEG-biotin protein capture were resuspended in 0.2 ml of 25 mM 
HEPES-NaOH, pH 7.7, containing 0.1 mM DTPA, 0.01 mM neocuproine, and 0.1 % 
SDS. Protein pellets for mPEG-biotin peptide capture were resuspended in 0.5 ml of 
0.1M ammonium bicarbonate containing 0.1 % SDS and immediately processed as 
described below. Protein concentration of mPEG-biotin protein capture samples were 
determined by the BCA protein assay and then adjusted to 0.8 ml with 25 mM HEPES-
NaOH, pH 7.7, containing 0.1 mM DTPA, 0.01 mM neocuproine. Equal protein amounts 
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were incubated with washed neutravidin beads (200 L of slurry per mg of protein 
washed with 25 mM HEPES-NaOH, pH 7.7, containing 0.1 mM DTPA and 0.01 mM 
neocuproine) for 2h at RT under gentle rocking. Samples were centrifuged at 800xg for 4 
min and then the unbound fraction was removed. Beads were washed with 10 volumes of 
50 mM Tris-HCl, pH 7.4, containing 300 mM NaCl and 1 % Triton X-100 followed 10 
volumes of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl. Bound proteins were 
eluted with 0.5 ml of 50 mM Tris-HCl, pH 7.4, containing 50 mM NaCl and 100 mM β-
mercaptoethanol for 20 min at RT under gentle rocking. Samples were centrifuged at 
1000xg for 4 min and the supernatant (eluted peptides) were recovered. This step was 
repeated to ensure removal of neutravidin-agarose beads. Samples were concentrated 25-
fold and analyzed by GeLC-MS/MS analysis. 
Protein digestion and mPEG-biotin-neutravidin affinity peptide capture. The protein 
concentration of mPEG-biotin-labeled proteins (0.5 ml) (prepared above) was determined 
by the BCA assay and equal amounts of proteins were transferred to Ultra-free MC 
10kDa cut-off filters (previously rinsed with methanol and washed with water) and 
incubated with trypsin (1:100 enzyme:protein ratio) in the dark for 16h at 37 
o
C. The 
following day if densitometric analysis of Colloidal blue-stained gel was satisfactory (see 
GeLC-MS/MS analysis below), samples were then passed through the filters and the 
filtrate containing the biotinylated peptides was recovered and incubated with neutravidin 
beads (200 L slurry per mg of initial protein; washed with 10 volumes of 0.1 M 
ammonium bicarbonate) for 2 hours at RT under gentle rocking. Samples were 
centrifuged at 1000xg for 4 min and the unbound fraction was removed. The beads were 
washed 4 x 2.5 volumes of 1 M ammonium bicarbonate containing 50 mM NaCl, 4 x 2.5 
volumes of 1 M ammonium bicarbonate, 2 x 2.5 volumes of 0.1 M ammonium 
bicarbonate, and finally 2 x 5 volumes of deionized water. Between each wash beads 
were rocked for 2 min and centrifuged at 1000xg for 1 min. Bound peptides were eluted 
with 0.5 ml of performic acid in water (produced by reacting 1.0 M formic acid with 0.8 
M H2O2 for 30 min in the dark) for 30 min at RT with gentle rocking. Samples were 
centrifuged at 1000xg for 5 min and supernatant (eluted peptides) were recovered. This 
step was repeated to ensure removal of neutravidin-agarose beads. Samples were reduced 
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in volume by Speedvac to < 5 l and adjusted to 10 l with Millipore water. Eluted 
peptides (5 l) were analyzed by LC-MS/MS as described below. 
GeLC-MS/MS analysis. The protein fractions obtained from MRC and mPEG-biotin 
protein capture methods were analyzed by GeLC-MS/MS. For each treatment condition 
described above, the proteins were mixed with 6X Laemmli sample buffer and equal 
volumes (20 l) were loaded on NuPAGE 10% Bis-Tris gels (Invitrogen, Carlsbad, CA). 
Proteins were electrophoresed in MOPS running buffer for approximately 1 cm and 
visualized by Colloidal blue (Invitrogen, Carlsbad, CA). Visual inspection and 
densitometric analysis was performed to verify that the intensity of UV-treated samples 
were less than 90% of the untreated samples, otherwise samples were not processed. 
Stained gels can be immediately processed by in-gel trypsin digestion or stored in 2 % 
acetic acid for up to 1 month. In-gel digestion with trypsin was performed as previously 
described
 
except each lane was cut into 3 slices and individually digested with trypsin. 
Tryptic peptide digests were analyzed by either an LTQ linear ion trap (IT) or hybrid 
LTQ-Orbitrap mass spectrometer (Thermo Electron, San Jose, CA) coupled to an 
Eksigent 2D LC system (Eksigent Technologies, Livermore, CA) and autosampler. 
Buffers A and B were 0.1 % formic acid/1 % methanol and 80% acetonitrile/0.1 % 
formic acid/1 % methanol, respectively. Peptides were loaded isocratically onto a C18 trap 
column (75 um i.d. x 25 mm; New Objective Proteopep 2) at a flow rate of 1 μl per 
minute in 2% B. Peptides were then eluted onto a C18 analytical column (75 um i.d. x 150 
mm; New Objective Proteopep 2). A linear gradient was then initiated at a flow rate of 
300 nL per minute for 90 min from 3 - 40% B.  The mass spectrometer was set to 
repetitively scan from 375 to 1600 m/z followed by data-dependent MS/MS scans on the 
five most abundant ions with dynamic exclusion enabled. 
Generation and evaluation of SEQUEST peptide assignments. DTA files were generated 
from MS/MS spectra extracted from the RAW data file (intensity threshold of 2500 for 
protein capture and 1000 for peptide capture approaches; minimum ion count of 50) and 
processed by the ZSA and Correction algorithms of the SEQUEST Browser program. 
DTA files were submitted to Sorcerer-SEQUEST (ver. 4.0.3, rev 11; Sagen Research, 
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San Jose, CA) using the following parameters: Database searching was performed against 
a Uniprot database (Release 12.7; 1/2008) containing Mus musculus sequences from 
Swiss-Prot plus common contaminants, which were then reversed and appended to the 
forward sequences (29, 294 sequences). The database was indexed with the following 
parameters: mass range of 600 – 3500, tryptic cleavages with a maximum of 1 missed 
cleavage and static modifications of cysteine by carboxyamidomethylation (+57 amu) for 
in-gel digestion or by sulfonic acid (+48 amu) and methionine sulfone (+32 amu) for 
peptide affinity capture.  The DTA files were searched with a 2.0 amu or 50 ppm peptide 
mass tolerance for LTQ or LTQ-Orbitrap, respectively, 1.0 amu fragment ion mass 
tolerance, and variable modification of methionine (+16 amu) for in-gel digestion, and 
maximum number of variable modifications of 3.  
Potential sequence-to-spectrum peptide assignments generated by Sorcerer-SEQUEST 
were loaded into Scaffold (version 2.2; Proteome Software, Portland, OR) to validate 
protein identifications and perform manual inspection of MS/MS spectra as well as to 
compare protein identifications across experimental conditions.  For in-gel digestion 
experiments, protein identifications were accepted at a threshold of ≥ 99 % protein 
confidence with ≥ 2 unique peptides at ≥ 90 % confidence. These criteria resulted in an 
estimated protein false discovery rate (FDR) of ≤ 5 %, as calculated by the number of hits 
to the reverse protein sequences. For in-solution digestion/peptide affinity capture, 
empirically defined SEQUEST Xcorr thresholds were applied to filter peptides IDs with at 
least one peptide per protein.  Xcorr thresholds were applied to sulfonic acid-containing 
and non-modified peptides independently so peptide FDR was ≤ 5%. Since one unique 
peptide per protein was permitted, manual inspection of all MS/MS spectra was 
performed. The criteria for manual inspection were the following: (i) assignment of the 
majority of fragment ion abundance, (ii) sulfonic acid (+48 amu) modification supported 
by either y- or b- ions series (≥ 4 consecutive fragments), and (iii) assigned charge state 
and diagnostic markers, such as N-terminal proline, C-terminal aliphatic amino acids, and 
loss of H2O/ammonia consistent with amino acid sequence (Tabb et al. 2006). Cysteine 
residues that participated in redox cycling and reflect catalytically active residues, e.g. 
thioredoxins, peroxiredoxins, and glutaredoxins were included, while eight cysteinyl 
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peptides that were predicted or experimentally determined to form disulfide bonds were 
excluded. Although these cysteine residues may represent true S-nitrosylation sites as 
evidenced by previous studies that have documented endogenous S-nitrosocysteine 
residues that also participate in disulfide bond formation (Guo et al. 2008; Takahashi et 
al. 2007), a conservative approach was taken.  
Denitrosylation assays. Liver homogenates (6mg of protein per condition) were (1) 
remained untreated (2) exposed to 150nM Trx, 150nM TrxReductase and 100μmM 
NADPH for 30 min at 37
⁰
C (3) exposed to 1mM GSH for 30min at 37 
o
C. Unreacted 
reagents was removed by acetone precipitation (20 min at -20 
o
C) followed by 
centrifugation at 3000 x g for 10 min at 4 
o
C. Then, proteins were processed by MRC and 
mPEG-biotin protein capture approaches and GeLC/MS/MS analysis.  
Gene ontology and functional protein analysis. Subcellular localization was determined 
by either existing UniProt (www.uniprot.org) annotation, while gene ontology 
classification was provided by UniProt. Functional Analysis identified the biological 
functions that were most significant was performed using Uniprot and Fatigo 
(www.fatigo.org).   
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2.6 Supplemental Figures 
 
Figure S2.1: Characterization of protein S-nitrosocysteine. (A) The chemical 
structure of MRC, containing a phenylmercuric acetate functional group tethered to 
agarose solid-phase resin. (B) The chemical structure of mPEGb, containing a 
phenylmercury functional group conjugated to biotin by a polyethyleneglycol spacer. (C) 
The identification and validation of protein S-nitrosocysteine (SNO) was performed by 
phenylmercury-based capture (PMC). As outlined, SNO-PMC used a complementary 
solid-phase mercury resin capture (i.e., MRC) and mPEGb. The method is divided into 
three main steps: (i) homogenization of mouse liver and blocking of reduced protein 
cysteine, (ii) displacement of cysteine-bound NO by organomercury and/or Neutravidin-
based affinity enrichment, and (iii) liquid chromatography-MS/MS analysis. Step I was 
performed for all analyses. In step II, MMTS-blocked proteins were loaded onto activated 
solid-phase MRC columns or incubated in-solution with mPEGb. For protein 
identification, bound proteins from MRC were eluted with b-mercaptoethanol (b-ME), 
whereas mPEGb-labeled proteins were captured by Neutravidin agarose beads and eluted 
with b-ME (i). Captured proteins were separated by one-dimensional SDS/PAGE and in-
gel trypsin digested. Site-specific identification of S-nitrosocysteine residues was 
performed by on-column (MRC) and in-solution (mPEGb) peptide capture. From a 
parallel MRC sample, captured proteins were digested on-column with trypsin, and 
cysteinyl peptides were eluted by mild performic acid (3%), which cleaved the 
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phenylmercury mercaptide bond and oxidized the cysteine thiol to sulfonic acid. Also, a 
parallel mPEGb-labeled protein sample was digested in-solution with trypsin. Then, 
mPEGb-labeled peptides were enriched by Neutravidin-based capture (ii) and eluted by 
mild performic acid. Step III (LC-MS/MS peptide analysis) was performed for all 
approaches, with differences in post-acquisition data analysis between protein and 
peptide capture approaches (Greco et al. 2006). RAW files generated by LC-MS/MS 
analysis from protein and peptide capture experiments were processed ExtractMSN to 
obtain MS2 spectra, searched by Sorcerer-SEQUEST against a concatenated forward-
reverse database , and then analyzed by Scaffold (Greco et al. 2006). 
 
 
Figure S2.2: GeLC-MS/MS analysis of protein S-nitrosocysteine. (A) Representative 
short (approximately 2 cm) colloidal blue-stained protein gels of MRC protein capture 
from WT mouse liver that were processed by GeLC-MS/MS analysis. (B) Representative 
base peak chromatograms from mPEGb protein capture demonstrate reduction in ion 
intensity after UV photolysis (red) compared with untreated sample (blue). 
Chromatograms represent analysis of tryptic peptides derived from a single gel slice. The 
equivalent gel slice was analyzed from the UV-treated sample. The base peak intensity in 
the UV-exposed trace (red) corresponded to trypsin autolysis peptides (asterisk). Inset: 
Average false-positive identification rate (FIR ± SD) represents the percentage of 
proteins that were identified in both the UV-treated and untreated samples across three 
independent biological replicates. 
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Figure S2.3: Ontological analysis of liver S-nitrosoproteome. (A) Histogram of 
subcellular localization represented by number of proteins (black bars) and total S-
nitrosocysteine (SNO) sites (open bars). The primary cellular localization reported by 
UniProt was used for proteins with multiple subcellular compartments. (B) Histogram of 
molecular function gene ontology analysis as a function of number of proteins (black 
bars) and total S-nitrosocysteine (SNO) sites (open bars). The top four catalytic activities 
are shown, with oxidoreductase and transferase activities significantly overrepresented in 
the liver S-nitrosoproteome compared with the entire mouse genome (P = 1.28e−20 and 
3.2e−3, respectively). (C) Sixteen S-nitrosylated proteins from WT liver as determined by 
Ingenuity Knowledge Base comprised the most significant protein interaction network 
and clustered around the hormone leptin. 
73 
 
 
 
Figure S2.4: Distribution of residues flanking unmodified cysteine residues in 
secondary structures. (A) Cysteine residues are denoted by Cys (position 0) and the 
frequency for 10 residues upstream (−10) and 10 residues downstream (+10) was 
calculated using the available crystal structures. Beta sheets (black bars), helices (white 
bars), coils (gray bars). (B) Primary sequence motifs for unmodified cysteine residues 
within S-nitrosylated proteins.  
 
 
 
2.7 Supplemental Tables 
 
Supplementary Table 2.1: Endogenously S-nitrososylated proteins in wild type mice liver 
Protein name Uniprot 
Accession 
MW, 
kDa 
Unique 
Peptides 
(MRC)
1
 
Unique 
Peptides 
(mPEGb)
1
 
Peptide sequence
2
 
11,4-alpha-glucan-branching enzyme 
Q9D6Y
9 80,349 
 
Q9D6Y9 80 3 3 C473VAYAESHDQALVGDK 
2-hydroxyacyl-CoA  lyase 1 Q9QXE0 64 7 3 
GVVPDNNHPNC264VGAAR 
KLVEQC243SLPFLPTPMGK 
TMLQNC415LPR 
3-hydroxyanthranilate 3,4-dioxygenase Q78JT3 33 - 5 ASFQPPVC23NKLMHQEQLK 
3-ketoacyl-CoA thiolase A, peroxisomal Q921H8 44 - 5 DC177LTPMGMTSENVAER 
3-ketoacyl-CoA thiolase B, peroxisomal 
precursor 
Q8VCH0 44 5 - 
DC177LIPMGITSENVAER 
GC218FHAEIVPVTTTVLNDK 
VNPLGGAIALGHPLGC381TGAR 
QC123SSGLQAVANAIAGGIR 
10-formyltetrahydrofolate dehydrogenase Q8R0Y6 99 33 29 
MKAVGQSLFGQEVYC17QLRK 
LRGEDGESEC404VINYVEK 
SC662ALSNVK 
TAAC587LAAGNTVVIKPAQVTPLTALK 
3-ketoacyl-CoA thiolase, mitochondrial Q8BWT1 42 17 - 
EDC179DRYALQSQQR 
VVGYFVSGC287DPTIMGIGVPAINGA 
40S ribosomal protein S2 P25444 31 - 3 GC229TATLGNFAK 
40S ribosomal protein S3 P62908 27 3 5 
GLC97AIAQAESLR 
RAC119YGVLR 
40S ribosomal protein S3a P97351 30 - 3 
NC96LTNFHGMDLTR 
AC201QSIYPLHDVFVR 
TTDGYLLRLFC139VGFTK 
40S ribosomal protein S4, X isoform P62702 30 - 3 
FDTGNLC181MVTGGANLGR 
LREC41LPLIIFLR 
40S ribosomal protein S6 P62754 29 - 3 MKLNISFPATGC12QK 
40S ribosomal protein S14 P62264 16 - 2 C85KELGITALHIK 74
40S ribosomal protein S8 P62242 
 
 
24 - 3 LLAC174IASRPGQC182GR 
4-hydroxyphenylpyruvate dioxygenase P49429 45 - 9 HGDGVKDIAFEVEDC103DHIVQK 
5-oxoprolinase Q8K010 138 2 - GHDPSAHVLACFGGAGGQHAC497AIAR 
60kDa heat shock protein, mitochondrial 
precursor 
P63038 61 11 10 
C237EFQDAYVLLSEK 
AAVEEGIVLGGGC442ALLR 
C447IPALDSLKPANEDQK 
60S ribosomal protein L3 P27659 46 - 4 TVFAEHISDEC114K 
60S ribosomal protein L12 P35979 18 - 2 C17TGGEVGATSALAPK 
60S ribosomal protein L17 Q9CPR4 21 - 2 
INPYMSSPC144HIEMILTEK 
YSLDPENPTKSC15K  
QC57VPFR 
60S ribosomal protein L27a P14115 17 2 - GVGAC144VLVA 
60S ribosomal protein L30  P62889 13 2 - TGVHHYSGNNIELGTAC85GK 
60S ribosomal protein L7a  P12970 30 - 3 TC199TTVAFTQVNSEDKGALAK 
Acetyl-CoA acetyltransferase, cytosolic Q8CAY6 41 3 2 
VNIDGGAIALGHPLGASGC360R 
VAPEEVSEVIFGHVLTAGC65GQNPTR 
Acetyl-CoA carboxylase 1 Q5SWU9 265 3 - RPGALDPGC812VAK 
Acetyl-CoA acetyltransferase, 
mitochondrial precursor 
Q8QZT1 45 6 5 
IHMGNC193AENTAK 
AIMMASQSLMC138GHQDVMVAGGMESMSNVPYVMS
R 
Acyl-CoA dehydrogenase family member 
11  
Q80XL6 87 - 2 C546KIAIVLGR 
Acyl-CoA dehydrogenase family member 
9, mitochondrial  
Q8JZN5 69 - 3 
AYIC617AHPLDR 
FSMGSAVAGMLKKLIELTAEYAC331TR 
 
Aconitate hydratase, mitochondrial Q99KI0 85 11 9 
VAVPSTIHC126DHLIEAQVGGEK 
C410KSQFTITPGSEQIR 
VGLIGSC385TNSSYEDMGR 
Actin, cytoplasmic 1  P60710 42 11 - C257PEALFQPSFLGMESC272GLHETTFNSMK  
Acyl-coenzyme A synthetase ACSM5,  
mitochondrial precursor 
Q8BGA8 64 2 - HC342LTGGEALNPDVR 
Adenosine kinase P55264 40 3 4 
AATFFGC105IGIDK 
TGC352TFPEKPDFH 
75
Adenosylhomocysteinase P50247 48 - 13 
SKFDNLYGC195R 
VAVVAGYGDVGKGC228AQALR 
ADP/ATP translocase 2 P51881 33 - 3 GLGDC160LVK 
Alanine--glyoxylate aminotransferase 2,  
mitochondrial precursor 
Q3UEG6 57 6 - 
TEVNQIHEDC463K 
GAYHGC199SPYTLGLTNVGIYK 
Alcohol dehydrogenase [NADP+]  Q9JII6 36 4 3 
HIDC46ASVYGNETEIGEALKESVGSGK 
KVIC260IPK 
 
Alcohol dehydrogenase 1 P00329 40 7 8 
VIPLFSPQC98GEC101R 
IC104KHPESNFC112SR 
VTPGSTC196AFGLGGVGLSVILGC212K 
IDGASPLDKVC171LIGC175GFSTGYGSAVK 
Aldehyde dehydrogenase family 8 
member A1 
Q8BH00 54 5 4 
ILC354GEGVDQLSLPLR 
ITQLSAPHC347K 
Aldehyde dehydrogenase X, 
mitochondrial 
Q9CZS1 58 5 - TIPMDGEHFC171FTR 
Aldehyde dehydrogenase, cytosolic 1 O35945 55 - 2 KFPVLNPATEEVIC50HVEEGDKADVDK 
Aldehyde dehydrogenase, mitochondrial 
precursor 
P47738 56 14 14 LLC388GGGAAADR 
Alpha-aminoadipic semialdehyde 
dehydrogenase 
Q9DBF1 56 3 3 
C633GGLPAPEHSDNPLR 
SSVVPVEGC342PELPHK 
GSDC450GIVNVNIPTSGAEIGGAFGGEKHTGGGR 
Amine oxidase [flavin-containing] B Q8BW75 58 3 2 LLHDC26GLSVVVLEAR 
Apoptosis-inducing factor 1, 
mitochondrial precursor 
Q9Z0X1 67 - 5 C255LIATGGTPR 
Argininosuccinate lyase Q91YI0 52 7 - 
VFGRC307AGLLMTLK 
QTC129SKLSALLRVLIGTMVDR 
Argininosuccinate synthase P16460 46 - 19 
FELTC132YSLAPQIK 
YLLGTSLARPC97IAR 
Arginyl-tRNA synthetase, cytoplasmic Q9D0I9 76 4 3 MLLC638EAVAAVMAKGFDILGIKPVQR 
Aspartate aminotransferase, 
mitochondrial precursor 
P05202 47 12 9 
TC187GFDFSGALEDISK 
VGAFTVVC295K 
NLDKEYLPIGGLAEFC106K 
ATP synthase subunit alpha, Q03265 60 16 18 LYC244IYVAIGQKR 76
mitochondrial 
ATP synthase subunit gamma, 
mitochondrial precursor 
Q91VR2 33 3 2   GLC103GAIHSSVAK 
ATP-binding cassette sub-family D 
member 3 
P55096 75 5 3 NTSLAGAAFLLLC24LLHKR 
ATP-citrate synthase Q91V92 120 5 5 
GVTIIGPATVGGIKPGC623FK 
KPASFMTSIC835DER 
YIC20TTSAIQNR 
 
Betaine--homocysteine S-
methyltransferase 1 
O35490 45 14 - 
QVADEGDALVAGGVSQTPSYLSC131K 
AGASIVGVNC267HFDPSVSLQTVK 
YIGGC299C300GFEPYHIR 
AYLMSQPLAYHTPDC256GK 
Bifunctional aminoacyl-tRNA synthetase  Q8CGC7 170 - 3 VTEAVEC856LLSLK 
Calcium-binding mitochondrial carrier 
protein Aralar 2 
Q9QXX4 101 14 14 AGQTTYNGVTDC566FRK 
Carbamoyl-phosphate synthase 
[ammonia],  
mitochondrial precursor 
Q8C196 165 - 64 
VVAVDC225GIK 
C920LGLTEAQTR 
TSAC761FEPSLDYMVTK 
SAYALGGLGSGIC600PNKETLIDLGTKA 
Carbonic anhydrase 3 P16015 29 - 8 
EAPFTHFDPSC182LFPAC187R 
TC68RVVFDDTYDRSMLR 
Calreticulin  P14211 48 7 6 C163KDDEFTHLY 
Catalase P24270 60 - 17 
SALEHSVQC425AVDVKR
 
LC460ENIAGHLK 
Catechol O-methyltransferase  O88587 29 2 2 GSSSFEC234THYSSYLEYMK 
Cathepsin B P10605 37 2 3 GENHC319GIESEIVAGIPR 
Complement C3  P01027 186 6 3 VELLHNPAFC873SMATAK 
Corticosteroid 11-beta-dehydrogenase 
isozyme 1  
P50172 32 4 2 
C78LELGAASAHY 
EEC241ALEIIK 
 
Cystathionine gamma-lyase  Q8VCN5 44 2 - 
  ISFVDC136SK 
  LADIGAC171AQIVHK  
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Cytochrome b-c1 complex subunit 1 Q9CZ13 53 4 - 
NALVSHLDGTTPVC410EDIGR 
LC380TSATESEVTR 
Cytochrome c, somatic P62897 12 3 - IFVQKC15AQC18HTVEK 
Cytochrome P450 27, mitochondrial Q9DBG1 61 - 3 IGC230LKPSIPEDTAAFIR 
Cytochrome P450 3A11  Q64459 58 5 4 FALMNMKLALTKIMQNFSFQPC469K 
Cytochrome P450 3A41 Q9JMA7 56 2 - VMQNFSFQPC469QETQPLK 
Cytochrome P450 2C50 Q91X77 56 3 4 
FIDLVPNSLPHEVTC372DIK 
RIC435AGEGLAR 
DIC51QSFTNLSK 
VQEEARC151LVEELRK 
Cytochrome P450 2C54 Q6XVG2 56 9 - FIDLVPNNLPHEVTC372DIK 
Cytochrome P450 2D10 P24456 57 5 4 RSC446LGEPLAR 
Cytochrome P450 2E1 Q05421 57 3 - 
DVTDC268LLIEMEKEK 
SLDINC261PR 
RVC437VGEGLAR 
EFKLC488VIPR 
Cytochrome P450 2F2 P33267 56 7 4 
DFIDC267FLTK 
PFQLC487MHIR 
RLC436LGEPLAR 
Cytosol aminopeptidase Q9CPY7 56 8 3 QVIDC445QLADVNNLGK 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial 
Q80XN0 38 - 5 
AILITGC63DSGFGFSLAK 
GFLVFAGC86LMK 
TIQLNVC115NSEEVEK 
D-dopachrome decarboxylase O35215 13 - 6 
LC24AATATILDKPEDR 
STEPC57AHLLVSSIGVVGTAEQNR 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial  
Q8CHT0 62 8 4 
FC94YADKALLNR 
LAGEC314GGKNFHFVHSSADVDSVVSGTLR 
 
Dimethylaniline monooxygenase [N-
oxide-forming] 3 
P97501 61 5 - 
GTC397TLPSVMDMMDDIDEK 
VLVGLGNSGC197DIAAELSHVAQK 
Dihydrolipoyl dehydrogenase, 
mitochondrial precursor 
O08749 54 3 2 VC484HAHPTLSEAFR 
Dihydropteridine reductase  Q8BVI4 26 2 4 GAVHQLC158QSLAGK 78
Dihydropyrimidinase Q9EQF5 57 7 - 
KMLALGITGPEGHELC220RPEAVEAEATLR 
AITIASAVNC242PLYVVHVMSK 
DQTC484TPVPVKR 
Dihydroxyacetone kinase Q8VC30 60 7 7 IC382TTLIGLEEHLNALDR 
Dolichyl-diphosphooligosaccharide--
protein  glycosyltransferase subunit 1 
Q91YQ5 68 6 4 
LKTEGSDLC546DR 
VAC478ITEQVLTLVNKR 
Electron transfer flavoprotein subunit 
alpha, mitochondrial  
Q99LC5 35 4 6 QFSYTHIC109AGASAFGK 
Electron transfer flavoprotein subunit 
beta 
Q9DCW4 28 5 5 HSMNPFC42EIAVEEAVR 
Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial 
Q921G7 68 7 7 
AAQIGAHTLSGAC118LDPAAFK 
VTVFAEGC248HGHLAK 
LQINAQNC585VHC588K 
Elongation factor 2 P58252 95 5 9 
STLTDSLVC41K 
DLEEDHAC567IPIKK 
TFC290QLILDPIFK 
C369ELLYEGPPDDEAAMGIK 
Enoyl-CoA hydratase, mitochondrial  Q8BH95 31 6 5 LVEEAIQC225AEK 
Epoxide hydrolase 2 P34914 63 13 11 VTGTQFPEAPLPVPC230NPNDVSHGYVTVKPGIR 
Ester hydrolase C11orf54 homolog Q91V76 35 2 - 
AHIMPAEFSSC226PLNSDEAVNK 
RTGELNFVSC187MR 
Estradiol 17 beta-dehydrogenase 5 P70694 37 - 14 
VC98LEQSLK 
YKPVC188NQVEC193HPYLNQGK 
LLDFC206R 
Fatty acid synthase P19096 272 - 12 
FVFTPHMEAEC1128LSESTALQK 
DC1590MLGMEFSGR 
C1464ILLSNLSNTSHAPK 
Fatty acid-binding protein, liver P12710 14 - 9 NEFTLGEEC69ELETMTGEK 
Formimidoyltransferase-cyclodeaminase Q91XD4 60 4 2 
TVYTFVGQPEC60VVEGALHAAR 
AC438ALQEGLR 
Fructose-1,6-bisphosphatase 1  Q9QXD6 37 13 10 AQGTGELTQLLNSLC39TAIKAISSAVR 
Fructose-bisphosphate aldolase B Q91Y97 39 14 - 
C135AQYKKDGVDFGK 
IADQC158PSSLAIQENANALAR 
RAMANC336QAAQGQYVHTGSSGAAATQSLFTASYTY 79
Glutamate dehydrogenase 1, 
mitochondrial 
P26443 61 - 20 
IIKPC112NHVLSLSFPIR 
C172AVVDVPFGGAKAGVK 
AC254VTGKPISQGGIHGR 
Glutathione peroxidase 1 P11352 22 - 8 GLVVLGFPC76NQFGHQENGK 
Glutathione S-transferase A3 P30115 25 - 3 KPFDDAKC212VESAK 
Glutathione S-transferase Mu 1 P10649 26 8 7 C174LDAFPN 
Fumarylacetoacetase P35505 40 7 - 
VGFGQC408AGK 
GEGMSQAATIC315R 
TFLLDGDEVIITGHC396QGDGYR 
Glutamine synthetase P15105 42 4 3 
RPSANC346DPYAVTEAIVR 
C269IEEAIDK 
LVLC99EVFK 
AC183LYAGVK 
Glyceraldehyde-3-phosphate 
dehydrogenase 
P16858 36 7 - 
VPTPNVSVVDLTC245R 
IVSNASC150TTNC154LAPLAK 
Glycerol-3-phosphate dehydrogenase, 
mitochondrial  
Q64521 81 3 2 C270KDVLTGQEFDVR 
Glycerol-3-phosphate dehydrogenase 
[NAD+], cytoplasmic 
P13707 38 4 5 C341LQNHPEHM 
Glycerol kinase  Q64516 61 2 - C299VFSEHGLLTTVAYK 
Glycine dehydrogenase 
[decarboxylating], mitochondrial 
Q91W43 113 3 - 
C230HPQTIAVVQTR 
TFC763IPHGGGGPGMGPIGVK 
Glycine N-methyltransferase Q9QXF8 33 - 5 
SFAHLPDC147K 
LSYYPHC247LASFTELVR 
NYDYILSTGC186APPGK 
Glycogen phosphorylase, liver form Q9ET01 97 10 14 INMAHLC446IVGC450HAVNGVAK 
Heat shock cognate 71 kDa protein  P63017 71 18 15 GPAVGIDLGTTYSC17VGVFQHGK 
Heat shock protein 75 kDa, 
mitochondrial  
Q9CQN1 80   IIIHLKSDC263KDFASESR 
Hemoglobin subunit beta 
P02088/ 
P02089 
16 2 4 GTFASLSELHC94DK 
Homogentisate 1,2-dioxygenase O09173 50 3 - 
YISGFGNEC14ASEDPRC21PGSLPK 
SNNGLAVHIFLC138NSSMENR 
QGGFLPGGSLHSAMTPHGPDADC377FEK 
80
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial 
P38060 34 2 2 
KNANC141SIEESFQR 
LLEAGDFIC307QALNR 
Hydroxymethylglutaryl-CoA synthase, 
mitochondrial 
P54869 57 - 15 
MGFC96SVQEDINSLC106LTVVQR 
ALDRC269YAAYR 
MIFHTPFC305K 
Isocitrate dehydrogenase [NADP], 
mitochondrial  
P54071 51 3 3 
C113ATITPDEARVEEFKLK 
  DLAGC418 IHGLSNVK 
 
Kynurenine 3-monooxygenase Q91WN4 54 2 2 
SHC299VLMGDAAHAIVPF 
C139IPEEGVLTVLGPDKVPR 
L-gulonolactone oxidase  P58710 50 5 3 
TYGC19SPEMYYQPTSVGEVR 
DSC360YMNIIMYRPYGK 
 
L-lactate dehydrogenase A chain P06151 36 2 8 
DYC84VTANSK 
ITVVGVGAVGMAC35AISILMK 
VIGSGC163NLDSAR 
Liver carboxylesterase 31  Q63880 63 14 10 DASINPPMC100LQDVER 
Liver carboxylesterase 31-like precursor Q8VCU1 63 3 - DASINPPMC97LQDVEK 
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
P51174 48 2 3 
C166IGAIAMTEPGAGADLQGVR 
LAELKTHIC342VTR 
Long-chain-fatty-acid--CoA ligase 1 P41216 78 20 18 
ALKPPC55DLSMQSVEIAGTTDGIRR 
GIQVSNNGPC109LGSR 
C242GVEIISLK 
GAMITHQNIINDC298SGFIK 
Long-chain-fatty-acid--CoA ligase 5 Q8JZR0 76 6 3 
C226GVEMLSLHDAENIGK 
KPVPPKPEDLSVIC259FTSGTTGDPK 
TAGHVGTPVAC471NFVK 
Malate dehydrogenase, mitochondrial 
precursor 
P08249 36 6 6 GYLGPEQLPDC89LK 
Membrane-associated progesterone 
receptor component 1 
O55022 22 4 3 GLATFC129LDK 
Methylcrotonoyl-CoA carboxylase beta 
chain, mitochondrial  
Q3ULD5 61 3 3 AATGEEVSAEDLGGADLHC267R 
Methionyl-tRNA synthatase, cytoplasmic Q68FL6 101 - 2 ILATSFIC789TLPAGHR 
Microsomal glutathione S-transferase 1 Q91VS7 18 4 3 VFANPEDC50AGFGKGENAK 81
NADPH--cytochrome P450 reductase  P37040 77 5 3 
  EQGKEVGETLLYYGC566R 
  LIHEGGAHIYVC630GDAR 
 VHPNSVHIC472AVAVEYEAK 
 
Nicotinate-nucleotide pyrophosphorylase 
[carboxylating] 
Q91X91 32 2 3 
C111SGIASAAATAVEVAR 
YGLQVGGAAC159HR 
Non-specific lipid-transfer protein P32020 59 12 12 ADC495TITMADSDLLALMTGK 
Ornithine aminotransferase, 
mitochondrial  
P29758 48 - 3 VLPMNTGVEAGETAC150K 
Peptidyl-prolyl  cis-trans isomerase A P17742 18 7 3 IIPGFMC62QGGDFTR 
Peroxisomal bifunctional enzyme Q9DBM2 78 10 13 LC17NPPVNAISPTVITEVR 
Peroxiredoxin-4  O08807 31 - 4 TRENEC54HFYAGGQVYPGEASR 
Peroxiredoxin-6 O08709 25 3 4 DFTPVC47TTELGR 
Peroxisomal carnitine O-
octanoyltransferase  
Q9DC50 70 3 - AFVFDVLHEGC210LITPPELLR 
Peroxisomal coenzyme A diphosphatase 
NUDT7  
Q99P30 27 - 5 IDFDLHDLIPSC223ER 
Peroxisomal multifunctional enzyme type 
2  
P51660 
 
79 7 12 
NNIHC189NTIAPNAGSR 
IC277DFSNASKPQTIQESTGGIVEVLHK 
 
Peroxisomal sarcosine oxidase Q9D826 44 2 - 
TFSDIQDVQILC299HFVR 
C319MYTNTPDEHFILDC333HPK 
Peroxisomal trans-2-enoyl-CoA reductase  Q99MZ7 32 2 - ELLHLGC43NVVIASR 
Phenylalanine-4-hydroxylase P16331 52 5 4 
VFHC265TQYIR 
NLADSINSEVGILC445HALQK 
Phosphate carrier protein, mitochondrial Q8VEM8 40 4 - 
AVEEYSC52EFGSMK 
C272AIVSHPADSVVSVLNK 
Phosphoglycerate kinase 1 P09411 44 5 3 AAVPSIKFC50LDNGAK 
Phosphoglucomutase-1  Q9D0F9 62 5 11 LSLC374GEESFGTGSDHIR 
Plastin-3  Q99K51 70 8 3 VDLNSNGFIC34DYELHELFK 
Probable D-lactate dehydrogenase, 
mitochondrial precursor 
Q7TNG8 52 5 - ALALGGTC439TGEHGIGLGK 
Probable 2-oxoglutarate dehydrogenase A2ATU0 103 - 2 LVGC393AIIHVNGDSPEEVVR 
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E1 component DHKTD1, mitochondrial  
Probable imidazolonepropionase  Q9DBA8 46 2 - ELHLSLSATYC189GAHSVPK 
Probable urocanate hydratase  Q8VC12 74 10 9 AAAIVGC265IGVIAEVDKAALVK 
Profilin-1 P62962 15 - 4 C128YEMASHLR 
Propionyl-CoA carboxylase beta chain, 
mitochondrial  
Q8VC12 58 2 - C92ADFGMAADKNKFPGDSVVTGR 
Protein disulfide-isomerase A3  P27773 57 - 16 FIQDSIFGLC244PHMTEDNKDLIQGK 
Protein transport protein Sec23A  Q01405 86   MVQVHELGC180EGISK 
Protein transport protein Sec61 subunit 
alpha isoform 1 
P61620 52 3 - FLEVIKPFC13VILPEIQKPER 
Pyruvate carboxylase, mitochondrial 
precursor 
Q05920 130 24 14 
ADFAQAC131QDAGVR 
FC663EVAKENGMDVFR 
DMAGLLKPAAC752TMLVSSLR 
Regucalcin Q64374 33 10 10 
MEKDEQIPDGMC207IDAEGK 
DYSEMYVTC262AR 
Retinal dehydrogenase 1  P24549 54 17 18 IGPALSC186GNTVVVKPAEQTPLTALHLASLIK 
Retinol dehydrogenase 7 O88451 36 2 - VLAAC60LTEK 
Ribosome-binding protein 1 Q99PL5 173 10 22 
LKELESQVSC1198LEK 
C1136EELSSLHGQLK 
S-adenosylmethionine synthetase isoform 
type-1 
Q91X83 43 - 4 
IC35DQISDAVLDAHLK 
VALEQQSPDIAQC121VHLDR 
TAC377YGHFGR 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
O55143 115 6 6 
C560LALATHDNPLK 
NYLEQPGKEC998VQPATK 
Sarcosine dehydrogenase mitochondrial 
precursor 
Q99LB7 102 - 13 
STVC382GPESFTPDHKPLMGEAPELR 
DPLHEELLGQGC498VFQER 
C672QLMDSSEDLGMLSIQGPASR 
SEC14-like protein 4 Q8R0F9 46 - 2 
VC128EMLLHEC135ELQSQK 
YNAHMVPEDGSLNC355LK 
Selenium-binding protein 1 P17563 52 - 10 
GPREEIVYLPC31IYR 
C8GPGYSTPLEAMK 
GGSVQVLEDQELTC371QPEPLVVK 
Selenium-binding protein 2 Q63836 52 - 15 C8GPGYPTPLEAMK 
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C131NVSNTHTSHC141LASGEVMVNTLGDLQGNGK 
FLHDPSATQGFVGC268ALSSNIQR 
GGSVQVLEDQELTC371QPEPLVVK 
Sodium/potassium-transporting ATPase 
subunit alpha-1 
Q8VDN2 113 6 7 
AC663VVHGSDLK 
LIIVEGC705QR 
Sorbitol dehydrogenase  Q64442 38 6 - 
VMIKC350DPNDQNP 
VLVC179GAGPVGMVTLLVAK 
 
Src substrate cortactin Q60598 61 2 - HC112SQVDSVR 
Staphylococcal nuclease domain-
containing protein 1  
Q78PY7 102   
EVC96FTIENKTPQGR 
GIVKMVLSGC31AIIVRGQPR 
 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
Q8K2B3 72 10 6 
GVIALC238IEDGSIHR 
TYFSC266TSAHTSTGDGTAMVTR 
Sulfite oxidase, mitochondrial  Q8R086 61 6 - 
HEVTVTLQC265AGNR 
LC300DVLAQAGHR 
 
Sulfotransferase 1A1 P52840 34 2 - 
LMTGC283DFTFR 
IPFLEFSC82PGVPPGLETLK 
Synaptic glycoprotein SC2  Q9CY27 36 2 - LC18FLDKVEPQATISEIK 
Thioredoxin domain- containing protein-
4 
Q9D1Q6 47 3 - VDC92DQHSDIAQR 
Thiosulfate sulfurtransferase P52196 33 7 - KVDLSQPLIATC248R 
Threonyl-tRNA synthetase, cytoplasmic Q9D0R2 83 5 - FMADTDLDPGC655TLNKK 
Triosephosphate isomerase  P17751 27 - 3 
IIYGGSVTGATC218K 
VSHALAEGLGVIAC127IGEK 
 
Tryptophan 2,3-dioxygenase P48776 48 9 - EVLLC266LFDEK 
Tubulin beta chain 
P68372 
(+5) 
50 9 2 EIVHIQAGQC12GNQIGAK 
Ubiquitin-like modifier-activating 
enzyme 1  
Q02053 118 7 - YSRPAQLHIGFQALHQFC340ALHNQPPRPR 
UPF0465 protein C5orf33 homolog  Q8C5H8 51 3 - SEGHLC181LPVR 
UDP-glucuronosyltransferase 1-1 Q63886 60 - 7 
VKNVLLAVSENFMC225R 
MVFIGGINC282LQK 84
UDP-glucuronosyltransferase 2B5 P17717 61 - 8 FLSLC128KDVVSNK 
Uricase   P25688 35 3 6 
NGIKHVHAFIHTPTGTHFC141EVEQMR 
NIETFAMNIC95EHFLSSFNHVTR 
 
Valyl-tRNA synthetase  Q9Z1Q9 140 8 3 C681GEMAQAASAAVTR 
Very long-chain acyl-CoA synthetase  O35488 70 11 9 GEVGLLVC427KITQLTPFIGYAGGK 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor 
P50544 71 11 9 SSAIPSPC238GK 
Vigilin  Q8VDJ3 142 7 4 RC948DIIIISGR 
Xanthine dehydrogenase/oxidase  Q00519 146 4 - C828MLDRDEDMLITGGR 
 
 
Sequence-to-spectrum assignments from three biological replicates were combined in Scaffold. The proteins listed above satisfied three criteria: (1) 
identified by at least one protein capture method (≥2 unique peptides), (2) confirmed by a sulfonic acid-containing peptide sequence and (3) not 
identified in the respective UV-exposed samples. Uniprot accession numbers correspond to the full-length unprocessed precursor when available 
(www.uniprot.org). Additional accessions were listed if the observed peptides could not distinguish between protein isoforms.  All the MS/MS 
spectra from peptide capture can be viewed at http://www.research.chop.edu/tools/msms/spectra.pdf;. 
1
Number of unique peptides identified in protein capture experiment from 3 biological replicates (does not include sulfonic acid-containing 
peptides). A null value indicates the protein did not meet the threshold criteria and was considered not identified. 
2
Cysteinyl-containing tryptic peptide sequences identified by peptide capture. The indicated cysteine residue(s) was identified as sulfonic acid 
and corresponds to the unprocessed mouse precursor protein. 
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Supplementary Table 2.2. Endogenously S-nitrosylated proteins in eNOS
-/-
 mouse liver 
Protein name 
Uniprot 
Accession 
MW, 
kDa 
Unique 
Peptides 
(MRC)1 
Unique 
Peptides 
(mPEGb)1 
Peptide sequence2 
40S ribosomal protein S3 P62908 27 4 - GLC97AIAQAESLR
3
 
60S ribosomal protein L12 P35979 18 2 4 C17TGGEVGATSALAPK
3
 
60S ribosomal protein L17 Q9CPR4 21 2 6 
QC57VPFR
3
 
INPYMSSPC144HIEMILTEK
3
 
60S ribosomal protein L24 Q8BP67 18 4 - C36ESAFLSK 
Alcohol dehydrogenase 1 P00329 40 4 3 VIPLFSPQC98GEC101R
3
 
Argininosuccinate synthase P16460 46 2 2 
YLLGTSLARPC97IAR
3
 
FELTC132YSLAPQIK
3
 
ATP synthase subunit gamma, mitochondrial precursor Q91VR2 33 2 2 GLC103GAIHSSVAK
3
 
Betaine--homocysteine S-methyltransferase 1 O35490 45 4 - 
AYLMSQPLAYHTPDC256GK
3
 
AGASIVGVNC267HFDPSVSLQTVK
3
 
YIGGC299C300GFEPYHIR
3
 
Carbamoyl-phosphate synthase [ammonia],  
mitochondrial precursor 
Q8C196 165 9 7 
VVAVDC225GIK
3
 
TSAC761FEPSLDYMVTK
3 
C920LGLTEAQTR
3
 
GNDVLVIEC1256NLR 
Catalase P24270 60 3 4 
SALEHSVQC425AVDVKR
3
 
LC460ENIAGHLK
3
 
Cytochrome P450 2C29 Q64458 56 5 3 
VQEEAQC151LVEELR 
FIDLLPTSLPHAVTC372DIK 
IC435AGEGLAR 
Cytochrome P450 2E1 Q05421 57 3 - SLDINC261PR
3
 
Dehydrogenase/reductase SDR family member 1 Q99L04 34 2 - LAADC177AHELR 
Dihydroxyacetone kinase Q8VC30 60 3 - GLC155GTVLIHK 
Electron transfer flavoprotein-ubiquinone oxidoreductase, 
mitochondrial precursor 
Q921G7 68 4 - LQINAQNC585VHC588K
3
 
Elongation factor 2 P58252 95 3 3 C728LYASVLTAQPR 
Formimidoyltransferase-cyclodeaminase Q91XD4 60 2 - AC438ALQEGLR
3
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Glyceraldehyde-3-phosphate dehydrogenase P16858 36 2 - VPTPNVSVVDLTC245R
3
 
Iron-sulfur cluster assembly enzyme ISCU,  
mitochondrial precursor 
Q9D7P6 18 3 - LHC139SMLAEDAIK 
Isocitrate dehydrogenase [NADP] cytoplasmic  O88844 47 - 2 DLAAC379IK 
L-lactate dehydrogenase C chain   P00342 36 3 - VIGSGC163NLDSAR 
Long-chain-fatty-acid--CoA ligase 1 P41216 78 3 2 C242GVEIISLK
3
 
Nicotinate-nucleotide pyrophosphorylase [carboxylating] Q91X91 32 4 3 C111SGIASAAATAVEVAR
3
 
Peptidyl-prolyl  cis-trans isomerase A P17742 18 - 3 IIPGFMC62QGGDFTR
3
 
Selenium-binding protein 1 P17563 52 2 4 C8GPGYSTPLEAMK
3
 
S-formylglutathione hydrolase  Q9R0P3 31 - 3 C11FGGLQK 
Three eNOS
-/-
 mouse livers were analyzed by MRC and mPEG-biotin protein capture methods and the mPEG-biotin 
peptide capture method (see Fig. 1C). Sequence-to-spectrum assignments from three biological replicates were 
combined in Scaffold. The proteins listed above satisfied three criteria: (1) identified by at least one protein capture 
method (≥2 unique peptides), (2) confirmed by a sulfonic acid-containing peptide sequence, and (3) not identified in 
the respective UV-exposed samples. Uniprot accession numbers correspond to the full-length unprocessed precursor 
when available (www.uniprot.org). Additional accessions were listed if the observed peptides could not distinguish 
between protein isoforms. 
1
Number of unique peptides identified in protein capture experiment from 3 biological replicates (does not include 
sulfonic acid-containing peptides). A null value indicates the protein did not meet the threshold criteria and was 
considered not identified. 
2
Cysteinyl-containing tryptic peptide sequences identified by peptide capture. The indicated cysteine residue(s) was 
identified as sulfonic acid and corresponds to the unprocessed mouse precursor protein. 
3
Cysteinyl-containing peptide sequences that were also identified in the wild type mouse liver (Supplementary Table 
1). 
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Supplementary Table 2.3: Cysteine residues coordinated with metals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein name Accession 
number 
PDB file Coordinated cysteines 
Alcohol dehydrogenase 1 P00329 1u3w 98, 101, 104, 112, 175 
Betaine--homocysteine S-
methyltransferase 1 
O35490 
 
1umy 299, 300 
Cytochrome c,  
P62897 
 
2b4z 15, 18 
Cytochrome P450 2D10 
P24456 
 
2f9q 443 
Cytochrome P450 2E1 
Q05421 
 
3e6i 437 
Cytochrome P450 2F2 P33267 2nnj 436 
Sulfite oxidase, mitochondrial  
Q8R086 
 
2a9d 265 
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Supplementary Table 2.4: Endogenously S-nitrosylated proteins sensitive to Trx/TrxR-mediated denitrosylation. 
Trx-sensitive  proteins   
Accession 
number 
Molecular 
weight 
(kDa) 
1,4-alpha-glucan-branching enzyme  Q9D6Y9 80 
10-formyltetrahydrofolate dehydrogenase Q8R0Y6 99 
2-hydroxyacyl-CoA  lyase Q9QXE0 64  
 40S ribosomal protein S3  P62908 27  
 40S ribosomal protein S4, X isoform  P62702 30  
4-hydroxyphenylpyruvate dioxygenase P49429 45 
5-oxoprolinase  Q8K010 138 
 60S ribosomal protein L17  Q9CPR4 21  
Acetyl-CoA acetyltransferase, cytosolic Q8CAY6 41 
 Acetyl-CoA acetyltransferase, mitochondrial precursor  Q8QZT1 45  
Aconitate hydratase, mitochondrial Q99KI0 85 
Adenosine kinase P55264 40 
 Alanine--glyoxylate aminotransferase 2, mitochondrial 
precursor  
Q3UEG6 57  
Aldehyde dehydrogenase family 8 member A1 Q8BH00 54 
Aldehyde dehydrogenase X, mitochondrial precursor Q9CZS1 58 
 Aldehyde dehydrogenase, mitochondrial precursor  P47738 57  
Alpha-aminoadipic semialdehyde dehydrogenase Q9DBF1 56 
Argininosuccinate lyase Q91YI0 52 
Aspartate aminotransferase, mitochondrial precursor P05202 47 89
ATP-citrate synthase Q91V92 120 
Betaine--homocysteine S-methyltransferase 1 O35490 45 
Bifunctional aminoacyl-tRNA synthetase  Q8CGC7 170 
 Catalase  P24270 60  
Cystathionine gamma-lyase Q8VCN5 44 
Cytochrome b-c1 complex subunit 1 Q9CZ13 53 
Cytochrome c, somatic P62897 12 
Cytochrome P450 27, mitochondrial Q9DBG1 61 
 Cytochrome P450 2C54  Q6XVG2 56  
 Cytochrome P450 2E1  Q05421 57  
 Cytochrome P450 2F2  P33267 56  
Cytosol aminopeptidase Q9CPY7 56 
Dihydrolipoyl dehydrogenase, mitochondrial precursor O08749 54 
 Dihydroxyacetone kinase  Q8VC30 60  
Dimethylaniline monooxygenase [N-oxide-forming] 3 P97501 61 
 Elongation factor 2  P58252 95  
Enoyl-CoA hydratase, mitochondrial precursor Q8BH95 31 
Epoxide hydrolase 2 P34914 63 
Ester hydrolase C11orf54 homolog Q91V76 35 
Fatty acid synthase P19096 272 
 Fructose-1,6-bisphosphatase 1  Q9QXD6 37  
 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic  P13707 38  
90
Glycine dehydrogenase [decarboxylating], mitochondrial Q91W43 113 
Glycogen phosphorylase, liver form Q9ET01 97 
Heat shock cognate 71 kDa protein P63017 71 
 Hemoglobin subunit beta-1  P02088 16  
Hydroxymethylglutaryl-CoA lyase, mitochondrial P38060 34 
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
precursor 
Q9D6R2 40 
Liver carboxylesterase 31 precursor Q63880 63 
Liver carboxylesterase 31-like precursor Q8VCU1 63 
L-lactate dehydrogenase A chain P06151 36 
Long-chain specific acyl-CoA dehydrogenase, mitochondrial P51174 48 
Long-chain-fatty-acid--CoA ligase 1 P41216 78 
 Long-chain-fatty-acid--CoA ligase 5  Q8JZR0 76  
Malate dehydrogenase, mitochondrial precursor P08249 36 
Membrane-associated progesterone receptor component 1 O55022 22 
 Microsomal glutathione S-transferase 1  Q91VS7 18  
Non-specific lipid-transfer protein P41216 78  
Peroxisomal carnitine O-octanoyltransferase Q9DC50 70 
Peroxisomal sarcosine oxidase Q9D826 44 
Phenylalanine-4-hydroxylase  P16331 52  
Phosphoglucomutase-1 Q9D0F9 62 
Probable urocanate hydratase Q8VC12 75 
Profilin-1 P62962 15 91
Pyruvate carboxylase, mitochondrial precursor  Q05920 130  
Regucalcin Q64374 33 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 O55143 115 
Sodium/potassium-transporting ATPase subunit alpha-1 Q8VDN2 113 
Sorbitol dehydrogenase Q64442 38 
Staphylococcal nuclease domain-containing protein 1 Q78PY7 102 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
P32020 59 
 Sulfotransferase 1A1  P52840 34  
Thiosulfate sulfurtransferase P52196 33 
Ubiquitin-like modifier-activating enzyme 1 X  Q02053 118 
UDP-glucuronosyltransferase 2B5 P17717 61 
Uricase P25688 35 
Very long-chain acyl-CoA synthetase O35488 70 
 Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial precursor  
P50544 71  
Liver lysates remained untreated or exposed to 150nM Trx, 150nM TrxR, 100uM NADPH, for 30 min at 37 
o
C. Following this, protein lysates 
were processed by the MCR and mPEGb protein capture approaches. Comparisons were made between the protein identifications from Trx 
sample and the untreated sample. Proteins confirmed as endogenously S-nitrosylated by complementary proteomic approaches (see Supplementary 
Table 1, main text), which were subsequently identified in the untreated sample but not in the Trx-treated sample were considered as sensitive to 
reduction and are putative targets for denitrosylation by these species. 
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3.1 Abstract 
S-nitrosylation is defined as the covalent addition of nitric oxide to selective 
protein cysteine residues that can regulate protein activity across a variety of organs and 
cellular systems. Nevertheless, fundamental questions regarding S-nitrosylation still 
remain unanswered, including the mechanism by which 
•
NO selectively modifies protein 
cysteine residues to form S-nitrosocysteine. One proposed mechanism mandates the 
transfer of a nitrosonium ion to a reduced thiol of a cysteine residue. S-nitrosoglutathione 
(GSNO), a major endogenous S-nitrosothiol, has been proposed as a mediator of these in 
vivo trans-S-nitrosation reactions. Herein, we precisely mapped the site of modification in 
a population of cysteine residues targeted for transnitrosation by GSNO and reveal 
specific electrostatic properties within the protein environment for S-nitrosocysteine 
formation. Using a transnitrosation intermediate, we describe a mechanism for GSNO 
catalysis that requires a single basic residue rather than the acid-base pair which has 
previously been described (Perez-Mato et al. 1999). Using this novel mechanism for 
transnitrosation via GSNO, our GSNOR
-/-
 dataset was then revisited to identify cysteines 
which may also be targeted via this mechanism. By extracting the structural elements that 
mediate GSNO transnitrosation, we explore the influence of protein structure on cysteine 
selectivity.  
 
3.2 Introduction 
S-nitrosothiols (RSNOs) are thioesters of nitrite thought to be a major store of 
nitric oxide (
•
NO) within the body. RSNOs have been identified across a variety of cell 
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types and found in many different tissues signifying their role in transport of nitric oxide 
throughout the body. They have also been shown to play an important role in health and 
disease (Butler et al. 2006) and have been used in many studies as exogenous sources of 
nitric oxide. While it is possible to synthesize and utilize these compounds for in vitro 
studies, the in vivo mechanisms of S-nitrosothiol formation and stability are not very well 
understood.  
Because of the proposed role of S-nitrosothiols in nitric oxide signaling, many in 
vitro studies have been aimed at investigating those factors that can influence the stability 
of S-nitrosothiols in vivo (Al-Sa’doni et al. 2000). S-nitrosothiols can modify thiols by 
transfer of a nitrosonium equivalent through a process known as transnitrosation. When 
this process occurs on reduced cysteine residues within proteins, it can result in alteration 
of protein function. These S-nitrosylated proteins have been implicated in a variety of 
cellular processes including apoptosis (Hara et al. 2001), chromatin remodeling (Nott et 
al. 2008), and cell permeability (Thibeault et al. 2010). Data have shown that it is a 
discriminating modification that only targets select cysteine residues on specific proteins. 
However, what remains unclear is how the selectivity of this modification is derived. It 
has been proposed that multiple chemistries occur in vivo resulting in different sites of S-
nitrosylation. While it is known that S-nitrosothiols can transnitrosate protein cysteine 
residues, the mechanism of this exact process (or processes) is unknown.  
It has been proposed that S-nitrosoglutathione is a major endogenous trans-S-
nitrosating agent. As a tripeptide, GSNO is a much larger molecule than the diatomic 
species nitric oxide. While its size may appear to be an impediment when compared to 
•
NO, the presence of its two additional residues (glutamic acid and glycine) may allow 
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for more controlled delivery of nitrosonium ion to the targeted cysteine. The literature 
provides several examples of GSNO-binding proteins that may offer insight into this 
mechanism during transnitrosation. Crystal structures of human glutathione transferase 
P1-1 (hGSTP1-1) show that GSNO binds to the enzyme in a manner similar to its  
substrate GSH by forming hydrogen bonding interactions with glutamic acid and glycine 
(Oakley et al., Tellez-Sanz et al.). Molecular modeling studies of the transcription factor 
OxyR also showed that GSNO docks to the protein via hydrogen bonding interactions 
between the γ-glutamyl amine of GSNO and the γ-carboxylate of Asp202 (Kim et al. 
2002). Docking simulations by Staab et al. similarly showed that residues in alcohol 
dehydrogenase 3 (most recently also identified as GSNO reductase) are capable of 
forming hydrogen bonds with the tripeptide (Staab et al. 2009). 
In addition to hydrogen bonding, electrostatic interactions have also been 
proposed to influence transnitrosation reactions involving GSNO. Stamler et al. posited 
that charged residues within hemoglobin were capable of influencing the S-nitrosylation 
of Cys93β (Stamler et al. 1997). Depending on the conformational state of the protein, 
the proximity of basic or acidic residues to Cys93β would either promote the S-
nitrosylation or denitrosylation of the cysteine, respectively. The role of flanking 
acidic/basic residues in S-nitrosylation has since been extended to incorporate the 
reactivity of GSNO within the three dimensional microenvironment of the targeted 
cysteine. Perez-Mato et al. proposed that γ-COOH of Asp355 in methionine 
adenosyltransferase (MAT) protonated GSNO resulting in the donation of a nitrosonium 
ion from GSNO to form SNO-Cys121 (Perez-Mato et al. 1999). Mutation of this Asp355 
to serine significantly reduced the ability of GSNO to transnitrosate Cys121 thereby 
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inactivating MAT. Acidic residues were now thought to play a more direct role in 
catalysis of GSNO.  
Several studies have been aimed at understanding the chemical reactivity of S-
nitrosothiols such as GSNO (Aruslamy et al 1999; Wang et al. 2002, Baciu et al. 2003). 
More recently, work within our own group utilized theoretical studies to better explain 
which resonance forms of RSNOs were favored under varying conditions (Timerghazin 
et al. 2007). Density-functional theory coupled with natural resonance theory analysis 
showed that S-coordination of the SNO group with various Lewis acids can promote the 
formation of an ionic species, i.e. a nitrosonium ion.  While Lewis acids were used as 
models of basic protein residues, the best assessment of RSNO reactivity would be to 
investigate its stability within its endogenous protein environment.  
To further explore mechanisms necessary for GSNO-mediated transnitrosation to 
occur in vivo, the S-nitrosoproteomes of mouse S-nitrosoglutathione reductase null 
(GSNOR
-/-
) liver and thymus were resolved. GSNOR is an enzyme previously shown to 
endogenously metabolize S-nitrosoglutathione (Liu et al. 2004).  By comparing these 
data to their wildtype SNO-proteomes, a GSNOR
-/-
 unique population was derived and 
further analyzed structurally for insight regarding the underlying molecular mechanism of 
GSNO-mediated transnitrosation.  
Herein, we present a novel approach for investigating the reactivity of GSNO as a 
function of its protein environment. Using a transnitrosation intermediate, we show that 
coordination of atoms in the surrounding cysteine environment controls the formation of 
specific reaction products. Surprisingly, our model suggests that a lone basic residue 
rather than an acid-base pair is sufficient for GSNO catalysis in vivo. Using this novel 
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mechanism for transnitrosation via GSNO, our GSNOR
-/-
 dataset was then revisited to 
identify cysteines which may also be targeted via this mechanism.  
 
3.3 Materials and Methods 
Chemicals and Reagents. Unless otherwise stated, all chemicals and reagents were 
purchased from Sigma-Aldrich.  
Generation of GSNOR null mice. All mouse studies were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Children’s Hospital of Philadelphia 
Research Institute. Generation of GSNOR
-/-
 mice has been previously described and 
characterized (Liu et al. 2004). WT C57BL/6 mice were obtained from Jackson 
Laboratories and intact organs were recovered as previously described (Doulias et al. 
2010). Intact livers and thymus were then immediately frozen in liquid nitrogen and 
stored at -80 °C until needed.  
Sample preparation for identification of S-nitrosylated proteins. Each organ was 
homogenized in 3 mL of lysis buffer (250 mM Hepes-NaOH, pH 7.7, containing 1 mM 
DTPA, 0.1 mM neocuproine, 1% Triton X-100, and protease inhibitors) on ice using a 
Teflon pestle and a Jumbo Stirrer (Fisher Scientific). The homogenates were then 
centrifuged at 13,000 × g for 30 min at 4 °C. The soluble protein fraction was collected 
and the protein concentration was determined by the Bradford assay. Each sample 
consisted of 21 mg of protein in 42 mL of lysis buffer (0.5 mg/mL). Liver protein lysates 
were supplemented with 100 mM mannitol and 5 mM MMTS and split into 1- 28 mL 
aliquot (untreated protein and peptide capture) and 1 – 14 mL aliquot (UV-illuminated). 
The 14 mL aliquot was illuminated under a conventional UV transilluminator for 7 min 
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on ice and the other aliquot was left untreated on ice. Liver and thymus lysates were then 
further prepared for capture as previously described (Doulias et al. 2010).  
Capture of S-nitrosylated proteins and peptides via organomercury resin capture 
(MRC). Wildtype and GSNOR
-/- 
SNO-proteomes of mouse thymus and liver were 
resolved using a previously described mercury-based mass spectrometric approach 
known as organomercury resin capture (MRC) (Doulias et al. 2010). An organomercurial 
derivative of Affi-Gel-10 N-hydroxysuccinimide-activated agarose gel for capture of S-
nitrosylated cysteines was synthesized as first described (McDonagh et al. 1976) and 
utilized/prepared as previously described. Protein samples were prepared as described 
above and loaded onto their respective MRC columns either for protein capture or on-
column digestion thereby yielding peptides.  
Detection of S-nitrosylated cysteines by mass spectrometric analysis. The protein 
fractions obtained from the MRC capture method were analyzed by gel electrophoresis 
liquid chromatography/tandem MS analysis (GeLC-MS/MS) as previously described 
(Doulias et al. 2010). Protein samples were mixed with 6× Laemmli sample buffer and 
equal volumes (20 μL) were loaded on NuPAGE 10% Bis-Tris gels (Invitrogen). Proteins 
were electrophoresed in Mops running buffer for approximately 1 cm and visualized by 
colloidal blue stain (Invitrogen). Stained gels were immediately processed by in gel 
trypsin digestion after each lane was cut into three slices and individually. Tryptic peptide 
digests were analyzed by a hybrid LTQ-Orbitrap mass spectrometer (Thermo Electron) 
coupled to a 2D LC system (Eksigent) and autosampler. Generation and Evaluation of 
SEQUEST Peptide Assignments. Peptide assignments were generated, evaluated, and 
analyzed as was previously described (Doulias et al. 2010). Briefly, DTA files were 
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generated from MS/MS spectra extracted from the RAW data file with previously 
described threshold criteria (Doulias et al. 2010) and submitted to Sorcerer-SEQUEST 
(version 4.0.3, revision 11; Sagen Research). Database searching was performed against a 
Uniprot database containing Mus musculus sequences from Swiss-Prot plus common 
contaminants, which were then reversed and appended to the forward sequences. The 
database was indexed with previously described parameters including static 
modifications of cysteine by carboxyamidomethylation (+57 amu) for in-gel digestion or 
by sulfonic acid (+48 amu) and methionine sulfone (+32 amu) for peptide affinity 
capture. After generation of potential sequence-to-spectrum peptide assignments by 
Sorcerer-SEQUEST, Scaffold (version 2.2; Proteome Software) was used to validate 
protein identifications and perform manual inspection of MS/MS spectra as well as to 
compare protein identifications across experimental conditions. Threshold criteria for 
acceptance of protein identification were applied as previously described (Doulias et al. 
2010). In-gel digestion experiments required a threshold of at least 99% protein 
confidence with at least two unique peptides and at least 90% confidence with an 
estimated protein false discovery rate of no greater than 5%. Xcorr thresholds were 
applied to sulfonic acid-containing and non-modified peptides independently, so peptide 
false discovery rate was no greater than 5%. Because one unique peptide per protein was 
permitted, manual inspection of all MS/MS spectra was performed as previously 
described.  
Generation of GSNOR
-/-
 unique SNO-proteome. Sulfonic acid-containing peptides 
identified for each biological condition (wildtype or GSNOR null) for both organs 
(thymus and liver) were pooled into 2-separate lists according to their experimental 
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condition (untreated or UV-illuminated) (n=2 thymus, n=3 liver). Any peptides found 
present in both the untreated and UV-illuminated lists were removed from the untreated 
list. The remaining sulfonic acid-containing peptides were then matched to proteins 
identified via the MRC protein capture method. The GSNOR
-/-
 unique population was 
derived by removing any sites of S-nitrosylation which were shared between the wildtype 
and GSNOR
-/-
 SNO-proteomes.  
Gene ontology analysis. Subcellular localization was determined using UniProt 
Knowledgebase protein database (www.uniprot.org) and statistics were calculated using 
Babelomics 4.2 (http://babelomics.bioinfo.cipf.es). Ingenuity Pathway Analysis was used 
to categorize molecular and cellular functions of proteins and calculate statistical 
significance as compared to the entire mouse proteome.  
Calculation of Hydropathy Indices. Kyte-Doolittle hydropathy indices for S-nitrosylated 
cysteines were calculated in a 13 amino acid window using the ExPASy ProtScale tool.  
Linear motif. Linear motifs surrounding all S-nitrosylated cysteines were calculated 
using the Motif-X program (Schwartz et al. 2005).  Sequences of identified SNO-peptides 
are used as input and compared to the entire mouse proteome to determine if any amino 
acids are overrepresented. Motifs were also calculated within a 13 amino acid window.  
Distribution of secondary structure. Proteins identified as S-nitrosylated were 
coordinated with their respective three dimensional structures in the RCSB Protein Data 
Bank (PDB). Matched structures required the conservation of the cysteine residue 
identified as S-nitrosylated and ≥ 50% sequence homology to target protein.  Secondary 
structure of SNO-cysteine and surrounding residues was obtained when structures were 
viewed in the PyMOL molecular visualization software.  
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Predicted pKa values. The program Propka 2.0 (Li et al. 2005) was used to calculate the 
predicted pKa values of S-nitrosylated cysteines using their corresponding three 
dimensional protein structures.  
Calculated surface exposure. The relative residue surface accessibility (RSA) for all 
cysteines within the S-nitrosoproteome was calculated with Naccess 2.1.1 using the 
radius of a water molecule (1.4 Å2) as a probe (Lee & Richards et al. 1971). Cysteines 
with a relative RSA less than 10% were designated as buried whereas a relative RSA 
greater than 10% meant that the cysteine residue was solvent accessible.  
Molecular dynamics simulations. The structure of 2DGV was obtained as previously 
described above. Molecular dynamics simulations were performed using Amber package 
with Amber99SB force field. Explicit solvent model was used with a TIP3P water in 
truncated octahedron periodic box with a spacing distance of 9.0 Å around the molecule. 
For modeling of the trans-S-nitrosation intermediate, an artificial residue named CYG 
was defined in place of target cysteine (Figure 3.1). CYG contains two fragments (-
glutamic acid and nitroxyl disulfide) which are undefined in the standard force field. 
Therefore, previously defined parameters were used to describe -glutamic acid (Rigsby 
et al. 2007) and parameters for nitroxyl disulfide were calculated using generalized 
Amber force field (GAFF) combined with B3LYP/6-31G(d) charges fitted by Restrained 
Electrostatic Potential (RESP) ESP charge Derive (R.E.D.) software (Dupradeau et al. 
2010).  
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Figure 3.1: CYG intermediate used in molecular dynamics simulations. Dotted line 
indicates intermediate which replaces cysteine residue and is attached to the protein.   
 
 
The protocol for MD simulations includes the following steps: waters were minimized, 
while the protein remains static using an initial 500 steps of the steepest descent (SD) 
algorithm with an additional 500 conjugate gradient (CG) algorithm steps to ensure 
complete minimization. The entire system was then minimized with 1000 steps of the SD 
algorithm and an additional 2500 steps of CG minimization. With the complex again held 
static, the solvent was then equilibrated to 300 K over the course of 20 picoseconds. For 
the simulation, time steps of 2 ps were used, periodic boundary conditions were 
employed, the SHAKE algorithm was applied, and a non-bonded cutoff of 10.0 Å was 
employed. 
For simulated annealing calculations, the same preliminary calculations were used to 
obtain an equilibrated system at 300 K. A series of MD simulations were run with the 
protein initially restrained (heating to 600 K for 60 ps, equilibrating at 600 K for 10 ps, 
cooling back to 300 K in 60 ps) and then unrestrained (heating to 600 K for 60 ps, 
constant temperature for 10, 30 or 50 ps followed by cooling down to 300 K). Instead of 
2ps, the time step was chosen to be 1 ps. Each simulation time was a total of 8 ns 
resulting in a total sampling time for each modified cysteine of 24 ns (trajectories with 
different annealing setup were merged). Dynamical Cross-Correlation Matrix (DCCM) 
- 
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plots were generated with a function available in the Amber toolkit using MD trajectories 
as inputs. Plots were generated only for arrays of distances over simulation time for 
charged groups pairs corresponding to DCCM elements greater than 0.75. 
Quantum mechanics/molecular mechanics (QM/MM) calculations. ONIOM-
PCM/X(ε=4.24)(PBE0/def2-SV(P)+d:Amber95) was used for QM/MM calculations to 
further investigate the interaction of close-lying arginine and -SN(O)S- group of Cyg675.  
 
3.4 Results  
 
Identification of the GSNOR
-/-
 Unique SNO-proteome 
By employing the MRC method, a total of 170 sites belonging to 150 proteins 
were identified as being unique to the GSNOR null liver and thymus (Table 3.1). This 
final SNO-proteome was derived by removing 69 sites which were shared between 
wildtype and GSNOR null organs. With the previous identification of 2 proteins from 
GSNOR null organs (Wei et al, Lima et al.), this corresponds to the discovery of 99% 
novel targets of S-nitrosylation in GSNOR null SNO-proteome. Gene ontology analysis 
using Babelomics 4.2 (Medina et al. 2010) revealed that the top four primary subcellular 
locations of GSNOR
-/-
 unique proteins were cytoplasm (n=25), mitochondria (n=24), 
membrane (n=15), and ribosome (n=16) (Figure 3.2A). Those proteins located in 
membrane, mitochondria, and ribosome were calculated to be statistically significant as 
compared to the entire mouse proteome (p-values=3.80E-04, 1.13E-10, and 6.12E-07, 
respectively). The molecular and cellular functions of these proteins were then identified 
using Ingenuity Pathway Analysis which calculates enrichment as compared to the entire 
mouse proteome. The majority of proteins were determined to be involved in small 
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molecule biochemistry (n=52, p-value=1.10E-06) followed by nucleic acid metabolism 
(Figure 3.2B). Thirty (30) proteins were found to also have additional sites of S-
nitrosylation in the wildtype unique population while sixteen (16) proteins were found to 
be poly-S-nitrosylated (i.e. having more than one cysteine residue modified).  
 
 
Figure 3.2: Gene ontology analysis of GSNOR null unique proteome. (A) Top four 
cellular localization of GSNOR
-/- 
unique S-nitrosylated cysteines. (B) Top four 
statistically significant cellular functions of GSNOR
-/- 
unique S-nitrosylated cysteines.  
 
GSNOR
-/-
 cysteines display large distribution of hydropathy indices 
To characterize our GSNOR
-/-
 unique S-nitrosated cysteines further, biochemical 
and bioinformatic tools were used to interrogate their individual microenvironments. It 
has been previously suggested that cysteines endogenously targeted for S-nitrosylation lie 
in areas of increased hydrophobicity (Nedaspov et al. 2000). To further investigate this 
hypothesis, Kyte-Doolittle hydropathy indices were calculated for GSNOR
-/-
 unique 
population of cysteine residues within a 13-residue window using the primary amino acid 
sequence. With an average hydropathy index of -0.158±0.616 (n=154), GSNOR
-/-
 unique 
cysteines were determined to be slightly hydrophilic. Kernel density approximation was 
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used to investigate the existence of subpopulations of hydropathy indices. The density of 
indices peaked near the average value with nearly 60% (n=91) corresponding to cysteines 
within hydrophilic regions of the protein with the remaining values corresponding to 
cysteines in hydrophobic regions of the protein (Figure 3.3). GSNOR
-/-
 unique cysteines 
did not show a predisposition to lie in hydrophobic regions of the protein. This does not 
differ significantly from what has been previously observed when examining the 
wildtype liver SNO-proteome (Doulias et al. 2010) and the NO-Cys data set curated by 
Marino and coworkers (Marino et al. 2010). With such a large amount of variation 
between hydropathy values, it is difficult to conclude that hydropathy is an indicator of 
endogenous S-nitrosation via S-nitrosoglutathione. 
 
 
Figure 3.3: Kernel density plot of S-nitrosylated cysteines from GSNOR
-/-
 unique 
SNO-proteome. Hydrophilic cysteines correspond to hydropathy indices values <0 
(n=91) whereas hydrophobic values correspond to values ≥0 (n=63).  
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Accessibility of S-nitrosoglutathione to targeted cysteines 
To learn more about the influence of structure on GSNO-mediated mechanisms of 
transnitrosation, a total of 111 GSNOR
-/-
 unique S-nitrosated cysteines were coordinated 
with their corresponding three dimensional structures as previously described (Table 3.2). 
Biological assemblies were downloaded from the Protein Data Bank (PDB) in place of 
the asymmetric unit to ensure that the protein was in its most physiologically relevant 
state. To first investigate the accessibility of modified cysteines to small molecules such 
as the tripeptide S-nitrosoglutathione, the surrounding secondary structures within a 21 
amino acid window were characterized. The flanking secondary structure was examined 
10 residues upstream and 10 residues downstream of the S-nitrosated cysteine which was 
denoted by position 0. GSNOR
-/- 
unique S-nitrosated cysteines were present most 
frequently in coils (38%) closely followed by β-sheets (36%) and found least frequently 
in α-helices (25%) (Figure 3.4). Modified cysteines were positioned near the end of a 
short β-strand region (positions -3 to -1) and at the beginning of an extended stretch of 
coils (position 1 to 10). With the exception of positions -3 to -1, coils were surprisingly 
the predominant secondary structure surrounding S-nitrosated cysteines (positions -10 to 
-4). The presence of these cysteines in more flexible regions of the proteins suggests that 
these proteins may be more adept at accommodating molecules like the tripeptide GSNO.  
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Figure 3.4: Distribution of secondary structure flanking S-nitrosylated GSNOR
-/-
 
unique cysteine residue. Position 0 denotes S-nitrosylated cysteine of interest whereas 
positions -10 to -1 denote residues upstream of cysteine and 1 to 10 denote residues 
downstream of cysteine (n=91).  
 
To further investigate the mechanism by which GSNO can transnitrosate cysteine 
residues, the relative residue surface accessibility (RSA) of each GSNOR
-/-
 unique 
cysteine was calculated. Using the program NAccess, a 1.4Å probe representing the 
radius of a water molecule was used to calculate RSA values for 65 GSNOR
-/-
 unique 
cysteines. With a value > 10% indicating solvent exposure, seventy-four percent of 
cysteines were found to be buried (N = 48) while the remaining 17 were solvent exposed 
(Figure 3.5). With an average relative RSA  
value of 1.38±2.3, buried cysteines remained tightly distributed while solvent accessible 
cysteines were much more broadly distributed (27.4±22.7). While these data are 
comparable to what was previously found regarding the wildtype liver (Doulias et al. 
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2010), it is a surprising result regarding potential mechanisms of GSNO-mediated S-
nitrosation. With > 50% of cysteines calculated as not being on the surface of the protein, 
this alludes to a mechanism which must allow the tripeptide GSNO access to these 
cysteines. This latter hypothesis is additionally supported by the above described data 
showing that coils exist as the predominant secondary structure surrounding S-
nitrosylated cysteines. 
 
 
Figure 3.5: Relative residue surface accessibility of GSNOR
-/-
 unique S-nitrosated 
cysteines (n=48 buried, n=17 exposed)  
 
 
Predicted reactivity of GSNOR null cysteines 
Using the program Propka 2.0, predicted pKa values were calculated for cysteines 
within the GSNOR
-/-
 unique SNO-proteome using their corresponding three dimensional 
structures. Ninety-two (92) cysteines had an average predicted pKa = 9.12±2.45 (Figure 
3.6). This is lower than the previously reported average pKa value of 10.0±2.10 (n=142) 
predicted for the wildtype liver SNO-proteome (Doulias et al. 2010).  These data suggest 
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that the GSNOR
-/-
 unique SNO-proteome may be enriched for a subpopulation of more 
reactive cysteines.   
 
 
Figure 3.6: Predicted pKa values for each S-nitrosylated GSNOR
-/-
 unique cysteine 
calculated using the program Propka 2.0 (n=92) 
 
 
 
 
Role of three-dimensional environment on transnitrosation via GSNO 
Molecular dynamics simulations were performed using the CYG intermediate in 
place of the cysteine residue (see Materials and Methods) to investigate the mechanism 
by which GSNO may transnitrosate cysteines endogenously (Houk et al. 2003). With the 
intermediate weakly bound between the protein and glutathione, it can effectively 
represent the influence of the protein environment on the formation of a specific reaction 
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product (i.e. GSNO or SNO-cysteine). The RNA binding domain of heterogeneous 
nuclear ribonucleoprotein M (PDB code 2DGV) was selected as the model protein. 
2DGV has a small size (92 amino acids) which proves to be fairly stable during 
molecular dynamic simulations (RMSD 1.14 Å after 2 ns simulation).  Although C675 is 
the only cysteine identified as being S-nitrosylated, 2DGV contains a total of 4 cysteines 
(C652, C675, C693, & C708). All four cysteines contain charged residues in their 
respective proximal environments making 2DGV a challenging system for identifying 
true sites of transnitrosation via GSNO.  
To analyze the influence of the protein environment on the intermediate CYG, 
correlated motions between CYG and other residues were investigated across MD 
simulations. Interactions of charged and polar groups of His, Arg, Lys, Asp, Glu, Gln, 
and Asn with S, N, and O atoms of the CYG intermediate were specifically scrutinized. 
Dynamical Cross-Correlation Matrices (DCCM) were used to visualize these interactions. 
A single pixel corresponds to the correlation between two specific atoms. Atoms 
displaying any correlated motions are given a positive cross-correlation coefficient with a 
value of 1 (white) being the most correlated. Blue pixels correspond to atoms which are 
the least correlated and therefore completely independent of onanother. DCCM plots 
were generated for all four cysteines in 2DGV. When compared to unmodified cysteines 
within the same protein, Cys675 displayed the largest region of atoms responsive to the 
CYG intermediate (cross-correlation coefficient > 0.75) (Figure 3.7, top right).  
Probability plots depicting the distances between highly correlated motions were 
generated for Cyg675 (Figure 3.8) using trajectories of the MD simulations. Statistically 
significant interactions between both sulfurs of nitroxyl disulfide and a close-lying 
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arginine, Arg706, were observed. Both Sγ (sulfur belonging to GSNO) and S1 (sulfur 
belonging to protein-cysteine residue) displayed maximum probability distances of 
slightly less than 4 Angstroms. However, S1 was equally likely to be either 6 or 8 Å 
(cumulative probability ~ 0.5) from Arg706 (Figure 3.8a) whereas Sγ showed a much 
greater likelihood to be 4 Å from Arg706 (Figure 3.8b). Observed distances between Sγ 
and Arg706 were calculated to be as large as 10 Å, but these states were far less 
populated and pronounced than the 4 Å distance. The remaining 3 cysteines were also 
examined to ascertain the influence of each microenvironment on the stabilization of the 
CYG intermediate (data not shown). Probability plots for Cys693 point to an interaction 
between Sγ and Lys684 but show that it occurs at a distance of nearly 7 Å. In fact, this 
same lysine residue was more closely coordinated to the OE atom of CYG. A similar 
finding of O-coordination was also observed between Cys708 and Arg709.  
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Figure 3.7: DCCM plots of all four cysteines in 2DGV.  Cyg652 (top left), Cys675 (top 
right), Cyg693 (bottom left), & Cyg708 (bottom right). Cyg675 displays the largest 
region of correlation as evidenced by large rectangular near bottom left of Cyg675 map.  
 
 
Figure 3.8: Distance probability plots of CYG675 intermediate interaction with 
neighboring basic residue. (A) Analysis of molecular dynamics trajectories shows 
interaction between S1 of CYG675 intermediate and Arg706 occurs most frequently at a 
4 Angstrom distance but also exists across a broad range of distances. (B) Sγ of CYG675 
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also interacts with Arg706 but displays a higher probability of being within a 4 Å 
distance.  
 
 
A novel mechanism of S-nitrosation catalysis 
A series of hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) 
calculations were performed to interrogate the interaction between Arg706 and the -
SN(O)S- group of Cyg675 and to also determine the final products of the transnitrosation 
reaction. Coordination of Arg706 at Sγ led to the elongation of the corresponding Sγ-N 
bond of GSNO (r(S-N) = 1.931 Å)), whereas the S1-N bond became shorter, suggesting 
an increase in double bond character (Figure 3.9). Coordination to Sγ promotes the 
formation of protein S-nitrosocysteine whereas coordination to S1 would lead back to the 
reactants (GSNO and Protein-SH). These data are additionally supported by our 
previously published data regarding the chemical reactivity of RSNOs based upon their 
interactions with Lewis acids (Timerghazin et al. 2007).  
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Figure 3.9: QM/MM calculations demonstrating S-coordination of Arg706 to 
CYG675 in 2DGV 
 
 
With a total of 111 S-nitrosocysteines coordinated to three dimensional structures, 
QM/MM and molecular dynamics calculations for the entire GSNOR
-/- 
unique proteome 
would prove to be computationally expensive. Therefore, after the identification of this 
novel GSNO-mediated mechanism in the model system 2DGV, the GSNOR
-/-
 unique 
proteome was then investigated to determine if any other cysteines might be subject to 
this particular mechanism. Of the 111 cysteines coordinated to structures, 109 had at least 
one charged residue within 6 Angstroms. Four cysteines had only acidic residues nearby 
while twenty-two had only basic residues nearby. A total of 83 cysteines had both a basic 
and acidic residue within 6 Angstroms.  
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3.5 Discussion 
To date, global investigations into the specificity of S-nitrosylation have revealed 
a diversity of data, suggestive of multiple mechanisms taking place in vivo (Marino et al. 
2009; Doulias et al. 2010). Therefore, the best approach for investigating a specific 
mechanism would be to isolate those cysteines specifically targeted by that mechanism. 
By perturbing the endogenous metabolism of GSNO, the GSNOR
-/-
 mouse was used to 
characterize those cysteines endogenously targeted for transnitrosation via GSNO. By 
removing any S-nitrosocysteine residues also identified in the wildtype proteomes, a 
novel GSNOR
-/-
 unique proteome was derived. The biochemical and biophysical 
properties of these cysteines did not differ significantly from those previously reported 
for the wildtype proteome (Doulias et al. 2010). This suggests that there must be another 
mechanism by which these cysteines are targeted for transnitrosation.  
The chemical reactivity and stability of S-nitrosothiols has long been of interest to 
the scientific community (Aruslamy et al. 1999; Wang et al. 2002, Baciu et al. 2003, 
Timerghazin et al. 2007). As more recent data reveal the importance of RSNOs in health 
and disease, it becomes even more critical to understand their reactivity in the 
intracellular environment. GSNO is frequently used as an exogenous source of nitric 
oxide for S-nitrosylation studies yet the mechanism by which it transnitrosates proteins in 
vivo is not very well understood. Many studies have suggested a role of charged residues 
in S-nitrosylation. Initially, charged residues were investigated to determine their 
influence on cysteine nucleophilicity. Perez-Mato et al.  further extended the role of 
charged residues in the reactivity of GSNO during transnitrosation reactions. They 
proposed a “push-pull” mechanism in the protein methionine adenosyltransferase 
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whereby which a basic residue would deprotonate cysteine residue (“pull”) and an acidic 
residue would promote donation of a NO
+
 from GSNO (“push”). Mutational analysis of 
the acidic residue resulted in decreased nitrosation, suggesting its role in transnitrosation.  
Herein, we describe a novel mechanism of transnitrosation which requires the 
coordination of a basic residue to S-nitrosoglutathione to promote S-nitrosocysteine 
formation. Utilizing the CYG intermediate allowed for a novel approach to monitoring 
reaction intermediates as a function of the surrounding protein environment. Our 
investigations demonstrate that positively charged residues coordinated to the sulfur atom 
promote the formation of a nitrosonium ion. In the case of S-Coordination, the bond 
length between the coordinated sulfur and nitrogen atom may increase, thereby 
promoting transnitrosation to the alternate sulfur atom. Coordination of arginine to other 
atoms in CYG such as oxygen CYG may alternatively help to stabilize the intermediate 
and decrease the likelihood of a transnitrosation reaction taking place. These data suggest 
that the surrounding protein environment can play both the dual role of catalyzing the 
formation of protein S-nitrosocysteine as well as stabilizing the S-nitrosocysteine residue 
once it is formed. 
While the overwhelming presence of charged residues suggests that a mechanism 
similar to 2DGV may occur in vivo for other GSNOR
-/-
 unique proteins, further 
experiments are needed to test this hypothesis. Although the majority of GSNOR
-/-
 
unique cysteines were buried, the presence of charged residues on the surface of the 
protein may also help to stabilize GSNO such that transnitrosation events can occur. This 
is what Marino et al. characterized as an extended acid base motif. Understanding the 
relationship between GSNO docking and base catalyzed-transnitrosation might help to 
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further distinguish populations of SNO-cysteines modified by GSNO. Those cysteines 
which have both favorable GSNO docking and base-catalyzed mechanisms of 
transnitrosation may refer to a population of cysteines which are most readily modified 
by GSNO. Alternatively, GSNO docking may be favorable near the site of 
transnitrosation yet no basic residues may be involved in catalysis. Transnitrosation via 
GSNO is one of several proposed mechanisms for forming SNO-proteins; still, GSNO-
mediated transnitrosation may itself contain multiple mechanisms involving protein 
electrostatics. Therefore, it is becoming increasingly important to design experiments that 
distinguish the contributions of differing protein electrostatics. Present studies are 
underway to investigate the influence of favorable GSNO docking on base catalyzed 
transnitrosation reactions.  
 
 
 
 
 
Table 3.1: Endogenously S-nitrosylated GSNOR
-/-
 unique proteins in liver and thymus 
Organ Protein name 
Uniprot 
Accession 
Protein 
molecular 
weight 
(kDa) Peptide sequence 
Liver 10-formyltetrahydrofolate dehydrogenase Q8R0Y6 99 AVQMGMSSVFFNKGENC707IAAGR 
Thymus 
26S proteasome non-ATPase regulatory 
subunit 1  Q3TXS7 106 C437VAYAESHDQALVGDK 
Liver 
2-oxo-4-hydroxy-4-carboxy-5-
ureidoimidazoline decarboxylase Q283N4 20 RLQC141QPESELR 
Liver 
2-oxoisovalerate dehydrogenase subunit 
alpha, mitochondrial P50136 50 QMPVHYGC194K 
Liver 
3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial Q8QZS1 43 RGC44GGVITLNRPK 
Thymus 40S ribosomal protein S11  P62281 18 
DVQIGDIVTVGEC131RPLSK 
KC60PFTGNVSIR 
NMSVHLSPC116FR 
Thymus 40S ribosomal protein S17  P63276 16 VC35EEIAIIPSKK 
Liver 40S ribosomal protein S2 P25444 31 KLLMMAGIDDC222YTSAR 
Thymus 40S ribosomal protein S26  P62855 13 LHYC74VSCAIHSK 
Liver 40S ribosomal protein S27 Q6ZWU9 9 ARLTEGC77SFR 
Liver 
4-aminobutyrate aminotransferase, 
mitochondrial 
P61922 56 TMGC224LATTHSK 
NKGVVLGGC467GDKSIR 
Liver 
4-trimethylaminobutyraldehyde 
dehydrogenase Q9JLJ2 56 AGAPPGLFNVVQGGAATGQFLC220HHREVAK 
Thymus 60S ribosomal protein L10a  P53026 25 VLC164LAVAVGHVK 
Liver 60S ribosomal protein L10-like P86048 25 
SRFC23RGVPDAK 
IC71ANKYMVK 
INKMLSC105AGADRLQTGMR 
RLIPDGC195GVK 
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Thymus 60S ribosomal protein L13a  P19253 23 C38EGINISGNFYR 
Liver 60S ribosomal protein L14 Q9CR57 24 C54MQLTDFILKFPHSAR 
Liver 60S ribosomal protein L23 P62830 15 ISLGLPVGAVINC28ADNTGAK 
Liver 60S ribosomal protein L24 Q8BP67 18 MKVELC6SFSGYK 
Liver 60S ribosomal protein L36a P83882 12 C88KHFELGGDKK 
Liver 60S ribosomal protein L4 Q9D8E6 47 SGQGAFGNMC96RGGR 
Liver 60S ribosomal protein L6 P47911 33 AKPHC51SRNPVLVR 
Thymus 60S ribosomal protein L7  P14148 31 FGIIC208MEDLIHEIYTVGKR 
Thymus 60S ribosomal protein L8  P62918 28 TELFIAAEGIHTGQFVYC90GKK 
Liver 7-dehydrocholesterol reductase O88455 54 AIEC376SYTSADGLKHHSK 
Thymus Actin, cytoplasmic 1  P60710 42 C285DVDIRKDLYANTVLSGGTTMYPGIADR 
Thymus Actin-related protein 2  P61161 45 LC221YVGYNIEQEQK 
Liver Adenylate kinase 2, mitochondrial Q9WTP6 26 LAENFC40VC42HLATGDMLR 
Thymus Adenylyl cyclase-associated protein 1  P40124 52 C355VNTTLQIK 
Liver Aldehyde dehydrogenase X, mitochondrial Q9CZS1 58 LGQKEGAKLLC388GGER 
Liver 
Alpha-aminoadipic semialdehyde synthase, 
mitochondrial Q99K67 103 SSPC776EKLKEVVFTK 
Liver Aspartoacylase-2 Q91XE4 35 VAVTGGTHGNEMC26GVYLAR 
Liver Aspartyl-tRNA synthetase, cytoplasmic Q922B2 57 LQSGIC203HLFR 
Thymus ATP-dependent RNA helicase A  O70133 149 VRPGFCFHLC779SR 
Thymus ATP-dependent RNA helicase DDX39  Q8VDW0 49 NC164PHVVVGTPGR 
Liver Bifunctional aminoacyl-tRNA synthetase Q8CGC7 170 SC1377QFVAVRR 
Liver C-1-tetrahydrofolate synthase, cytoplasmic Q922D8 101 SC326KPKLIGNLAR 
Liver 
Carnitine O-palmitoyltransferase 1, liver 
isoform P97742 88 C394RQTYFAR 
Thymus Caspase-6  O08738 32 
IFIIQAC146R 
KLHFC271PKPSK 
Liver Catalase P24270 60 LVNADGEAVYC232KFHYKTDQGIK 
Liver Choline dehydrogenase, mitochondrial Q8BJ64 66 AKADSAYHPSC516TC518K 120
WSTAC244AYLHPVLSRPNLR 
Liver Citrate synthase, mitochondrial Q9CZU6 52 
FRGYSIPEC101QK 
YSC359QREFALK 
Thymus Cofilin-1  P18760 19 LTGIKHELQANC139YEEVKDR 
Thymus Coronin-1A  O89053 51 DGALICTSC195R 
Thymus 
Cullin-associated NEDD8-dissociated 
protein 1  Q6ZQ38 136 C356LDAVVSTRHEMLPEFYK 
Thymus Cysteine and glycine-rich protein 1  P97315 21 NLDSTTVAVHGEEIYC58K 
Liver Cysteine-rich protein 2 Q9DCT8 23 C129NKRVYFAEK 
Both Cysteine-rich protein 2 Q9DCT8 23 C8DKTVYFAEK 
Liver Cytochrome P450 2D10 P24456 57 NLGVFPFPVAPYPYQLC496AVMREQGH 
Liver Cytochrome P450 3A11 Q64459 58 VC378KKDVELNGVYIPK 
Thymus Cytoplasmic FMR1-interacting protein 2  Q5SQX6 146 C98NEQPNRVEIYEK 
Thymus Cytosolic non-specific dipeptidase  Q9D1A2 53 DVGAETLLHSC300K 
Thymus D-3-phosphoglycerate dehydrogenase  Q61753 57 
VLISDSLDPC18C19RK 
 NAGTC369LSPAVIVGLLR 
Liver 
D-beta-hydroxybutyrate dehydrogenase, 
mitochondrial Q80XN0 38 SPYC209ITK 
Liver 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial Q8CHT0 62 SAFEYGGQKC347SAC350SR 
Thymus Destrin  Q9R0P5 19 AVIFC39LSADKK 
Thymus Dihydropyrimidinase-related protein 2  O08553 62 THNSALEYNIFEGMEC439R 
Liver 
Dihydropyrimidine dehydrogenase 
[NADP+] Q8CHR6 112 RGLPLAVKPVC1025 
Liver 
Dimethylaniline monooxygenase [N-oxide-
forming] 3 P97501 60 
VVSKVQKSC509SHFYSR 
ILC294GMVTIKPNVK 
Liver 
Dimethylaniline monooxygenase [N-oxide-
forming] 5 P97872 60 LLLGPC468TPVQYR 
Thymus DNA replication licensing factor MCM7  Q61881 81 GNIHIC378LMGDPGVAK 121
Thymus 
DNA-directed RNA polymerase II subunit 
RPB9  P60898 15 C89GHKEAVFFQSHSAR 
Thymus 
ES1 protein homolog, mitochondrial 
precursor  Q9D172 28 ALGAKHC219VKGVTEAHVDQK 
Liver Fatty acid synthase P19096 272 VGDPQELNGITRSLC313AFRQAPLLIGSTK 
Liver Fructose-bisphosphate aldolase B Q91Y97 40 ALNDHHVYLEGTLLKPNMVTAGHAC240TK 
Thymus Galectin-9  O08573 40 
C258GGDIAFHLNPR 
FEEGGYVVC73NTK 
GMPFELC101FLVQR 
Liver 
GDH/6PGL endoplasmic bifunctional 
protein Q8CFX1 89 C390LPQQIIFYIGHGELGHPAILVSR 
Liver Gephyrin Q8BUV3 83 C326SSKENILR 
Thymus 
Glucosamine-fructose-6-
phosphateaminotransferase [isomerizing] 1 Q9Z2Z9 33 
C2GIFAYLNYHVPR 
ETDC461GVHINAGPEIGVASTK 
Liver Glutamine synthetase P15105 42 KPAETNLRHIC117K 
Thymus Glutaredoxin-3  Q9CQM9 38 LTHAAPC148MLFMK 
Thymus 
Glutathione reductase, mitochondrial 
precursor  P47791 54 GVYAVGDVC355GK 
Liver 
Glycerol-3-phosphate dehydrogenase 
[NAD+], cytoplasmic P13707 38 IC102DQLKGHLK 
Thymus 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1  P62874 37 ELAGHTGYLSC148C149R 
Thymus 
Guanine nucleotide-binding protein subunit 
beta-2-like 1  P68040 35 TNHIGHTGYLNTVTVSPDGSLC207ASGGK 
Thymus 
H-2 class II histocompatibility antigen, A 
beta chain precursor  P14483 30 TRAELDTVC106RHNYEGPETHTSLR 
Thymus Heat shock protein HSP 90-beta  P11499 83 C412LELFSELAEDKENYKK 
Thymus Heterogeneous nuclear ribonucleoprotein F  Q9Z2X1 46 DLSYC267LSGMYDHR 
Thymus 
Heterogeneous nuclear ribonucleoprotein 
M  Q9D0E1 78 DKFNEC675GHVLYADIK 122
Thymus 
Heterogeneous nuclear ribonucleoproteins 
C1/C2  Q9Z204 34 IVGC46SVHKGFAFVQYVNER 
Thymus Histidine triad nucleotide-binding protein 1  P70349 14 IIFEDDRC38LAFHDISPQAPTHFLVIPK 
Thymus Histone-binding protein RBBP7  Q60973 48 
TPSSDVLVFDYTKHPAKPDPSGEC166NPDLR 
VHIPNDDAQFDASHC97DSDKGEFGGFGSVTGK 
Liver 
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial P38060 34 TSSKVAQATC323KL 
Thymus 
Hypoxanthine-guanine 
phosphoribosyltransferase  P00493 25 DLNHVC206VISETGK 
Liver Importin-5 Q8BKC5 124 TKENVNATENC972ISAVGK 
Liver Indolethylamine N-methyltransferase P40936 29 VLRC142DVTK 
Thymus Inositol monophosphatase  O55023 30 EKYPC64HSFIGEESVAAGEK 
Thymus 
Isocitrate dehydrogenase [NAD] subunit 
alpha, mitochondrial precursor  Q9D6R2 40 C351SDFTEEIC359R 
Liver Kynureninase Q9CXF0 52 
GVVC425DKREPDGIR 
NC45FYIPK 
Liver Kynurenine 3-monooxygenase Q91WN4 55 VAVIGGGLVGALNAC25FLAK 
Thymus Lamin B1 P14733 67 C199QSLTEDLEFRK 
Liver L-gulonolactone oxidase P58710 50 FTRGDDILLSPC354FQR 
Thymus Lymphocyte antigen 75 precursor  Q60767 197 C83LGLDITK 
Thymus Macrophage migration inhibitory factor  P34884 13 LLC81GLLSDRLHISPDR 
Thymus Malate dehydrogenase, cytoplasmic  P14152 37 SAPSIPKENFSC154LTR 
Thymus 
Malate dehydrogenase, mitochondrial 
precursor  P08249 36 EGVVEC275SFVQSK 
Liver 
Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial Q99MR8 79 YC450LHQYNIVGLR 
Thymus Myosin light polypeptide 6  Q60605 17 ILYSQC32GDVMR 
Thymus 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
precursor  Q99LC3 41 VITVDGNIC67SGK 123
Liver 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6, mitochondrial P52503 13 TGTC104GYC107GLQFKQHHH 
Thymus 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial precursor  Q91VD9 80 FC64YHERLSVAGNC75R 
Thymus NADPH--cytochrome P450 reductase  P37040 77 
LIHEGGAHIYVC630GDAR 
VHPNSVHIC472AVAVEYEAK 
Liver Nitrilase homolog 1 Q8VDK1 36 THLC161DVEIPGQGPMR 
Thymus 
Non-POU domain-containing octamer-
binding protein  Q99K48 55 FAC147HSASLTVR 
Thymus PDZ and LIM domain protein 1  O70400 36 GHFFVEDQIYC305EKHAR 
Thymus Peptidyl-prolyl cis-trans isomerase A  P17742 18 HTGPGILSMANAGPNTNGSQFFIC115TAK 
Liver Peroxisomal 2,4-dienoyl-CoA reductase Q9WV68 31 HGC53HTVIVGR 
Liver Peroxisomal acyl-coenzyme A oxidase 1 Q9R0H0 75 
NLC559LLYSLYGISQK 
ASEAHC531HYVTVK 
Liver 
Peroxisomal carnitine O-
octanoyltransferase Q9DC50 70 LHGRPGC437C438YETAMTR 
Liver Phenylalanine-4-hydroxylase P16331 52 VFHC265TQYIR 
Liver Probable cation-transporting ATPase 13A1 Q9EPE9 132 AVVGNAVPC10GARPGGAR 
Liver Probable urocanate hydratase Q8VC12 75 AYPIDQYPC95R 
Thymus Profilin-1  P62962 15 C71SVIRDSLLQDGEFTMDLR 
Thymus Proliferating cell nuclear antigen  P17918 29 C62DRNLAMGVNLTSMSK 
Thymus Proliferation-associated protein 2G4  P50580 44 KADVIKAAHLC149AEAALR 
Thymus Proteasome subunit beta type-10 precursor  O35955 29 ATNDSVVADKSC70EKIHFIAPK 
Thymus Protein FAM115C  Q921K8 102 VVLAAHEAMLC279APK 
Liver Protein transport protein Sec31A Q3UPL0 134 C1140LSSATDPQTKR 
Liver Pyruvate carboxylase, mitochondrial Q05920 130 INGCAIQC376R 
Thymus 
Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial precursor  Q9D051 39 PVGHC249LEAAAVLSK 
Liver Quinone oxidoreductase P47199 35 VHAC45GVNPVETYIR 
Thymus Ras-related protein Rab-14  Q91V41 24 FMADC40PHTIGVEFGTR 
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Liver Regucalcin Q64374 33 VEC8VLRENYR 
Thymus RNA-binding protein Raly  Q64012 33 VAGC51SVHKGYAFVQYANER 
Liver 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 O55143 115 SMSVYC498TPNKPSR 
Liver Sepiapterin reductase Q64105 28 LKSDGALVDC235GTSAQK 
Thymus Serine protease inhibitor A3K  P07759 47 HFRDEELSC259SVLELK 
Thymus 
Serine/threonine-protein phosphatase 2A 56 
kDa regulatory subunit gamma isoform  Q60996 55 C334VSSPHFQVAER 
Thymus 
Serine/threonine-protein phosphatase 6 
regulatory ankyrin repeat subunit B  B2RXR6 107 TC408LHAAAAGGNVEC420IK 
Liver S-formylglutathione hydrolase Q9R0P3 31 AYDATC206LVK 
Liver Splicing factor 1 Q64213 70 
C282GGAGHIASDC292KFQRPGDPQSAQDK 
SITNTTVC279TK 
Thymus 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
precursor  Q8K2B3 73 GC357GPEKDHVYLQLHHLPPEQLATR  
Liver 
Succinyl-CoA ligase [GDP-forming] subunit 
alpha, mitochondrial Q9WUM5 36 IIC60QGFTGK 
Thymus SUMO-activating enzyme subunit 1  Q9R1T2 39 DVIIKVDQIC150HR 
Liver T-complex protein 1 subunit theta P42932 60 NIQAC36KELAQTTR 
Liver Tetratricopeptide repeat protein 36 Q8VBW8 20 RQLVLLNPYAALC168NR 
Thymus Thyroid hormone-inducible hepatic protein  Q62264 17 SIC67VEVDHGLLPR 
Thymus Transcription elongation factor SPT5  O55201 121 VELHSTC734QTISVDR 
Thymus 
Transitional endoplasmic reticulum 
ATPase  Q01853 89 LADDVDLEQVANETHGHVGADLAALC415SEAALQAIR 
Thymus Transketolase  P40142 68 TVPFC386STFAAFFTR 
Thymus 
Trifunctional enzyme subunit beta, 
mitochondrial precursor  Q99JY0 51 KDGGQYALVAAC459AAGGQGHAMIVEAYPK 
Thymus Tubulin beta-5 chain  P99024 50 REIVHIQAGQC12GNQIGAK 
Both Ubiquitin-like modifier-activating enzyme 1 Q02053 118 C588VYYRKPLLESGTLGTK 
Liver UDP-glucose 6-dehydrogenase O70475 55 AADLKYIEAC112ARR 
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Liver 
Uncharacterized protein KIAA0564 
homolog Q8CC88 213 HNNC1415VTLTHTNQVVR 
Liver 
UPF0317 protein C14orf159 homolog, 
mitochondrial Q8BH86 66 AFLC419KDGDPKSPR 
Liver Uricase P25688 35 C188FATQVYC195K 
Thymus Valyl-tRNA synthetase  Q9Z1Q9 140 C1184SIHLQLQGLVDPAR 
Thymus 
Voltage-dependent anion-selective channel 
protein 1  Q60932 32 
EHINLGC140DVDFDIAGPSIR 
YQVDPDAC245FSAK 
Thymus 
Voltage-dependent anion-selective channel 
protein 3  Q60931 31 YKVC65NYGLTFTQK 
Thymus WD repeat-containing protein 1  O88342 66 C438FSIDNPGYEPEVVAVHPGGDTVAVGGTDGNVR 
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Table 3.2: GSNOR
-/- 
unique proteins coordinated to PDB structures 
Protein name 
 UNIPROT 
Accession Peptide sequence Structure 
10-formyltetrahydrofolate 
dehydrogenase Q8R0Y6 AVQMGMSSVFFNKGENC707IAAGR 2o2p (98%) 405-902 
2-oxoisovalerate dehydrogenase 
subunit alpha, mitochondrial P50136 QMPVHYGC194/152K 2bff (93%) 48-442 
3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial Q8QZS1 RGC44/45GGVITLNRPK 3bpt (83%) 34-385 
40S ribosomal protein S11  P62281 KC60/59PFTGNVSIR 3iz6 (68%) 41-126/chain P 
40S ribosomal protein S11  P62281 NMSVHLSPC116/115FR 3iz6 (68%) 41-126/chain P 
40S ribosomal protein S11  P62281 DVQIGDIVTVGEC131/128RPLSK 3jyv (74%)69-149/chain Q 
40S ribosomal protein S14 P62264 C85KELGITALHIK 2zkq (100%) 23-147/chain k 
40S ribosomal protein S2 P25444 KLLMMAGIDDC222/130YTSAR 2zkq (96%) 101-249/chain e 
40S ribosomal protein S27 Q6ZWU9 ARLTEGC77/79SFR 3iz6 (84%) 31-80 
4-aminobutyrate aminotransferase, 
mitochondrial P61922 TMGC224/196LATTHSK 1ohv (93%) 39-499 
4-aminobutyrate aminotransferase, 
mitochondrial P61922 NKGVVLGGC467/439GDKSIR 1ohv (93%) 39-499 
4-trimethylaminobutyraldehyde 
dehydrogenase Q9JLJ2 AGAPPGLFNVVQGGAATGQFLC220/229HHREVAK 1a4s (69%) 2-494 
60S ribosomal protein L10a  P53026 VLC164/163LAVAVGHVK 3izr (63%)3-217 
60S ribosomal protein L10-like P86048 SRFC23/22RGVPDAK 2zkr (99%) 4-169 (chain h) 
60S ribosomal protein L10-like P86048 INKMLSC105/104AGADRLQTGMR 2zkr (99%) 4-169 (chain h) 
60S ribosomal protein L10-like P86048 IC71/70ANKYMVK 2zkr (99%) 4-169 (chain h) 
60S ribosomal protein L13a  P19253 C38/37EGINISGNFYR 2zkr (97%)7-142 (chain j) 
60S ribosomal protein L23 P62830 ISLGLPVGAVINC28ADNTGAK 2zkr (100%) 16-139/chain k 
60S ribosomal protein L24 Q8BP67 MKVELC6SFSGYK 2zkr(100%)4-56/chain u 
60S ribosomal protein L36a P83882 C88KHFELGGDKK 2zkr(100%)2-93/chain 4 
60S ribosomal protein L4 Q9D8E6 SGQGAFGNMC96/95RGGR 2zkr (97%) 7-263/chain c 
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60S ribosomal protein L7  P14148 FGIIC208MEDLIHEIYTVGKR 2zkr (98%)111-270/chain w 
60S ribosomal protein L8  P62918 TELFIAAEGIHTGQFVYC90GKK 2zkr (99%)2-246/chain a 
Actin, cytoplasmic 1  P60710 C285DVDIRKDLYANTVLSGGTTMYPGIADR 2btf(100%)2-375 
Actin-related protein 2 P61161 C20GYAGSNFPEHIFPALVGRPIIR 2p9i (76%)9-362 
Actin-related protein 2  P61161 LC221YVGYNIEQEQK 1tyq(100%)143-350/chain B 
Adenylyl cyclase-associated protein 1  P40124 C355/356VNTTLQIK 1k8f (98%)318-474 
Aldehyde dehydrogenase X, 
mitochondrial Q9CZS1 LGQKEGAKLLC388/369GGER 3inj (75%) 26-519 
Aspartoacylase-2 Q91XE4 VAVTGGTHGNEMC26GVYLAR 3nh4 
Aspartyl-tRNA synthetase, 
cytoplasmic Q922B2 LQSGIC203/255HLFR 1asy (56%) 22-501 
ATP-dependent RNA helicase A  O70133 VRPGFCFHLC779/440SR 3kx2(25%)374-1115 
ATP-dependent RNA helicase DDX39  Q8VDW0 NC164/165PHVVVGTPGR 1xti(93%)45-425 
ATP-dependent RNA helicase 
DDX3X Q62167 VRPC298VVYGGAEIGQQIR 2i4i(97%)168-5880 
Carbonyl reductase [NADPH] 1 P48758 ALKNC150/149RLELQQK 1wma(88%)7-277 
Caspase-6  O08738 IFIIQAC146/163R 3od5 (86%)14-273 
Catalase P24270 LVNADGEAVYC232/231KFHYKTDQGIK 4blc  (92%)4-501 
Citrate synthase, mitochondrial Q9CZU6 FRGYSIPEC101/74QK 3enj (96%) 28-464 
Citrate synthase, mitochondrial Q9CZU6 YSC359/332QREFALK 3enj (96%) 28-464 
Cofilin-1  P18760 LTGIKHELQANC139YEEVKDR 1q8g (98%)1-166 
Coronin-1A  O89053 DGALICTSC195R 2aq5 
Cysteine and glycine-rich protein 1  P97315 NLDSTTVAVHGEEIYC58K 1b8t(89%)1-193 
Cysteine-rich protein 2 Q9DCT8 C129/15NKRVYFAEK 2cu8 (81%) 126-184 
Cysteine-rich protein 2 Q9DCT8 C8/15DKTVYFAEK 2cu8 (98%) 1-63 
Cytochrome P450 2D10 P24456 NLGVFPFPVAPYPYQLC496/493AVMREQGH 2f9q (69%) 37-500 
Cytochrome P450 3A11 Q64459 VC378/377KKDVELNGVYIPK 1tqn (73%) 30-499 
Cytosolic non-specific dipeptidase  Q9D1A2 DVGAETLLHSC300K 2zog 
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Destrin  Q9R0P5 AVIFC39LSADKK 1ak6 (95%)2-165 
Dihydrolipoyl dehydrogenase, 
mitochondrial O08749 VC484/449HAHPTLSEAFR 1zmd(95%)37-509 
Dihydropyrimidinase-related protein 
2  O08553 THNSALEYNIFEGMEC439R 2vm8 (98%)14-490 
DNA-directed RNA polymerase II 
subunit RPB9  P60898 C89/78GHKEAVFFQSHSAR 3h0g (48%)14-125/chain I 
Electron transfer flavoprotein-
ubiquinone oxidoreductase, 
mitochondrial Q921G7 VTVFAEGC247/215HGHLAK 2gmh(93%)38-616 
Fatty acid synthase P19096 VGDPQELNGITRSLC313AFRQAPLLIGSTK 3hhd (87%) 2-853 
Fructose-bisphosphate aldolase B Q91Y97 ALNDHHVYLEGTLLKPNMVTAGHAC240/239TK 1qo5 (96%) 2-349 
Galectin-9  O08573 FEEGGYVVC73NTK 2d6n 
Galectin-9  O08573 GMPFELC101FLVQR 2d6n 
Glucosamine-fructose-6-
phosphateaminotransferase 
[isomerizing] 1 Q9Z2Z9 C2/1GIFAYLNYHVPR 2bpl (37%)2-682 
Glucosamine-fructose-6-
phosphateaminotransferase 
[isomerizing] 1 Q9Z2Z9 ETDC461/459GVHINAGPEIGVASTK 2zj3 (83%) 316-682 
Glutamine synthetase P15105 KPAETNLRHIC117K 2qc8 (94%) 10-365 
Glutathione reductase, mitochondrial 
precursor  P47791 GVYAVGDVC355/333GK 3dk9 (88%)41-500 
Glycerol-3-phosphate dehydrogenase 
[NAD+], cytoplasmic P13707 IC102DQLKGHLK 1x0v (93%) 1-349 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  P68040 TNHIGHTGYLNTVTVSPDGSLC207ASGGK 2zkq (99%)4-311 
H-2 class II histocompatibility 
antigen, A beta chain precursor  P14483 TRAELDTVC106/105RHNYEGPETHTSLR 1lnu 
Heat shock protein HSP 90-beta  P11499 C412LELFSELAEDKENYKK 3pry (95%)284-546 
Heterogeneous nuclear Q9D0E1 DKFNEC675GHVLYADIK 2dgv (100%)651-729 
129
ribonucleoprotein M  
Heterogeneous nuclear 
ribonucleoproteins C1/C2  Q9Z204 IVGC46SVHKGFAFVQYVNER 1wf2 (94%)2-92 
Histidine triad nucleotide-binding 
protein 1  P70349 IIFEDDRC38LAFHDISPQAPTHFLVIPK 1kpe (94%)14-126 
Histone-binding protein RBBP7  Q60973 TPSSDVLVFDYTKHPAKPDPSGEC166NPDLR 3cfv (95%)1-410 
Hydroxymethylglutaryl-CoA lyase, 
mitochondrial P38060 TSSKVAQATC323KL 2cw6 (87%) 28-323 
Hypoxanthine-guanine 
phosphoribosyltransferase  P00493 DLNHVC206/205VISETGK 1bzy (97%)5-218 
Indolethylamine N-methyltransferase P40936 VLRC142/141DVTK 2a14 (57%) 6-262 
Kynureninase Q9CXF0 GVVC425DKREPDGIR 2hzp (83%) 6-460 
Lymphocyte antigen 75 precursor  Q60767 C83/55LGLDITK 1dqg (20%)32-155 
Macrophage migration inhibitory 
factor  P34884 LLC81/80GLLSDRLHISPDR 2gdg 
Malate dehydrogenase, cytoplasmic  P14152 SAPSIPKENFSC154/153LTR 5mdh (94%)2-334 
Malate dehydrogenase, mitochondrial 
precursor  P08249 EGVVEC275/251SFVQSK 1mld (95%)25-337 
Myosin light polypeptide 6  Q60605 ILYSQC32/31GDVMR 1br1 (89%)4-151 
NADPH--cytochrome P450 reductase  P37040  VHPNSVHIC472AVAVEYEAK 1ja1 (98%)63-678 
Non-POU domain-containing 
octamer-binding protein  Q99K48 FAC147HSASLTVR 2cpj (68-153) 
PDZ and LIM domain protein 1  O70400 GHFFVEDQIYC305/65EKHAR 1x62 (91%)249-316 
Peptidyl-prolyl cis-trans isomerase A  P17742 HTGPGILSMANAGPNTNGSQFFIC115TAK 3k0m (96%)2-164 
Peroxisomal 2,4-dienoyl-CoA 
reductase Q9WV68 HGC53/54HTVIVGR 1g0o (23%)1-273 
Peroxisomal acyl-coenzyme A oxidase 
1 Q9R0H0 NLC559LLYSLYGISQK 1is2 (89%) 1-655 
Peroxisomal acyl-coenzyme A oxidase 
1 Q9R0H0 ASEAHC531HYVTVK 1is2 (89%) 1-655 
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Phenylalanine-4-hydroxylase P16331 VFHC265TQYIR 1phz (96%)19-427 
Profilin-1  P62962 C71/70SVIRDSLLQDGEFTMDLR 1pne (96%)2-140 
Proliferating cell nuclear antigen  P17918 C62DRNLAMGVNLTSMSK 1vyj (97%)1-257 
Proliferation-associated protein 2G4  P50580 KADVIKAAHLC149AEAALR 2v6c 
Proteasome subunit beta type-10 O35955 ATNDSVVADKSC70/31EKIHFIAPK 1iru(57%)40-259, chain I 
Protein DJ-1 Q99LX0 VTVAGLAGKDPVQC46SR 1q2u(91%)1-189 
Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial P35486 EATKFAAAYC273/244R 1ni4(98%)29-390 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial Q9D051 
IERQGTHITVVAHSRPVGHC249/219LEAAAVLS
K 2ozl(94%)30-359 
Quinone oxidoreductase P47199 VHAC45GVNPVETYIR 1yb5 (80%) 6-331 
Ras-related protein Rab-14  Q91V41 FMADC40PHTIGVEFGTR 1z0f (100%)7-173 
Regucalcin Q64374 VEC8VLRENYR 3g4e (88%) 3-299 
RNA-binding protein Raly  Q64012 VAGC51/58SVHKGYAFVQYANER 1wf1 (94%)3-97 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 O55143 SMSVYC498TPNKPSR 3ar4 (84%)1-992 
Sepiapterin reductase Q64105 LKSDGALVDC235GTSAQK 1oaa 
Serine hydroxymethyltransferase, 
cytosolic P50431 LIIAGTSC198/204YSR 1eji  
Serine protease inhibitor A3K  P07759 HFRDEELSC259/258SVLELK 1yxa (73%)48-418 
Serine/threonine-protein phosphatase 
2A 56 kDa regulatory subunit gamma 
isoform  Q60996 C334/324VSSPHFQVAER 3fga (99%)34-436 
S-formylglutathione hydrolase Q9R0P3 C11FGGLQK 3fcx(90%)3-281 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial precursor  Q8K2B3 GC357/315GPEKDHVYLQLHHLPPEQLATR  1zoy (96%)52-664 
Succinyl-CoA ligase [GDP-forming] 
subunit alpha, mitochondrial Q9WUM5 IIC60/20QGFTGK 1euc (93%) 42-346 
SUMO-activating enzyme subunit 1  Q9R1T2 DVIIKVDQIC150/146HR 3kyd (87%)29-349 
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Superoxide dismutase [Cu-Zn] P08228 AVC7VLKGDGPVQGTIHFEQK 3gtt 
Transcription elongation factor SPT5  O55201 VELHSTC734/740QTISVDR 2e70 (96%) 696-751 
Transitional endoplasmic reticulum 
ATPase  Q01853 
LADDVDLEQVANETHGHVGADLAALC415SEAAL
QAIR /1e32 
Transketolase  P40142 TVPFC386STFAAFFTR 3mos (95%) 4-618 
Trifunctional enzyme subunit beta, 
mitochondrial precursor  Q99JY0 KDGGQYALVAAC459/386AAGGQGHAMIVEAYPK 1ulq (32%)53-473 
Tubulin beta-5 chain  P99024 REIVHIQAGQC12GNQIGAK 1tvk (97%)2-427 
Ubiquitin-like modifier-activating 
enzyme 1 Q02053 C588/556VYYRKPLLESGTLGTK 3cmm(51%)48-1057 
UDP-glucose 6-dehydrogenase O70475 AADLKYIEAC112ARR 3khu (97%) 1-466 
Voltage-dependent anion-selective 
channel protein 1  Q60932 EHINLGC140/127DVDFDIAGPSIR 3emn 
Voltage-dependent anion-selective 
channel protein 1  Q60932 YQVDPDAC245/232FSAK 3emn 
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4.1 Abstract 
Understanding the structural consequences of S-nitrosylation has proved to be 
difficult due to a lack of structures for SNO-proteins. A recent study has revealed that S-
nitrosylation may regulate the function of very long chain acyl-coA dehydrogenase 
(VLCAD), a mitochondrial enzyme that catalyzes the first rate-limiting step in the β-
oxidation of fatty acids. Upon S-nitrosylation, the Km of the enzyme decreases by 5-fold, 
suggesting that the protein can bind the substrate more efficiently. Normal mode analysis 
was used to investigate this hypothesis and identify protein movements which might be 
correlated to enhanced substrate binding upon S-nitrosylation. S-nitrosylation did not 
induce global conformational changes in the protein. However, smaller motions were 
observed across four different regions in the binding site, with the most apparent 
movement near the VLCAD S-nitrosocysteine, Cys238. This work further supports the 
hypothesis that S-nitrosylation may induce protein conformational changes that influence 
activity. 
 
4.2 Introduction 
A global proteomic investigation into the endogenous S-nitrosoproteome of 
mouse liver identified 328 sites belonging to 192 proteins (Doulias, et al. 2010). Protein 
network mapping revealed that sixteen of the S-nitrosylated proteins were clustered 
around the hormone leptin (Figure 4.1). Leptin is a hormone secreted by adipose tissue 
which acts on the central nervous system to maintain energy homeostasis. Leptin has also 
been shown to play a role in liver metabolism through its repression of stearoyl-CoA 
desaturase-1 which is the rate limiting step in monosaturated fat biosynthesis (Cohen et 
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al., 2004). Mice lacking leptin (ob/ob) can be nearly triple the size of their wildtype 
littermates with increased adipocyte size and number (Halaas et al., 1995; Pelleymounter  
 
 
Figure 4.1: Ingenuity pathway analysis (IPA) identifies indirect relationship 
between leptin and Very long chain acyl-CoA dehydrogenase (A) Protein network 
mapping reveals significant clustering of 16 S-nitrosylated liver proteins around the 
hormone leptin. Very long chain acyl-CoA dehydrogenase (gene name: ACADVL, red 
circle) was revealed as indirect target (dashed line) of leptin. (B) Very long chain acyl-
CoA dehydrogenase (VLCAD) catalyzes the first step in the β-oxidation of fatty acids. It 
oxidizes the substrate palmitoyl-CoA, forming a double bond between α and β carbons to 
form trans-Δ2-Enoyl-CoA.  
 
et al.,1995; Jackson Laboratories).  
A study conducted in 2008 (Oliveira, et al. 2008) investigated the role of nitric 
oxide in nonalcoholic fatty liver, a disease that is characterized by an accumulation of fat 
deposits in the liver which can then result in impairment of its function. Administration 
of the S-nitrosothiol S-nitroso-N-acetylcysteine (SNAC) to ob/ob mice by gavage 
inhibited and reversed the phenotype. Interestingly, mice lacking endothelial nitric oxide 
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synthase also exhibited accumulation of lipids, further substantiating a role for nitric 
oxide in lipid metabolism (Schild et al. 2008).  
Very long-chain specific acyl-CoA dehydrogenase (VLCAD), a mitochondrial 
enzyme, is one of the sixteen proteins identified as having an indirect link to leptin. 
VLCAD catalyzes the rate limiting first step in the β-oxidation of fatty acids in the liver 
(Figure 4.1). With a catalytic glutamate as its proton acceptor, VLCAD oxidizes the 
substrate palmitoyl-CoA, producing a double bond between its α and β carbons to form 
trans-Δ2-Enoyl-CoA. Its recent identification has led to the hypothesis that S-nitrosylation 
of VLCAD may function as a molecular link between nitric oxide and liver metabolism. 
Therefore, when nitric oxide is unable to S-nitrosylate VLCAD, its function is impaired 
leading to the accumulation of fatty acids. Recent work within the lab has confirmed that 
Cys238 is S-nitrosated in ob/ob mice after GSNO treatment (Figure 4.2). Upon S-
nitrosylation, the kinetics of VLCAD are altered such that its Km is decreased by nearly 
5-fold (Figure 4.2), suggesting an increased binding efficiency of its substrate palmitoyl-
CoA. However, the molecular mechanism by which S-nitrosylation might alter substrate 
binding is largely unknown.  
VLCAD consists of a 67 kiloDalton homodimer and is a member of the acyl-CoA 
deydrogenase (ACAD) family (McAndrew et al. 2008). Its substrate specificity is derived 
from a salt bridge formed between two helices which extends its binding cavity as 
compared to other ACADS.  It also has an additional 180 residues on its carboxyl-
terminal end shown to be essential in mitochondrial membrane binding (Souri et al. 
1998b). Several studies have attempted to correlate VLCAD modifications with its 
activity. Mutation of a phosphorylation site resulted in reduced electron transfer activity 
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of the enzyme (Kabuyama et al. 2010). Souri et al. demonstrated abnormal Km values for 
palmitoyl-CoA after mutation of an alanine to a proline near the carboxyl-terminus (Souri 
et al. 1998a). A more comprehensive study investigated the effect of missense mutations 
on substrate binding, enzyme-cofactor interaction, dimerization, & folding of the 
polypeptide chain (Gobin-Limballe et al. 2010). A glycine-to-alanine mutation  
 
 
 
Figure 4.2: Cysteine238 confirmed as S-nitrosation site after GSNO treatment. (A) 
Cys238 identified as site of S-nitrosylation in VLCAD peptide sequence: 
SSAVPSPC238GKYYTLNGSK. (B) Kinetics of VLCAD altered after GSNO treatment.  
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disrupted a hydrophobic pocket lining the substrate binding cavity whereas a R453Q 
mutation induced changes in the positioning of its catalytic glutamate.   
Herein, we describe attempts to elucidate the structural consequences of S-
nitrosylation for the enzyme VLCAD. We first began with an interrogation into the 
structures of existing S-nitrosylated cysteines to acquire favorable rotamer conformations 
for S-nitrosocysteine. Using normal mode analysis, we investigated the influence that 
introducing a nitric oxide moiety might have on protein structure in an attempt to explain 
our kinetic data.  
 
4.3 Methods 
Sequence conservation. Basic local alignment search tool (BLAST) was used to align 
the sequences of human (Uniprot Accession Number: P49748) and mouse VLCAD 
(Uniprot Accession Number: P50544).  
Calculating bond angles and lengths. Bond angles and lengths of existing S-
nitrosylated proteins were calculated by editing Perl scripts made available by the 
Dunbrack laboratory.  
Generation of S-nitrosylated cysteine. S-nitrosocysteine was generated using the “S-
nitrosator”` Python script from Timerghazin laboratory in the Molecular Modeling 
Toolkit. “S-nitrosator” utilizes the coordinates of thioredoxin and χ3 values calculated 
using from PCM-ONIOM(PBE0/def2-TZVPPD:AmberFF) calculation of an S-
nitrosocysteine residue in an alpha–helix content. 
Normal mode analysis using elNemo. ElNemo (Suhre et al. 2004) was used to observe 
the 100 lowest frequency modes and perturbed models were generated for the first five 
non-trivial modes of VLCAD. Residue mean square displacement (r
2
) (as calculated by 
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elNemo) was used to identify protein movement. The substrate binding site was separated 
into four regions for the purpose of analysis. Region 1: 160Tyr, 163Leu, 164Val, 167Val, 
174Val, 176Ile, 178Leu, 179Gly, 180Ala, 182Gln, 183Ser, and 184Ile; Region2: 214Phe, 
216Leu, 217Thr, 222Gly, 223Ser, 224Asp, and 225Ala; Region3: 334Met, 337Leu, 
340Gly, 341Arg, 343Gly, 344Met, and 347Ala; Region4: 458Phe, 460Ile, 461Phe, 
462Glu, 463Gly, and 464Thr.   
 
 
 
 
4.4 Results and Discussion 
 
Use of existing S-nitrosylated protein structures for prediction of Cys238 side chain 
conformation 
 
There is currently no published structure of mouse very long chain acyl-CoA 
dehydrogenase; however, the PDB contains two structures of human VLCAD. The first 
structure (PDB ID: 2UXW) was released in 2007. It is at 1.45 Å resolution, crystallized 
with trans-Δ2-Palmitenoyl-CoA and contains residues 72-655. The second structure is at 
1.91 Å resolution and contains amino acids 69-655 (PDB ID: 3B96); however, 3B96 is 
instead crystallized with myristoyl-CoA, a fatty acid of shorter chain length. The 
structure of 2UXW was selected for the purposes of this study (Figure 4.3).  
Basic Local Alignment Search Tool (BLAST) was used to identify sequence 
homology between mouse and human VLCAD. The sequence alignment of mouse 
VLCAD (mVLCAD) and human VLCAD (hVLCAD) showed that the two share more 
than 80% sequence homology. More importantly, there was conservation of the S-
nitrosylated cysteine residue (Cys238 in mouse; Cys237 in human) as well as high 
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conservation near the substrate binding site. In addition to being conserved between mice 
and humans, Cys238 is conserved across other mammalian species including rat, bovine, 
canine, and pig.  
To investigate the influence of S-nitrosocysteine on VLCAD dynamics, it was 
first necessary to generate an S-nitrosylated form of the protein. The program SCWRL 
(Bower et al. 1997) can be used to predict the position of the cysteine side chain using a 
χ1-dependent rotamer library; however, because S-nitrosylation is still an emerging 
posttranslational modification, the library must be appended to incorporate the S-
nitrosocysteine residue. The rotamer library is composed of a curated set of residues from 
high resolution structures in the PDB with low B-factors (Wang et al. 2008). A search of 
the PDB for the ligand S-nitrosocysteine (SNC) resulted in a total of 9 structures of 
which 6 were nonredundant: hemoglobin (1BUW), hypoxia inducible factor prolyl 
hydroxylase domain 2 (2Y33 and 2Y34), protein tyrosine phosphatase 1B (3EU0), 
blackfin tuna myoglobin (2NRM), thioredoxin (2HXK, 2IFQ, and 2IIY) and 
dimethylarginine dimethylaminohydrolase (2CI1).  
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Figure 4.3: VLCAD structure 2uxw. Cysteine 238 is shown in sphere representation 
with coloring based upon elemental composition. Trans-Δ2-Palmitenoyl-CoA is shown in 
purple in stick representation. Electron acceptor FAD is shown in blue in sticks 
representation. Catalytic glutamate shown in red in sphere representation.  
 
 
In total, bond lengths and angles were calculated for twelve S-nitrocysteine 
residues across 9 different structures. The χ3 (chi3) value measures the bond angle 
between CB-SG-ND-OE; therefore, it is a detailed descriptor of the S-nitrosocysteine 
rotamer conformation. The chi3 data exhibited some variance but values for all 
thioredoxin S-nitrosocysteines remained fairly close to 0 (Table 4.1). Measured bond 
lengths of r(N-CA), r(CA-C), r(CA-CB), and r(CB-SG) remained fairly consistent across 
all S-nitrosocysteine residues (Table 4.2) with Cα carbon bond lengths being the most 
tightly distributed. Bond lengths between SG-ND and ND-OE were the most dispersed. 
r(SG-ND) ranged in length from 1.63 to 1.806 Å and r(ND-OE) ranged in length from 
1.193 to 1.472 Å (Table 4.2). When comparing structures of hypoxia inducible factor 
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prolyl hydroxylase which forms S-nitrosocysteine by two different chemical reactions 
(GSNO soaked versus NO exposed), there is a striking difference in bond lengths for 
(ND-OE). The GSNO soaked structure (which would form S-nitrosocysteine through a 
transnitrosation reaction with a nitrosonium ion) had a measured length of 1.193 Å 
compared to the same protein treated with an 
•
NO donor, which had a bond length of 1.46 
Å. These data suggest that chemical species other than –Cys-S-N=O may exist. In fact, 
QM/MM studies conducted in the English Laboratory at Concordia University show that 
geometries for S-nitrosocysteine residues in published crystal structures are oftentimes 
more consistent with –C-S-NH-OH (personal communication). 
With a total of six independent data points, these data were not incorporated into 
the rotamer library for side chain prediction. Additionally, the diversity of data calculated 
suggests that all residues classified as an S-nitrosocysteine may not be the same chemical 
species as an S-nitrosocysteine residue. Interestingly, that is what Chen and coworkers 
proposed when they published the structures of hypoxia inducible factor prolyl 
hydroxylase (Chen et al. 2008). They suggest that they were instead observing a reaction 
intermediate between nitric oxide and the cysteine residue. This again underscores that 1) 
the field of S-nitrosylation is in dire need of three dimensional structures of protein S-
nitrosocysteine, and 2) exogenous sources of nitric oxide can result in different reaction 
products. Additionally, it is unfortunate that the Protein Data Bank still classifies 2Y33 
and 2Y34 as containing S-nitrosocysteine residues when the authors themselves doubt its 
existence (Chen et al. 2008).  
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Table 4.1: Calculated bond angles of existing S-nitrosylated cysteines 
PDBid  ResNum  Chain  phi  psi  omega  chi1  chi2  chi3  
2IFQ  69  A  -88.69  3.06  178.45  -68.42  -71.19  1.22  
2IFQ  69  C  -84.94  2.70  178.52  -66.26  -84.91  151.85  
1BUW  93  B  -79.99  -60.79  -176.99  -54.71  -99.84  87.55  
1BUW  93  D  -81.96  -70.29  -179.79  -54.16  -79.77  -75.65  
2CI1  83  A  -139.30  111.23  177.56  175.12  79.42  -69.50  
2HXK  62  B  -121.26  66.48  -174.47  -92.66  -156.02  -0.56  
2HXK  69  B  -96.58  7.66  178.68  -63.56  -81.45  2.49  
2IIY  62  A  -125.61  56.22  -161.63  -65.03  -81.52  1.30  
2IIY  69  A  -82.42  -2.56  -173.57  -64.35  -71.75  0.71  
2Y33  302  A  -135.82  113.66  -178.52  -168.91  -83.34  -76.06  
2Y34  302  A  -128.28  117.37  176.77  178.34  -76.24  -93.49  
3EU0  215  A  -138.14  -132.92  179.22  175.05  -56.03  41.08  
 2IFQ: S-nitroso thioredoxin (only Cys69 modified) 
1BUW: S-nitroso hemoglobin 
2CI1: Dimethylarginine dimethylaminohydrolase in complex with S-nitroso-L-homocysteine 
2HXK: S-nitroso thioredoxin (both 62 and 69 modified) 
2IIY: S-nitroso thioredoxin (both 62 and69 modified)  
2Y33: S-nitrosylated hypoxia inducible factor prolyl hydroxylase domain 2 (GSNO soaked) 
2Y34: S-nitrosylated hypoxia inducible factor prolyl hydroxylase domain 2 (NO exposed) 
3EU0: S-nitrosylated protein tyrosine phosphatase 1B 
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Table 4.2: Calculated bond lengths of existing S-nitrosylated cysteines 
PDBid  ResNum  Chain  r(N-CA)  r(CA-C)  r(CA-CB)  r(CB-SG)  r(SG-ND)  r(ND-OE)  
2IFQ  69  A  1.458  1.533  1.532  1.764  1.783  1.196  
2IFQ  69  C  1.469  1.506  1.532  1.795  1.797  1.188  
1BUW  93  B  1.466  1.514  1.566  1.839  1.757  1.202  
1BUW  93  D  1.478  1.522  1.557  1.855  1.762  1.209  
2CI1  83  A  1.455  1.526  1.519  1.787  1.646  1.472  
2HXK  62  B  1.485  1.523  1.567  1.787  1.806  1.205  
2HXK  69  B  1.479  1.525  1.535  1.779  1.804  1.199  
2IIY  62  A  1.437  1.509  1.535  1.768  1.759  1.193  
2IIY  69  A  1.483  1.538  1.519  1.785  1.803  1.207  
2Y33  302  A  1.432  1.512  1.522  1.778  1.788  1.193  
2Y34  302  A  1.47  1.53  1.53  1.83  1.63  1.46  
3EU0  215  A  1.454  1.524  1.53  1.8  1.665  1.308  
 
 
Normal mode analysis reveals movement near S-nitrosylated cysteine 
 
QM/MM calculations were used to generate an S-nitrosocysteine residue within 
the protein structure of VLCAD (2UXW). VLCAD was modified at Cysteine238 to form 
SNO-Cysteine (SNC) using the Python script “S-nitrosator” developed by the 
Timerghazin Laboratory. Using the program elNemo: The Elastic Network Model, low 
frequency vibrational modes of the protein were calculated (Suhre and Sanejouand, et al. 
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2004). The lowest frequency normal modes (modes 7-10) were initially examined to 
determine if S-nitrosylation induced large  
 
 
Figure 4.4: S-nitrosylation does not induce large scale motions in VLCAD. Residue 
mean square displacement values were examined for lower frequency normal modes 
before and after S-nitrosylation.   
 
conformational changes. Large global or collective motions of a protein are described 
using low-frequency modes. Examination of Modes 7, 8, 9, and 10 revealed no global 
motions which may have been induced by S-nitrosylation of Cys238. In these modes, 
residue mean square displacement (r
2
) remained consistent between wildtype and SNO-
VLCAD (Figure 4.4).  
Mode 7 Mode 8 
Mode 9 Mode 10 
r2
 
r2
 
r2
 r2
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The binding site of palmitoyl-CoA was next examined to determine if S-
nitrosylation induced any quantifiable structural changes. Although Uniprot identifies the 
substrate binding pocket as 338-341 and 462-463, viewing the three dimensional 
structure of VLCAD in PyMol  
 
Figure 4.5: Binding site of trans-Δ2-Palmitenoyl-CoA in VLCAD. Binding site is 
composed of 35 residues divided into 4 different regions: Region 1 (in black), Region 2 
(orange); Region 3 (blue); Region 4 (red).  Image generated in PyMol Viewer.  
 
 
revealed that the substrate is in close proximity of 35 residues when bound (Figure 4.5).  
To better characterize the entire substrate binding site, it was grouped into 4 different 
regions based upon its neighboring residues (Figure 4.5). Residues comprising each 
region are previously described in Materials and Methods section. Region 4 (in red) 
included the catalytic glutamate residue 462. 
The higher frequency modes 45 through 50 were examined to investigate smaller 
local motions which might occur near the binding site. Examination of Modes 49 & 50 in 
particular revealed the greatest difference in the movement of atoms in response to S-
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nitrosylation. Region 4 consists of 214Phe, 216Leu, 217Thr, 222Gly, 223Ser, 224Asp, 
and 225Ala. Upon S-nitrosylation, these residues within the binding site do not show 
much movement (Figure 4.6); however, examination of residues surrounding Cys238 
shows a large difference in residue displacement (r
2
) upon S-nitrosylation.  The region 
displaying the most movement (Residues 232-240) is composed of the cysteine-
containing loop as well as an adjacent beta sheet. Preservation of the shape upon S-
nitrosylation also suggests a correlated movement of these flanking amino acids. Region 
4 also appears to display movement; however, these motions are an artifact since these 
residues are involved in membrane anchoring in the mitochondria and are not contained 
within the structure.  
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Figure 4.6: Higher frequency mode indicates extensive movement of Cys238 upon S-
nitrosylation. Mode 49 is examined across the four different regions of the binding site 
with Region 1. Mode 49 is also representative of Mode 50.  
 
Collectively, these data suggest that the loop region containing Cys238 may be 
involved in enhancing the enzymatic activity of very long chain acyl-CoA 
dehydrogenase. Interestingly, Cys238 is measured to be ≥ 30 Angstroms from the 
substrate binding site, suggesting that longer range motions can influence the ability of 
the enzyme to bind substrate.  After S-nitrosylation inhibited the activity of the protein 
methionine adenosyltransferase, Perez-Mato et al. concluded that S-nitrosylation of 
cysteine in a flexible loop changed its conformation and did not allow access of the 
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substrate to its binding site (Perez-Mato et al. 1999). In the case of VLCAD, S-
nitrosylation instead appears to make the loop even more flexible (Figure 4.6). This is a 
particularly intriguing finding since the ligand that VLCAD is crystallized with is the 
product and not the substrate. Trans-Δ2-Palmitenoyl-CoA is the product that is formed 
upon oxidation of palmitoyl-coA. This suggests that S-nitrosylation may play a role in 
helping to release the product once it is formed. However, additional experiments, 
possibly molecular dynamics simulations, are necessary to fully elucidate these local 
protein motions. 
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CHAPTER FIVE: SUMMARY AND GENERAL DISCUSSION 
 
5.1 Summary  
S-nitrosylation is an emerging posttranslational modification (PTM) by which 
nitric oxide can exert its biological function. However, gaps in knowledge regarding its 
mechanism of formation, the specificity of its targets, and the molecular mechanism by 
which S-nitrosylation can alter protein function remain resolved. This thesis aimed to 
address each one of these questions with the use of a global proteomic method for the 
identification of endogenous protein S-nitrosocysteine residues.  
 
5.2 Proteomic techniques are essential for characterization of the 
endogenous S-nitrosoproteome 
 
While there are still large gaps in knowledge regarding S-nitrosylation, many 
cysteines have been and continue to be identified as being S-nitrosylated in vivo. Initial 
investigations into the identification of S-nitrosocysteine protein residues began with 
techniques which did not allow for a priori hypotheses regarding the identity of the 
protein. Sample preparations mandated that the protein either be in isolation or that an 
antibody must be available to validate its identification. 
 
The application of tandem mass spectrometry allowed for proteins to be identified 
in complex solutions when coupled to chromatographic separation techniques. The 
advent of this technology helped to test hypotheses on a much larger scale. For S-
nitrosylation, many answers to the gaps in knowledge lie in the identification of its 
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targets. While LC-MS/MS is a powerful tool, it is useless without a method upstream that 
is sensitive enough to enrich for endogenous protein S-nitrosocysteine. To that end we 
developed a complementary mercury-based mass spectrometric approach for the 
identification of endogenous S-nitrosoproteomes. Without the development of this global 
unbiased enrichment technique, the data would not have as effortlessly revealed a 
population of cysteines which has yet to be described.  
 
While cysteine residues are not one of the most frequently occurring amino acids, 
they are highly conserved, suggesting an important role in biochemical processes. 
Cysteines are known to be highly reactive; therefore it was a surprising finding that 
identification of S-nitrosylated cysteines resulted in the characterization of an entirely 
unique population of cysteine residues. Cysteines identified using our global proteomic 
approach were not predicted or experimentally shown to be redox active, engaged in 
disulfide bonds, coordinated to metals, glutathionylated, or alkylated. The identification 
of this unique population of cysteine residues underscores their biological importance.  
 
 Although our proteomic tool does provide a robust proteomic tool for 
interrogating an endogenous S-nitrosoproteome, it does have some limitations. By 
applying our stringent criteria (i.e. 2 unique protein peptides as well as 1 cysteic acid 
containing peptide), the sites of identification may not always be consistent with those 
previously found to be S-nitrosylated by others. In addition, because S-nitrosylation is an 
emerging signaling mechanism that has been shown to be regulated, the dynamic nature 
of SNO may not always allow for the capture of the protein in its S-nitrosylated state. 
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Identification of the wildtype liver SNO-proteome resulted in nearly 50% complementary 
between both the MRC and mPEG-biotin approach with 25% being unique to either 
method. Consequently, when only a single method is used as with the GSNOR
-/-
 
proteome, a fraction of the proteome may be unaccounted for. To be consistent, the same 
approach should be employed when making comparisons between different proteomes.  
 
 
 
5.3 Transnitrosation by GSNO is a precisely controlled and targeted 
mechanism  
 
After identifying that multiple mechanisms of S-nitrosocysteine formation could 
be taking place in vivo in Chapter 2, Chapter 3 sought to delve further into the 
mechanism by which GSNO can modify protein cysteine residues. Using a knockout of 
the enzyme responsible for in vivo metabolism of GSNO, we were able to identify a 
subset of cysteine residues which may form S-nitrosocysteine using this GSNO-mediated 
mechanism of transnitrosation. When biochemically/biophysically characterizing the 
cysteine residues, there were two novel findings within the GSNOR
-/- 
unique SNO-
proteome. The first was that cysteine residues were surrounded by charged residues. Only 
2 out of 111 cysteines with structures did not have a single charged residue within 6 
Angstroms. This is not a completely surprising finding, since the presence of charged 
residues near cysteines in the wildtype liver proteome supported our hypothesis regarding 
a GSNO-mediated mechanism. However, there does seem to be enrichment for charged 
residues within this population since all but 2% fall into this category.  
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The second finding is regarding the presence of cysteines in their surrounding 
secondary structure. The data revealed that these GSNOR
-/- 
unique cysteines were more 
frequently in coils than cysteine within the previously published wildtype proteome 
(Doulias et al.). Our initial hypothesis was that S-nitrosylated cysteines lie in these more 
flexible regions of the protein in order to accommodate whatever their mechanism of S-
nitrosocysteine formation might be. This suggests that cysteines targeted by GSNO may 
need to exist in these flexible regions to accommodate the tripeptide. This claim is further 
supported when examining the relative residue surface accessibility of the cysteines. With 
the majority of cysteines classified as being buried, it only underscores that the protein 
needs to be flexible to allow access to the residue.  
  
Chapter 3 also presented a novel mechanism of GSNO mediated transnitrosation. 
Previous data has posited the idea that the process of transnitrosation is an acid-base 
catalysis. Using mutational analysis, Perez-Mato et al. (Perez-Mato et al. 1999) 
demonstrate that an acidic residue is somehow involved in the formation of protein S-
nitrosocysteine. They propose that the acidic residue promotes the leaving of a 
nitrosonium ion from GSNO by promoting GSH formation and that basic residues are 
involved in increasing the nucleophilicity of the cysteine residue through its 
deprotonation. 
However, our data support the idea of a base catalysis mechanism of GSNO-
mediated transnitrosation. Using a model protein which was identified in the GSNOR
-/-
 
unique dataset, the data show that coordination of a basic residue (Arg) to the sulfur atom 
of the CYG intermediate can promote the formation of S-nitrosocysteine to the opposing 
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cysteine residue. Therefore, coordination of a basic residue to the SG of GSNO would 
result in formation of protein S-nitrosocysteine. In addition, coordination of this same 
basic residue to other atoms such as N or O had the opposite effect and did not form 
protein S-nitrosocysteine. These findings illustrate how the protein environment can 
tightly regulate the reactivity of the transnitrosating agent (GSNO) and promote the 
formation of specific reaction products. Initially these findings seem to conflict with what 
was previously suggested for the push/pull or acid-base catalyzed mechanism of GSNO 
transnitrosation; however, as the QM/MM calculations illustrate, the coordination of the 
residue to a specific atom in the S-nitrosothiol is really what drives its reactivity. 
Previous calculations conducted by the Timerghazin Laboratory have illustrated how 
coordination of acidic residues to atoms other than S (O, N) can actually promote 
nitrosonium formation as well.  
Collectively, these findings imply that ex vivo supplementation with GSNO does 
not faithfully replicate in vivo transnitrosation. Cellular processes are in place to readily 
metabolize GSNO when it is in a cellular environment (i.e. GSNOR, reactivity with other 
molecules). However, when samples such as cell lysates are treated with GSNO, it can 
result in an uncontrolled and non-specific manner. While this is concentration-dependent, 
data within our own lab has shown this to be the case (data not shown).  
Another important fact to consider is the population of GSNOR
-/-
 unique cysteines 
that are identified by comparison between the GSNOR
-/-
 and wildtype proteomes. S-
nitrosylated cysteines shared between both proteomes were removed to enrich for the 
population of cysteines targeted by GSNO-mediated mechanisms of transnitrosation. By 
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deriving this unique population of GSNOR
-/-
 cysteines in this way, the data may be 
skewed toward more extreme examples of GSNO-mediation. Because our previous 
wildtype data suggested that multiple mechanisms may be occurring in vivo, it is likely 
that stable GSNO-targeted cysteines would also exist within this population. However, by 
subtracting out those cysteines which belong to both groups, this population is not 
included in the bioinformatics analysis.  
5.4 Implications of this work  
 
Collectively, this body of work illustrates how a global tool can be used to 
generate testable hypotheses leading to more targeted investigations regarding cellular 
processes. This thesis begins which a global investigation into the identification of an S-
nitrosoproteome containing over 300 proteins and ends with an investigation into the S-
nitrosylation induced structural consequences of a single protein. Existing knowledge in 
the field of S-nitrosylation can be broadly divided into 5 categories (in decreasing order 
of knowledge): 1) identification of S-nitrosylated proteins, 2) alteration in protein 
functionality, 3) dependency of target on a specific NOS isoform, 4) regulation of the 
signal by denitrosylation, and 5) structural consequences. The data described herein have 
contributed in some form to each one of these five categories.  
 
The identification of many proteins as being S-nitrosylated has resulted in the 
development of several predictive tools (Lee et al. 2011; Xue et al. 2010). For S-
nitrosylation, this still remains a challenge due to the fact that there are not specific 
motifs which are required for S-nitrosylation. This is largely due to the fact that unlike 
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other posttranslational modifications such as acetylation or phosphorylation, no specific 
group of proteins has been identified as mediators in the process of S-nitrosylation. 
Therefore, protein-protein interactions which have helped to derive motifs and predictive 
tools for other PTMs, do not appear to be essential for all S-nitrosocysteine formation. 
While several proteins have been shown to transfer nitrosonium ion to another protein, 
there is no general category of ―S-nitrosyl‖-ases. Those tools which do exist often use 
data which have been obtained using exogenous sources before. As was described 
previously, exogenous forms of nitric oxide can result in a myriad of different chemical 
species. Therefore, it does not accurately describe endogenous mechanisms of S-
nitrosocysteine formation.  
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